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Abstract 
 
Background 
Antiepileptic drugs are prescribed for chronic conditions such as epilepsy and 
bipolar disorder. Without adequate management, such conditions can have 
detrimental effects in pregnancy. However, first trimester use of some 
antiepileptic drugs is associated with a two-threefold increase in the risk of major 
congenital malformations. When women and their health care professionals 
consider treatment regimens, quantified relative risks can help decide which drug, 
if any, would be taken during pregnancy.  
 
Methods 
Three studies were performed using UK primary care data from The Health 
Improvement Network (THIN). Prescribing patterns of antiepileptic drugs in 
pregnancy were examined. A validation study for recording of major congenital 
malformations and perinatal death was performed. Lastly, a cohort study of 
pregnant women prescribed antiepileptic drugs prior to pregnancy was conducted 
to examine the risk of major congenital malformations or perinatal death in 
different first trimester antiepileptic drugs regimens. 
 
Results 
One in 200 women were prescribed antiepileptic drugs in pregnancy. 
Carbamazepine, sodium valproate and lamotrigine were the most commonly 
used antiepileptic drugs in pregnancy between 1994 and 2012.  
 
In this period, 353,171 pregnancies were identified in THIN. The incidence of 
major congenital malformations was 1.9% and perinatal death was 0.4%. 
 
Amongst 1,633 pregnant women regularly prescribed antiepileptic drugs before 
pregnancy, there were 54 cases of major congenital malformations and perinatal 
deaths (3.3%, 95% CI 2.5-4.3%). The risk amongst women prescribed sodium 
valproate polytherapy was 12% (95% CI 5.9-21.0%) - significantly greater than 
those prescribed carbamazepine monotherapy (IRR 2.72, 95% CI 1.23-5.99), 
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sodium valproate monotherapy (IRR 3.42, 95% CI 1.35-8.66) and lamotrigine 
monotherapy (IRR 5.03, 95% CI 1.99-12.74).  
 
Conclusions 
Women taking sodium valproate polytherapy face a greater risk of major 
congenital malformations or perinatal death compared to other common 
monotherapy regimens. Further research is needed to corroborate these findings, 
however women and their physicians should aim to avoid sodium valproate 
polytherapy if possible.  
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Chapter 1 
Background and Literature Review 
 
1.1. Aim of the chapter 
The aim of this chapter is to provide a rationale for the main study presented in 
this thesis. In this chapter I give the background to antiepileptic drugs, their uses 
and why there are concerns over the safety of their use in pregnancy. Further to 
this I review of the current literature up to the point when I started my PhD 
(October 2010) on antiepileptic drugs in pregnancy and risk of major congenital 
malformations. 
 
1.2. Introduction 
In 1957, the pharmaceutical company Chemie-Grunenthal launched an over-the-
counter drug to the German market. The drug was a ‘wonder’ drug which claimed 
to alleviate a number of problems including morning sickness in pregnant women 
and, remarkably, this drug appeared safe and tolerable for pregnant women to 
take. Its rapid success led to worldwide distribution. But over the next five years 
one of the greatest medical tragedies was unfolded. Early estimates suggested 
that 40% of babies whose mothers had taken this drug whilst they were pregnant 
did not survive birth.1 Of around 10,000 survivors, many were born with major 
congenital malformations - notably severe deformities of the limbs - and only 
3,000 remain alive today.  The drug which caused this was thalidomide.  
 
Lessons were learned from the thalidomide scandal, however nearly 60 years 
later, we are still unable to know for certain whether or not a drug is harmful in 
pregnancy before it is marketed. Instead, it is increased testing, post-marketing 
surveillance and reporting of adverse drug reactions, which has led to around 30 
drugs being identified as teratogenic – that is, the drug (known as the teratogen) 
is known to cause congenital malformations when taken in pregnancy.2   
 
In the United Kingdom (UK), the background risk (the average risk in any 
pregnancy) of major congenital malformations (also known as birth defects, 
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congenital abnormalities or anomalies) in the general population is between 1 
and 3%, of which only 2-5% is estimated to be caused by drugs.3 Thalidomide 
increased the risk of major congenital malformations to a startling 20-30%; most 
other drug teratogens increase the risk by much less.2 Certain older antiepileptic 
drugs are associated with two- to three-fold increase in the risk of major 
congenital malformations.4;5 One older antiepileptic drug in particular, sodium 
valproate, is strongly linked with major congenital malformations and reduced 
childhood development.6 Newer, or second generation, antiepileptic drugs have 
emerged in the last 20 years, but with the exception of one popular antiepileptic 
drug, lamotrigine, little research on their teratogenic effects has been conducted.  
 
1.3. Prescribing drugs in pregnancy 
Many women are prescribed drugs in pregnancy. Studies have found at least 
45%, and as many as 95% of pregnant women receive one or more prescriptions 
during pregnancy, and on average a woman will receive three prescriptions over 
the course of pregnancy.7;8 However, the decision to prescribe a drug to a 
pregnant woman can be a difficult one for both the woman and health care 
professionals. Most pregnant women understand the background risk of 
malformations is below 5% but many overestimate the teratogenic risk of taking 
drugs in pregnancy and have chosen not to take a drug because of this reason.9 
A small study of 36 women taking antidepressants or benzodiazepines found over 
90% stopped when they realised they were pregnant, and 78% had been advised 
to stop by their general practitioner. Moreover, 70% reported physical and 
psychological effects in pregnancy, which potentially may have been prevented 
by drugs leaving one questioning whether or discontinuation itself caused more 
harm than good.10  
 
Health care professionals are thus required to keep abreast of guidelines and 
research on the safe use of drugs in pregnancy, understanding not just the risk 
but also the benefits of maintaining therapy and thus the woman’s health in 
pregnancy. This is especially relevant for managing women taking antiepileptic 
drugs. A particular  antiepileptic drug mentioned earlier, sodium valproate, has 
been  frequently linked to increased risks of major congenital malformations - 
evidence of teratogenicity has also been observed for some other antiepileptic 
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drugs, albeit to a lesser extent than sodium valproate.6;11-20 However, antiepileptic 
drugs are usually taken regularly and for the long term to treat epilepsy, and more 
recently to treat the severe mental illness, bipolar disorder. Ceasing antiepileptic 
drug treatment due to concerns over the teratogenic risk must be considered 
alongside the benefits of managing the underlying condition. Poorly controlled 
epilepsy can result in seizures which themselves may harm the foetus, or the 
foetus may be at risk indirectly through falling from a seizure. Detrimental risks 
are also associated inadequately managed bipolar disorder.21;22 Whilst 
alternative medication exist for bipolar disorder in terms of antipsychotics and 
antidepressants, none exists for epilepsy.   
 
1.3.1. Antiepileptic drug prescribing in pregnancy 
Advice on how to treat pregnant women with epilepsy and bipolar disorder can 
be found in the clinical guidelines from the National Institute for Health and 
Clinical Excellence (NICE). They advise pre-pregnancy planning involving 
individual assessment of the woman, her illness, treatment regimen, and lifestyle 
options.23;24 Women must be made aware of the risks associated with 
antiepileptic drugs in pregnancy, as well as the benefits. For women with 
epilepsy, there is little advice on drug specific risks – the exception being sodium 
valproate where they specifically state that doses higher than 800mg/day or 
prescribed in polytherapy, further increases the risk of major congenital 
malformations.  Furthermore, the guidelines note that there are limited data in 
relation to newer antiepileptic drugs and that seizure freedom should be aimed 
for but balanced with the teratogenic risks. In contrast, the guidance for managing 
bipolar disorder specifically advises against the use of sodium valproate, 
carbamazepine and lamotrigine in pregnancy for risk of harm to the foetus.24 The 
British National Formulary (BNF), a reference for prescribing and pharmacology 
for health care professionals in the UK, goes further to specifically state 
phenytoin, primidone, phenobarbital, lamotrigine, carbamazepine and topiramate 
are associated with increased teratogenicity.25 The BNF acknowledges that some 
women may be able to stop treatment before falling pregnant, but only if their 
condition allows. However, for unplanned pregnancies, they do not recommend 
stopping or changing treatment as the risk of harm to the mother and foetus from 
convulsive seizures outweighs the risk of continued therapy. These guidelines 
16 
 
from NICE and the BNF are exactly that – only guidance – each woman must be 
treated as an individual due to the heterogeneous nature of the underlying 
condition, particularly so with the epilepsies and bipolar disorder.  
 
Many women are prescribed drugs in pregnancy, but both women and their health 
care providers have stated a need for more consistent information on the risks 
and benefits of their use during pregnancy.9;26 There is even greater need for this 
information for antiepileptic drugs because some older drugs are teratogenic, 
newer drugs have been introduced but not thoroughly examined for 
teratogenicity, and because stopping treatment altogether is not an option for the 
large majority of women.  
 
1.4. Background 
1.4.1. Pregnancy and foetal development 
From conception, a full term pregnancy lasts on average 38 weeks. The first 17 
days post conception are the pre-embryonic phase where if the embryo is 
exposed to harm, it will result in either early pregnancy loss or powerful regulatory 
properties of the developing embryo will protect it. Major congenital 
malformations do not result from exposure to harmful agents during this period. 
However, week three to eight are the most vulnerable period for the developing 
embryo, which at this stage is in the embryonic phase. In this time, many of the 
organs are being defined and are highly sensitive to insult – once cells are 
damaged, they are unlikely to be replaced, resulting in major congenital 
malformations. This period of organ formation is called organogenesis. Each 
organ system has a specific critical period of development, for example, the heart 
forms between weeks three and eight, the most sensitive time being week three 
to six, whereas the central nervous system is developed over the entire 
pregnancy, but is most sensitive between weeks three and seven.27 This 
understanding of the critical timeline of foetal development allows us to identify a 
time period in which a drug may cause specific deficits. For example, research 
conducted after the effects of thalidomide had unfolded found that it was only a 
risk for major congenital malformations if the drug was taken between the 20th 
and 36th day post conception  and the commonly observed limb defects were a 
result of the exposure between the 24th and 31st day.28;29  
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The period of organogenesis falls across the first trimester (the first three months 
of pregnancy), hence much advice surrounding the prescribing of drugs to 
pregnant women is to avoid first trimester exposures if possible and safe. The 
foetal phase begins from week nine onwards as the organs are growing and 
maturing. Although major congenital malformations are less likely to occur in this 
time since the organs have now formed, the foetus is still vulnerable to teratogens 
which may affect the functioning of the organs, or cause minor malformations.27 
 
1.4.2. Antiepileptic drugs 
There are over 20 antiepileptic drugs available on the market in the UK and they 
are generally classified into two groups – older and newer. Phenytoin and 
phenobarbital were some of the earliest antiepileptic drugs and have been 
popular choices of treatment in the past but carry unfavourable side effects. Later, 
sodium valproate and carbamazepine were introduced and remain  drugs of 
choice for particular kinds of seizures in epilepsy (focal and generalised seizures, 
respectively),30 - they were later also found to be effective in treating bipolar 
disorder. Phenytoin, phenobarbital, sodium valproate and carbamazepine are 
thus considered as older antiepileptic drugs. Few drugs were introduced in the 
20 years that followed until 1991 which marked the release of lamotrigine, a drug 
popular for treating focal seizures in epilepsy.23;30  A further influx of another 10 
antiepileptic drugs has included levetiracetam, gabapentin, pregabalin and 
topiramate. These 11 antiepileptic drugs are commonly referred to as the “newer” 
antiepileptic drugs. 
 
The vast majority of people taking antiepileptic drugs in the UK will be for the 
treatment of epilepsy which is the primary indication for these drugs. Bipolar 
disorder, acute depression, acute mania, and other conditions including insomnia 
and pain, can also be treated with antiepileptic drugs. These are discussed in 
more detail later in this chapter.  
 
The exact choice of treatment depends not only on symptoms of the underlying 
condition, but also takes into account the individual’s lifestyle and preferences 
(such as how often is practical for individuals to take their medicines), co-
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medication, co-morbidity, and tolerance of side effects. Side effects in particular 
can vary greatly between drugs and from one person to the next – Table 1 
describes some of the common ones associated with each antiepileptic drug. 
These can range from mild effects on nausea to serious problems in mood and 
weight control which can affect ones daily life, however newer antiepileptic drugs 
are considered to be more tolerable than older antiepileptic drugs. This can be 
further complicated if polytherapy is needed – this is where more than one drug 
is used to treat the condition. A drug prescribed on its own (monotherapy) is 
preferable to prescribing polytherapy which can lead to toxicity and drug 
interactions. 31 
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Table 1 Antiepileptic drugs in the UK, indications and potential side effects30 
Generic name Brand names Conditions other 
than epilepsy 
Side effects 
Acetazolamide  Diamox   Nausea, vomiting, pins and needles/tingling when used in high 
doses 
Carbamazepine  Tegretol Bipolar disorder, 
trigeminal neuralgia 
Nausea, vomiting, dizziness, drowsiness, headache, unsteadiness, 
confusion, blurred or double vision, rash, low white blood cell count 
Clobazam Frisium  Drowsiness, confusion, unsteadiness 
Clonazepam Rivotril  Drowsiness, confusion, unsteadiness 
Eslicarbazepine acetate* Zebinix  Gastro-intestinal disturbances, dizziness, drowsiness, headache, 
impaired coordination, tremor, visual disturbances, fatigue, rash 
Ethosuximide Emeside, Zarontin  Nausea, vomiting, headache, diarrhoea, abdominal pain, reduced 
appetite 
Gabapentin* Neurontin Neuropathic pain, 
trigeminal neuralgia 
Drowsiness, lethargy, nausea, weight gain 
Lacosamide* Vimpat  Nausea, vomiting, constipation, flatulence, dizziness, headache,  
impaired coordination, cognitive disorder, drowsiness, tremor, 
depression, fatigue, abnormal gait, blurred vision, nystagmus, 
pruritus  
Lamotrigine* Lamictal Trigeminal neuralgia Rash and other allergic reactions, liver dysfunctions, nausea, 
vomiting, headache, fatigue, dizziness, sleep disturbances, tremor, 
agitation, confusion 
Levetiracetam* Keppra  Nausea, vomiting, indigestion weight changes, drowsiness, 
unsteadiness and dizziness, emotional liability, insomnia, anxiety, 
aggression and irritability 
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Generic name Brand names Conditions other 
than epilepsy 
Side effects 
Oxcarbazepine* Trileptal Trigeminal neuralgia Nausea, vomiting, constipation, diarrhoea, abdominal pain, 
dizziness, headache, drowsiness, agitation, unsteadiness, 
confusion, impaired concentration, rash, double or blurred vision 
Phenobarbital  N/A  Liver dysfunction, jaundice, behavioural disturbances, irritability, 
drowsiness, lethargy, depression, unsteadiness, impaired memory, 
rash 
Phenytoin Epanutin Trigeminal neuralgia Nausea, vomiting, constipation, insomnia, dizziness, headache, gum 
swelling, rash, acne, facial hair, coarsening of facial features 
Pregabalin* Lyrica Neuropathic pain Dry mouth, constipation, nausea, vomiting, dizziness, drowsiness, 
irritability, reduced memory and concentration, fatigue, weight gain 
Primidone Mysoline Benign essential 
tremors 
Liver dysfunction, jaundice, behavioural disturbances, irritability, 
drowsiness, lethargy, depression, unsteadiness, impaired memory, 
rash 
Rufinamide* Inovelon  Drowsiness, dizziness, headache 
Sodium valproate  Epilim 
Epilim Chrono 
Epilim 
Chronosphere 
Episenta 
Migraine, bipolar 
disorder (valproic acid) 
Nausea, gastric irritation, diarrhoea, weight gain, 
hyperammonaemia, thrombocytopenia, transient hair loss 
Tiagabine* Gabitril  Diarrhoea, dizziness, tiredness, nervousness, tremor, impaired 
concentration, emotional liability, speech impairment 
Topiramate* Topamax Migraine Nausea, abdominal pain, weight loss, headache, fatigue, dizziness, 
speech difficulty, reduced concentration and memory, anxiety, 
depression 
Vigabatrin Sabril  Increased appetite, irritability, visual field constriction(possibly 
irreversible) 
21 
 
Generic name Brand names Conditions other 
than epilepsy 
Side effects 
Zonisamide* Zonegran  Nausea, diarrhoea, abdominal pain, reduced appetite, weight loss, 
drowsiness, dizziness, confusion, agitation, irritability, depression, 
unsteadiness, impaired memory and attention, double vision and 
rash 
*Newer antiepileptic drugs
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Antiepileptic drugs also have several drug interactions that need to be considered 
when choosing a treatment regimen: 
 carbamazepine, phenytoin, phenobarbital, topiramate and rufinamide 
interfere with the oral contraceptive pill 
 the combined oral contraceptive pill interferes with lamotrigine 
 sodium valproate taken with aspirin can lead to excessive bleeding after a cut 
 theophylline, a drug taken for asthma, interferes with carbamazepine 
 some antibiotics interact with some antiepileptic drugs.30 
 
A person who is well-established on treatment and has successfully managed their 
underlying condition may, in the future, consider withdrawing from medication. 
Withdrawal from antiepileptic drugs is, like the introduction of a new drug, a gradual 
process and evidence on whether or not there is an improved quality of life is 
conflicting.32;33  
 
Antiepileptic drugs are essential for many people with epilepsy, bipolar disorder and 
pain related conditions. The process by which drugs are chosen is not 
straightforward and varies greatly between individuals to meet the demands on their 
practical circumstances and their tolerance to side effects. It is a fine balance of 
effectiveness and management for the individual which highlights the need of a 
health care professional to advise, monitor and review the treatment regimen as and 
when is needed.  
 
1.4.3. Indications for antiepileptic drugs 
A number of conditions can be treated with antiepileptic drugs, mostly neurological 
including epilepsy, migraine and neuropathic pain, and some mental health 
disorders namely bipolar disorder, but also depression and anxiety. Described here 
are epilepsy – the main indication for antiepileptic drugs – and bipolar disorder, a 
severe mental illness where antiepileptic drugs have been increasingly prescribed.34  
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Epilepsy 
Epilepsy is the most common neurological condition affecting 3-4% of the population 
by the age of 75.30 It is characterised by frequent, often unprovoked, seizures caused 
by abnormal, sudden excess electrical discharges of nerve cells in the brain. These 
discharges vary in their origin in the brain and the way they spread, resulting in 
differences in the way they are externally observed. These variations form epilepsy 
syndromes, or epilepsies, which differ in the antiepileptic drugs used to treat them. 
These epilepsies are commonly unified and referred to as epilepsy.  
 
The majority of people diagnosed with epilepsy use antiepileptic drugs to manage 
their seizures, which is successful at stopping seizures for approximately 60% of 
users.30  Other interventions include surgery and a ketogenic diet, however, there is 
no cure. The long term prognosis is a higher risk of death, estimated to be threefold 
that of an age-matched general population.35-37 Most deaths are, however, from 
causes unrelated to epilepsy.37 There is a risk of sudden death from epilepsy  but 
this is rare affecting less than one percent of those with epilepsy.38 
 
In pregnancy, the great majority of women with epilepsy have healthy, normal 
births.23;30 There are however some elevated risks - the risk of maternal death is 
approximately ten times than that of the general population and the risk of 
complications in pregnancy and labour are also higher.5;21;23  Women with epilepsy 
also need closer monitoring throughout pregnancy due to altered clearance of 
antiepileptic drugs in the blood, thus doses may need to be increased to ensure 
seizure freedom is maintained. Certain seizures, if they do occur in pregnancy 
(generalised tonic-clonic seizures) carry a risk of harm to the unborn foetus during 
the seizure, but the absolute risk is still low.23  
 
Bipolar disorder 
Bipolar disorder is a mood disorder characterised by extreme changes in mood from 
intense mania to deep depression, and sometimes a “mixed” state of mania and 
depression. It is a chronic and lifelong condition which can have a devastating impact 
on one’s personal, work and social life and is associated with a greater risk of 
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suicide.39  In the UK, it is estimated to affect around 1-2% of adults in their lifetime.40 
Its cause is still unknown. In some cases it is triggered by a major event in one’s life 
such as childbirth, a major birthday or the wedding of a close friend or relative, and 
in others there are familial links.41 The diagnosis of bipolar disorder is set out in the 
Diagnostic and Statistical Manual (DSM-IV),42 which defines four types of bipolar 
disorder - bipolar I, bipolar II, cyclothymia and bipolar not otherwise specified. Each 
type has a pattern of episodes of major depression, mania, hypomania or mixed 
states.  
 
Drug treatment is used to reduce the severity of symptoms, stabilise the mood and 
prevent a relapse. Lithium (not an antiepileptic drug) is the only drug licensed for the 
prophylaxis of bipolar disorder, however antiepileptic drugs (sodium valproate, 
lamotrigine and carbamazepine) have also been used. Some antipsychotics and 
valproic acid (a form of sodium valproate) are licensed for treating acute manic 
episodes and antidepressants are used for treating depressive episodes.24  
Psychotherapy is also available as a non-pharmacological intervention. This 
includes cognitive behavioural therapy and family focussed treatment. However, it is 
unclear as to the effectiveness of these types of treatment alone as opposed to in 
conjunction with medication.43-45 Management of the illness can therefore be tricky 
and effective pharmacological intervention can highly depend on current mood 
episode.  
 
Treatment and management provide control of mood but the prognosis is poor – 
50% of episodes last on average for three months, full recovery is rare and the risk 
of death and in particular, suicide, are high as are other co-morbid conditions 
including alcohol and drug abuse and other psychiatric disorders, namely anxiety 
disorders, schizophrenia and personality disorders.24;39;46;46-50 
 
Pregnant women with bipolar disorder face a similar dilemma to pregnant women 
with epilepsy – the decision over whether or not to continue antiepileptic drug use in 
pregnancy requires weighing up the risks of the drugs to the foetus and benefits of 
being stable. As mentioned earlier, bipolar disorder can be treated with other 
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antidepressants and antipsychotics, which have a more favourable safety profile in 
pregnancy, but whether or not these alternative adequately manage one’s bipolar 
disorder comes down to the individual. The need for women with bipolar disorder to 
remain stable in pregnancy is compounded by the general increased risk of relapse 
of a mood episode during pregnancy,51 and the increased risk of postpartum 
psychosis after birth – an acute, sudden  psychotic episode usually in the first few 
weeks after birth  which can lead to high mania, depression, confusion, delusions 
and hallucinations.22;52;53 
 
There are clear clinical differences between epilepsy and bipolar disorder, however 
they are similar in that: 
- drugs are the main stay treatment; 
- they are lifelong conditions; 
- there are elevated risks associated with pregnancy; 
- there can be detrimental maternal and foetal outcomes associated with poor 
management of the condition in pregnancy.  
Thus, the research in this thesis is aimed at these women who rely on antiepileptic 
drugs to maintain their health and who have to consider how pregnancy affects the 
management of their condition.  
 
Having described some of the background to the exposure of interest in this thesis 
– antiepileptic drugs during pregnancy - the next section gives an overview of the 
primary outcome of interest – major congenital malformations.  
 
1.4.4. Major congenital malformations 
Major congenital malformations are structural abnormalities, present at birth, which 
lead to severe physical disability or functional impairment resulting in medical 
treatment, care, surgery or death.27 They are also commonly referred to as major 
congenital abnormalities, anomalies, or birth defects. The latter term can be 
misleading – major congenital malformations are a result of structural changes which 
have occurred during pregnancy, and are present at birth – they are not defects of 
birth, which is how “birth defects” is sometimes interpreted. The majority of major 
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congenital malformations will be obvious at birth though it is possible for some to be 
unnoticed until later in life.  An example of a major congenital malformation is spina 
bifida which is the abnormal development of the neural tube (the tube which 
eventually becomes the spine and spinal cord). Usually, spina bifida requires surgery 
and long term therapy to improve the quality of life.  
 
It is important to distinguish major and minor congenital malformations – minor 
malformations are also structural abnormalities but, as the name suggests, they are 
minor and are less likely to affect one’s life and furthermore, may not need any 
correction. Such examples include birthmarks and slight curvature of fingers or toes 
(clinodactyly).  
 
The prevalence of major congenital malformations amongst all births in the general 
population is low – between 1 and 3%. However, they are a leading cause of infant 
mortality contributing to 20% of deaths in infancy.54 There are thousands of different 
types, many with multiple causes and over 50% with unknown causes.3 Several 
factors can contribute to causing congenital malformations – but it is estimated that 
only 2-5% are caused by medication, such as antiepileptic drugs.3 Other factors 
include genetic mutations, infections, maternal diet and other teratogenic agents 
such as alcohol and certain chemicals.  
 
In the UK, pregnant women are screened for congenital abnormalities at around 20 
weeks gestation. At this point, many major structural abnormalities, which developed 
in the first trimester, should be detected by ultrasound scan. Further imaging and 
possibly other techniques such as sampling the amniotic fluid can help to diagnose 
a major congenital malformation prenatally. This provides women and their partners 
valuable information on the implications of the diagnosis in the future care of the 
child, in some cases whether or not to continue the pregnancy.  
 
Antiepileptic drug exposure in pregnancy and major congenital malformations have 
long been researched. In the 60s, the first questions were raised about antiepileptic 
drugs and major congenital malformations following case reports of cleft lip and 
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palate in children born to women with epilepsy.55 Then, in 1967, it was recognised 
that antiepileptic drugs could pass across the placenta  after phenobarbital was 
found in human umbilical cord serum at 95% concentration of that in maternal 
serum.56 Much research followed on investigating the link with epilepsy and the link 
with the antiepileptic drugs themselves. It soon became clear that there were key 
antiepileptic drugs which were associated with structural abnormalities observed at 
birth, prompting syndromes of common features to be defined. An example is the 
foetal hydantoin syndrome which is found in babies exposed to the antiepileptic drug 
phenytoin in utero. The features of the syndrome include growth deficiencies such 
as being small at birth, abnormalities of the skull or facial features – notably flat nasal 
bridge, eyes slanted downwards, spaced widely apart and crossed – and as well as 
the structural abnormalities, mild developmental delays.57;58 
 
Sodium valproate is an antiepileptic drug which was licensed for use in 1978. It is 
commonly prescribed for different epilepsies either on its own or with other 
antiepileptic drugs. Concerns over its use in pregnancy emerged soon after it was 
licensed in around 1980 and since then several outcomes have been associated 
with prenatal exposure including the foetal valproate syndrome which describes a 
pattern of mainly facial malformations, delays in childhood development and notably 
a specific malformation, neural tube defects – abnormalities of the neural tube which 
includes the aforementioned spina bifida.59 Compared to other antiepileptic drugs, 
the research in this area has been consistent and evident enough for 
recommendations against it use in pregnancy to be made in clinical practice.31   
 
For other antiepileptic drugs, the effects, if any, are less understood – evidence is 
lacking, sparse or inconsistent. Some common malformations have been identified 
including heart defects, cleft lip and palate and midline facial deformities. 
 
Exactly how antiepileptic drugs cause congenital malformations is not known for 
certain. Animal studies have been performed and several theories have been 
postulated which centre on interference with critical development of the foetus. For 
example, Bittigau et al found antiepileptic drugs used on foetal rats caused apoptotic 
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neurodegeneration – cell death – of the developing brain.60 More recently 
Hernandez-Diaz et al suggested that the mechanism, by which antiepileptic drugs 
attain seizure control in epilepsy, can interfere with controlled regulatory 
mechanisms vital for cued processes to occur in foetal development.61 Similar 
theories related to an interference of foetal development also exist.62  
 
Major congenital malformations are rare; however, they can have a heavy burden 
on the parents of a child with a malformation at a time in life which is already 
challenging. Technology allows some diagnoses to be made before the child is born, 
somewhat preparing the parents, however identifying causes and preventing 
malformations occurring can protect parents from making such difficult decisions on 
their child’s future. One potential cause is antiepileptic drugs, and although the 
elevated risks of one particular antiepileptic drug have been established, there is 
little guidance on the use of other antiepileptic drugs leaving women in a dilemma 
over how to weigh up the risks and benefits of continuing antiepileptic medication 
throughout pregnancy. 
 
1.5. Literature review 
1.5.1. Aim 
In the next section a systematic review of the literature is presented which aims to 
collate the current research findings (up to October 2010) on the effect of 
antiepileptic drugs on the risk of major congenital malformations and to highlight 
areas where research is lacking and thus inform my research for this PhD.  
1.5.2. Hypotheses 
1) The use of antiepileptic drugs in the first trimester of pregnancy significantly 
increases the risk of major congenital malformations.  
2) These risks differ between antiepileptic drugs with sodium valproate bearing 
the highest risk.  
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1.5.3. Methods 
In 2009, the American Academy of Neurology and American Epilepsy Society 
published a systematic review of the teratogenicity of antiepileptic drugs in order to 
inform a practice parameter guideline advising health care professionals on the 
treatment of pregnant women.63 To avoid duplication of research, I performed a 
literature review covering the period since this published review. Thus, the published 
review examines literature published prior to January 2007 and my updated literature 
review examines articles from January 2007 to October 2010. The method used for 
the updated literature search is described next. 
  
Updated literature search 
Searches of published articles were carried out using electronic journal databases 
PubMed, EMBASE and Web of Science - the latter database also providing 
conference abstracts. The search consisted of synonyms and combinations of words 
used to describe the following: mother, baby, antiepileptic drugs, and congenital 
malformations. The time period for this search was January 2007 to October 2010. 
Literature was restricted to human studies and those available in English. The search 
strategy in PubMed is supplied in Appendix 1. Similar search strategies were used 
in EMBASE and Web of Science. Conference abstracts, review articles and 
references of journal articles were perused for any further articles not identified in 
the search. 
 
Inclusion and exclusion 
All identified articles were downloaded to Reference Manager and sifted for 
duplicates. There were two stages of review which followed, based on a set of 
inclusion and exclusion criteria which are listed in the Table 2 overleaf. Titles and 
abstracts were reviewed first, and those which fulfilled the criteria then had the full 
text reviewed.  
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Table 2 Inclusion and exclusion criteria for article selection for systematic review 
 Inclusion Exclusion 
Population Women with clinical indication for antiepileptic drugs (e.g. epilepsy, 
bipolar disorder) 
 
Comparisons 
groups of interest 
 Eight specific comparisons of interest were: 
- Compared to women who did NOT take antiepileptic drugs in 
the first trimester of pregnancy: 
o Any monotherapy 
o Any polytherapy 
o Carbamazepine monotherapy 
o Sodium valproate monotherapy 
o Lamotrigine monotherapy 
- Pairwise comparisons of three common monotherapies - 
sodium valproate, carbamazepine and lamotrigine -  giving the 
following comparisons: 
o Carbamazepine monotherapy vs. sodium valproate 
monotherapy 
o Carbamazepine monotherapy vs. lamotrigine 
monotherapy 
o Sodium valproate monotherapy vs. lamotrigine 
monotherapy 
- No comparison group 
- Other antiepileptic drug regimens 
 
Outcome Major congenital malformations Minor congenital malformations 
Type of study Case-control, cohort, randomised controlled trials  
Other Human 
English language 
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Analyses 
It was made clear reading the published review by the American Academy of 
Neurology and American Epilepsy Society that the degree of heterogeneity amongst 
previous studies prevented a useful meta-analysis.63  The studies varied greatly in 
their populations, exposures and outcome measures and types therefore descriptive 
accounts of groups of comparable studies are given, which was the same approach 
used previously.63 
 
In the next section, I present the results of both reviews. Firstly, a summary of the 
characteristics of each review is given. Secondly, results are grouped between the 
two reviews according to the pairwise exposures being compared, as listed in Table 
2 and described. 
 
1.5.2. Results  
Overview of the systematic review in the report of the Quality Standards 
Subcommittee (QSS) and Therapeutics and Technology Assessment (TTA) 
Subcommittee of the American Academy of Neurology (AAN) and American 
Epilepsy Society (AES) 
 
In 1998, a group of experts in the US published on various issues related to 
managing women with epilepsy aimed at the health care professional.64 Ten years 
later, another panel of experts in epilepsy were brought together to reassess the 
literature to date and consequently, three “practice parameter” updates were 
published and offered to health care professionals. Each one had a different focus – 
obstetrical complications and changes to seizure frequency;65 vitamin K, folic acid, 
blood levels, and breastfeeding;66 and teratogenesis and perinatal outcomes.63 
Discussed here is the latter report on antiepileptic drug teratogenesis and perinatal 
outcomes. This practice parameter update was based on a systematic review which 
addressed a number of questions, however in this thesis I will focus on aspects of 
the review relating to the risk of major congenital malformations associated with in 
utero antiepileptic drug exposure. 
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Their search strategy was similar to that I adopted for the updated literature review. 
The review was based on research published between 1985 and 2007. They 
supplemented their search by interrogating other reviews for missed references.  
The filtering and review process involved two panel members performing initial 
screening and four panel members reviewing full-text articles for relevance. 
Identified articles were categorised into classes dependent on their risk of bias using 
criteria developed by the American Academy of Neurology which assesses studies 
for evidence of causality particularly in situations where clinical trials are not 
practical. Evidence was classed from I to IV, with Class I representing optimal study 
designs for causal inference including requirements such as prospective, 
representative, comparison groups matched for confounders, defined and validated 
risk factors and outcomes. Class IV on the other hand represented poor quality – 
non-comparative, unrepresentative, major biases etc. Only studies which achieved 
Class III rating or above were included in their review.  Studies were only classified 
as class I and II if they accounted for confounding.  
 
The outcome sought in their review was major congenital malformations which were 
defined as structural anomalies with surgical, medical or cosmetic importance. The 
exposure was restricted to the first trimester, which is the period of organ formation 
and a vulnerable time for the growing foetus. The control group was restricted to 
women with untreated epilepsy to account for possible effects of epilepsy. 
 
In total, only nine studies were identified. Four studies were classified as Class 
III,15;18;67;68 three as Class II,4;11;69 and two Class I.17;20 Six studies were 
prospective,15;17;18;20;67;68 most of them from early pregnancy when women were 
taking antiepileptic drugs in the first trimester. The remaining studies were 
retrospective and based on medical records – one study was prospective in terms 
of outcome but women were enrolled in labour or delivery therefore retrospective in 
terms of exposure.4 Settings were varied – three from pregnancy registries,17;18;68 
two from epilepsy centres,15;67 one from hospital,4 and the remaining through medical 
records.11;20;69 
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Six studies had a sample size of over 1,000 pregnant women.4;11;17;20;68;69 There were 
333 women in another study,15 565 women in a further study18 and one study did not 
provide this information.67 The number of children with exposure to a specific 
monotherapy was over 100 in all but one study.4 Five studies included children born 
to women with epilepsy who were untreated during pregnancy – one study had less 
than 50 children,67 whilst more recent studies were larger yielding sample sizes of 
235,17 6064 and 93911 pregnancies with no treatment in the first trimester and one 
study with over 1000.69 The remaining four studies only made pair-wise comparisons 
between specific monotherapies.  
 
All studies separated antiepileptic drug treatment as monotherapy and polytherapy 
as well as providing information on rates of major congenital malformations 
according to a specific monotherapy exposure, the most common form of 
monotherapy being carbamazepine.  
 
Outcome definitions were slightly varied. Two studies grouped together major and 
minor congenital malformations,11;67 and a further two studies reported on serious 
adverse outcomes which comprised major congenital malformations or foetal 
death.4;15 Some studies did not give a definition,18;20 and of those which did, four 
specified a time period during which major congenital malformations were defined – 
two studies measured major congenital malformations which were detected  within 
the first six weeks since birth,17;69 whilst the other two studies used five days as the 
cut-off.67;68 Three studies further classified major congenital malformations by the 
affected organ system.11;15;17 
 
Two studies only included pregnancies which ended in live birth,11;20 three had the 
potential to record other pregnancy outcomes but did not describe any other than 
live born babies,4;15;17 whilst the rest of the studies described alternative pregnancy 
outcomes such as still birth, spontaneous abortions and elective abortions. Results 
of prenatal screening after enrolment were captured in four studies.15;17;67;69  
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The authors of the review looked at the research question in two parts – 1) do 
antiepileptic drugs taken in the first trimester of pregnancy increase the risk of major 
congenital malformations in the offspring of women with epilepsy compared to the 
offspring of women with epilepsy not on antiepileptic drugs? 2) Is exposure to a 
specific antiepileptic drug during the first trimester of pregnancy associated with an 
increased risk of major congenital malformations compared to exposure to other 
antiepileptic drugs (i.e. pair-wise comparisons)? In Part 1) they examined 
antiepileptic drugs in general as well as specific antiepileptic drugs sodium valproate, 
carbamazepine and lamotrigine and concluded possible increased risks associated 
with sodium valproate monotherapy and probable increased risks with sodium 
valproate polytherapy and carbamazepine, however there was insufficient data on 
lamotrigine to make any conclusions. In Part 2) sodium valproate was compared with 
carbamazepine, lamotrigine and phenytoin monotherapy. Sodium valproate was 
concluded as being very likely to be related to major congenital malformations in 
comparison with carbamazepine, and possibly contributory to the development of 
major congenital malformations in comparison with phenytoin and lamotrigine 
monotherapy.  
 
The overall conclusions of their review were limited by the small number of studies 
which were eligible for inclusion. The recommendations were generally around 
avoidance of sodium valproate in the first trimester, if possible.  
 
Overview of updated literature search 
The search strategy detailed in the methods section of this current review was used 
to identify the literature in this area which was available since 2007. After removal of 
duplicates, 57 articles were identified from electronic journal databases and 
screened for meeting the inclusion and exclusion criteria set out in Table 2. An 
additional inclusion criterion was used in that the exposure had to be during the first 
trimester. On review of the title and abstracts, 11 were retained and had their full text 
reviewed. One study did not have a comparison group,70 another did not report risks 
in the comparison group,71 two compared to the general population instead of to 
offspring of women with epilepsy72;73 and one did not report adequately on the risks 
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in the exposed population.74 There were two conference abstracts from the UK and 
Ireland Epilepsy and Pregnancy Register study group which were updates from the 
material published in 2006,17;75;76 and is covered in the AAN review. Since both 
abstracts reported on the same cohort I took the latest abstract which contained the 
most up to date data.75 Five articles therefore remained which are included in this 
current review of the literature since 2007 to 2010.  
 
Of the five studies, there were five independent cohorts. Participants were enrolled 
through pregnancy registers in three studies including the Kerala Registry of 
Epilepsy and Pregnancy and the Australian Pregnancy Registry.19;75;77 One study 
was based on medical records78 and one from the prospective LMNDG cohort.5  Four 
cohorts were prospectively followed.5;19;75;77;79 
 
All studies included more than 200 pregnancies, and three of which contained over 
1000.19;75;78 Only one study did not report specific antiepileptic drug monotherapy 
risks,78 but of those which did, carbamazepine was generally the most popular and 
numbers varied from 74 to 302.5;19 One study examined exposure to one 
antiepileptic, lamotrigine.19 The conference abstract on the UK Epilepsy and 
Pregnancy Register did not quote the number of children exposed sizes, but made 
pair-wise comparisons of antiepileptic drugs and reported the relative risks.75 Effects 
of any monotherapy were reported in three studies5;75;77 and effects of polytherapy 
in four studies.5;75;77;78 Children born to women with untreated epilepsy was used as 
a comparison group in four studies,5;19;77;78 and numbers ranged from 46 to 1900.5;78  
 
Major congenital malformations were the measured in four out of the five studies. 
One study specifically sought cardiac malformations.77 The exact definition of major 
congenital malformations was not given in one study.19 In those which did provide a 
definition, the threshold for time since birth in which a major congenital malformation 
was defined varied between six weeks and a year for most studies, and in one study 
major congenital malformations could be identified at any point in the follow-up 
period of six years.5 Categories of major congenital malformations were described 
in two studies.5;78  
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Spontaneous abortions were noted in three studies,19;77;78 and stillbirths in two 
studies.77;78 Results from prenatal scans performed after enrolment was reported in 
two studies.5;78  
 
Descriptive summaries of studies from AAN review and updated literature 
search 
The following sections describe the studies which make each of the eight 
comparisons of interest. Results from the published review were collated with those 
found in the updated search of the literature to give an overall view of the current 
literature. Table 3 lists all studies in each section along with their characteristics.  
 
1) Any antiepileptic drug monotherapy versus no antiepileptic drugs in 
women with epilepsy 
Summary of AAN findings 
Three studies reported on the risk of major congenital malformations associated with 
exposure to any monotherapy in comparison with children born to women with 
epilepsy who were not taking antiepileptic drugs during the first trimester.  
 
In 2001, Holmes et al conducted a study in the U.S across five maternity units where 
women were recruited during labour or delivery.4 A total of 128,049 pregnant women 
were screened for inclusion and 386 women were found to have taken antiepileptic 
drug monotherapy during pregnancy and 98 women who had taken none but had a 
history of seizures. Only 223 monotherapy exposed children and all 98 unexposed 
children were eventually included in the analysis. The primary outcome was a pattern 
of antiepileptic drug related embryopathy which included major malformations, 
hypoplasia of the mid face and fingers, microcephaly and small body size and was 
determined blindly by a physician, although it is not described when after birth the 
examination took place. Questionnaires were used to collect data retrospectively on 
exposure and possible confounders. In their study, the authors reported 10 of 223 
(4.5%) monotherapy exposed children and none of the 98 unexposed had a major 
congenital malformation. From this, the authors of the AAN review derived an 
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unadjusted odds ratio (OR) of 4.40 (95% confidence interval (CI) 1.29-11.90) 
showing a possible increased risk of major congenital malformations in the 
monotherapy exposed group of children.  
 
However, two studies did not support this finding. A retrospective study of a Finnish 
population was conducted by Artama et al using medical records held in the Medical 
Birth Register and prescription reimbursement records.11 In Finland, everyone is 
entitled to reimbursement from prescriptions, and those with epilepsy are entitled to 
a full reimbursement provided they hold a medical certificate from the neurologist, 
which shows that the person has been clinically diagnosed.  A total of 6,535 women 
with epilepsy taking antiepileptic drugs were identified from this population between 
1985 and 1994 and their records linked with birth data to further identify 2,350 
children born between 1991 and 2000. Information on first trimester exposure to 
antiepileptic drugs was taken from hospital data and malformations classified 
according to the International Classification of Diseases (version 9). Minor and major 
congenital malformations were pooled into one group due to lack of detail in the 
medical records. Of 857 women with first trimester antiepileptic drug exposure, 1,411 
babies were born and of 561 untreated women with epilepsy, 939 babies were born. 
Of 1,231 children who were exposed to antiepileptic drug monotherapy, most had 
been exposed to carbamazepine (n = 805) and sodium valproate (n = 263). Amongst 
all children in the study, malformations of the cardiovascular system, cleft lip and 
palate and malformations of the genital organs were commonly featured. In total, 52 
of 1,231 (4.2%) exposed children, and 26 of 939 (2.8%) unexposed children were 
found to have either minor or major congenital malformations. The adjusted OR was 
1.55 (95% CI 0.94-2.60) deeming the results to show no evidence of an association 
between antiepileptic drug monotherapy exposure and congenital malformations. 
Morrow et al had similar findings in their prospective study of women enrolled in the 
UK and Ireland Epilepsy and Pregnancy Register.17 Here, women were referred to 
the register by health care professionals and information was collected at registration 
from the women themselves as well as the referee. Women were eligible if the 
outcome of pregnancy was not known. Information on major congenital 
malformations and pregnancy details and outcomes was requested by questionnaire 
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three months after expected date of delivery from the woman’s general practitioner 
as well as any other health care professionals identified during the woman’s 
pregnancy. Major congenital malformations were limited to those present at birth or 
discovered within six weeks of birth. Overall, 2,598 births were exposed to 
antiepileptic drug monotherapy, and 227 unexposed in women with epilepsy. 
Carbamazepine (n = 900) and sodium valproate (n = 715) were the most common 
monotherapies and some newer antiepileptic drugs were also present including 
lamotrigine (n = 647) and gabapentin (n = 31). In total, eight children (3.5%) in the 
unexposed group and 91 children (3.5%) in the exposed group were born with major 
congenital malformations, which is equivalent to an OR of 1.03 (95% CI 0.49-2.17) 
after adjusting.   
 
Updated search 
No further studies were found which compared these two groups. However, two 
studies reported the outcome in exposed and unexposed groups, but no OR or 
relative risk (RR) was provided by the article, I therefore calculated unadjusted ORs 
for the purposes of this review. Mawer et al of the Liverpool and Manchester 
Neurodevelopment Group (LMNDG) studied major congenital malformations in the 
children of women enrolled in their prospective study of women with epilepsy.5 The 
outcome here was major congenital malformations identified at any point in the six 
years of follow-up and were classified between major and minor using the 
EUROCAT definitions. EUROCAT is a European surveillance system of congenital 
anomalies collecting data from 43 countries on approximately 30% of all cases 
(http://www.eurocat-network.eu/).  In this study, 185 babies were exposed to 
antiepileptic drug monotherapy in utero, most commonly to carbamazepine and 
sodium valproate as well as 40 children with lamotrigine monotherapy exposure. 
Forty six children were unexposed to antiepileptic drugs and were born to mothers 
with epilepsy. Only one (2.2%) unexposed child and 10 (5.4%) exposed children had 
a major congenital malformation, equivalent to an unadjusted OR of 2.57 (95% CI 
0.32-20.6) indicating no difference between the two groups. In support of this, a 
study from the Kerala Registry of Epilepsy and Pregnancy, Thomas et al studied the 
presence of cardiac malformations in children born to mothers with epilepsy.77 Of 
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462 babies born to women with epilepsy, 262 were exposed to monotherapy, whilst 
75 were not exposed. Three months after birth, babies were examined blindly by a 
cardiologist for cardiac malformations. No ORs were reported but 8.0% of the 
unexposed children and 6.5% of monotherapy exposed children had cardiac 
malformations, equivalent to an unadjusted OR of 0.80 (95% CI 0.30-2.10).  
 
Section summary 
The results are conflicting. Although four out of five studies suggest no increase in 
risk of major congenital malformations associated with antiepileptic drug 
monotherapy but one study reports a four-fold increase in risk. One of the studies 
which found no difference pooled together minor and major malformations, which 
may have biased the results. The studies were not entirely comparable given the 
definition of outcome, composition of different antiepileptic drugs in the monotherapy 
group and lack of adjusting for confounders, therefore one cannot conclude 
antiepileptic drug monotherapy leads to higher rates of major congenital 
malformations compared to no use of antiepileptic drugs in the first trimester of 
pregnancy.  
 
2) Any antiepileptic drug  polytherapy versus no antiepileptic drugs in 
women with epilepsy 
Summary of AAN findings 
The three studies which examined monotherapy in the last section, also examined 
polytherapy exposure in comparison with no antiepileptic drug exposure in children 
born to women with epilepsy.  
 
Holmes et al examined 93 babies born to women receiving polytherapy in pregnancy 
and found eight (8.6%) to have major congenital malformations but none in the 
unexposed group - the authors of the AAN review calculated an unadjusted OR of 
8.34 (2.05-34.64).4 In support, the study by Artama et al, there were 180 babies with 
polytherapy exposure, the majority of which had been exposed to carbamazepine (n 
= 114) and sodium valproate (n = 98).11 Of these, 13 (7.2%) babies were born with 
minor or major congenital malformations giving an adjusted OR of 2.73 (95% CI 
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1.26-5.64) compared to babies unexposed to antiepileptic drugs of mothers with 
epilepsy. Notably, the subset of the exposed group whose mothers were receiving 
polytherapy excluding sodium valproate, the OR compared to unexposed babies fell 
to 1.80 (95% CI 0.45-5.38) indicating no increased risk of minor or major congenital 
malformations. Morrow et al also found that polytherapy excluding sodium valproate 
did not lead to an increase in risk of major congenital malformations (OR 1.10, 95% 
CI 0.48-2.52) however they also found this true for polytherapy in general.17 Amongst 
718 babies exposed to polytherapy, 43 (6.0%) were identified as having major 
congenital malformations and after adjusting for maternal age, parity, family history 
of major congenital malformations, periconceptional folic acid exposure and sex of 
baby, there was no evidence of a difference in the two groups (OR 1.76, 95% CI 
0.80-3.86).17 However, they did find that polytherapy including sodium valproate 
increased the risk two-fold compared to no therapy (OR 2.52, 95% CI 1.17-5.44).17  
 
Updated search 
No studies were identified which compared the two groups, however three studies 
reported the rate of major congenital malformations for both groups, and ORs were 
calculated for the purposes of this review. Mawer et al found 4 out of 46 children with 
polytherapy exposure to have major congenital malformations, and sodium valproate 
was included in the polytherapy regimen for the mothers of each of the four children.5 
One child of the 46 unexposed children had a major congenital malformation, and 
the rates of major congenital malformations were no different (unadjusted OR 4.29, 
95% CI 0.46-39.9). Similarly, Thomas et al of the Kerala  Registry of Epilepsy and 
Pregnancy found comparable rates of major congenital malformations in had 125 
children with polytherapy exposure, of which 10.4% had cardiac malformations 
compared to 8.0% in 75 unexposed children (unadjusted OR 1.33, 95% CI 0.48-
3.67).77 Slightly lower absolute rates were observed by Veiby et al in their study of 
Norwegian births, however, they found significantly higher risks in the polytherapy 
exposed children.78 This study used data from the Medical Birth Registry where 
details on pregnancy, including medication, are collected at delivery for entry into the 
register. All births at 12 weeks gestation or more were entered into the register in 
Norway, and information on congenital malformations was collected within a year of 
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birth. Between 1998 and 2005, 2,861 children were born to women with epilepsy. In 
contrast to other studies, here the majority of women were untreated (n = 1,900) but 
135 were receiving polytherapy. Major congenital malformations were found in 8 
(6.1%) of exposed children and in 49 (2.6%) of unexposed children indicating a two-
fold increase in risk (unadjusted OR 2.38, 95% CI 1.10-5.13).  
 
Section summary 
Although three studies show some evidence of a difference in rates of major 
congenital malformations between babies with and without polytherapy exposure, 
the largest study which also captured the effects of confounders, did not find a 
difference. There is a suggestion that polytherapy without sodium valproate may not 
increase the risk of major congenital malformations but that polytherapy with sodium 
valproate does. The balance of different polytherapy regimens will vary between 
studies therefore comparability of these studies may be questionable.  
 
3) Carbamazepine monotherapy versus no antiepileptic drugs in women 
with epilepsy   
Summary of AAN review 
Two studies were found described in the AAN review. Holmes et al found three out 
of 58 children (5.2%) with carbamazepine monotherapy exposure had major 
congenital malformations and found this rate to be no different to that amongst the 
unexposed children (0/98 children with outcome).4 Similar conclusions were made 
in the study of the Australian Pregnancy Registry cohort by Vajda et al.18 This is an 
ongoing registry which enrols women prospectively before the outcome of birth is 
known, as well as retrospectively after the birth. The purpose of the registry is to 
determine the incidence of adverse pregnancy outcomes in women with treated and 
untreated epilepsy and in women who are treated with antiepileptic drugs for non-
epileptic conditions.80 Women enrolled are interviewed by telephone up to four times 
between first trimester and a year after delivery to obtain details on medication, 
pregnancy, and birth outcome. To support the interview data, their medical records 
are also obtained from health care professionals. At the time of the study, 630 
pregnant women had enrolled and 565 had known pregnancy outcomes. There were 
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40 births to untreated epileptic women and 155 births to women who received 
carbamazepine monotherapy in the first trimester. One (2.5%) unexposed baby and 
six (3.8%) exposed babies were identified with major congenital malformations, and 
no difference in rates of major congenital malformations was detected.  
 
Updated search 
Only one study since 2007 has been identified. This is a later follow up on the 
Australian Pregnancy Registry from the 2006 study, hence there is some overlap of 
women and children. 18 By 2010, Vajda et al had recruited over 1000 women to their 
registry, with 302 babies exposed to carbamazepine monotherapy and 118 with no 
antiepileptic drug exposure.19 They reported major congenital malformations using 
two definitions - within one month of birth and within one year. Using the first 
definition, a major congenital malformation had to be detected within a month of the 
child being born. There were four unexposed and eight exposed babies diagnosed 
with a major congenital malformations by one month. The second definition captured 
major congenital malformations up to one year after birth. The total number in the 
exposed group increased to 16, giving an unadjusted OR of 1.59 (95% CI 0.52-4.97) 
indicating no difference.  
 
Section summary 
Only three studies are presented here which examine major congenital 
malformations rates in carbamazepine monotherapy exposed children and in 
unexposed children, two studies with overlapping populations. The results are 
consistent and suggest that carbamazepine monotherapy exposure does not 
increase the risk of major congenital malformations, however the overlap in these 
studies, lack of control for confounders and few studies in number prohibit a definitive 
conclusion.  
 
4) Sodium valproate monotherapy versus no antiepileptic drug use in 
women with epilepsy 
Summary of AAN findings 
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Of the studies included in the AAN review, there were two studies which compared 
major congenital malformations in babies exposed to sodium valproate monotherapy 
in the first trimester with those with no antiepileptic drug exposure born to women 
with epilepsy. 
 
Artama et al found 28 babies with minor and major congenital malformations 
amongst the offspring of 263 women who were taking sodium valproate in the first 
trimester of pregnancy, and in comparison with 26 out of 939 babies not exposed to 
antiepileptic drugs, the chances of minor and major congenital malformations in the 
exposed group was four times that in the unexposed group (OR 4.01, 95% CI 2.32-
7.01)11.  After adjusting for maternal age and number of previous births, the risk 
estimates were unaffected. Vajda et al showed some support for this finding.18 In the 
exposed group, 19 out of 113 babies (16.8%) were born with major congenital 
malformations. The incidence rate was significantly higher than in the unexposed 
group, where one in 40 (2.5%) was born with a major congenital malformation.  
 
Updated search 
Only the follow up study of the Australian Pregnancy registry was identified in our 
updated search. This later study by Vajda et al reinforced their findings in the earlier 
study described above - 34 out of 224 (15.1%) exposed babies had a major 
congenital malformation within a year of birth, which equated to a five-fold increase 
in risk compared to babies with no antiepileptic drug exposure (OR 4.99, 1.73-
14.44).19 
 
Section summary 
The three studies suggest that there is higher risk of major congenital malformations 
in sodium valproate monotherapy exposed babies, and that the rate is around four 
or five times higher when compared to unexposed children. Bearing in mind that two 
of these studies overlap, one of which did not quantify the magnitude of the 
increased risk and both studies did not account for confounding, further studies 
would still be needed to further evaluate these findings. 
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5) Lamotrigine monotherapy versus no antiepileptic drug use in women 
with epilepsy 
Summary of AAN findings 
The AAN review only found one study comparing these two groups. In the UK 
Epilepsy and Pregnancy Register study by Morrow et al, 647 babies with lamotrigine 
monotherapy exposure, 21 (3.2%) of which had major congenital malformations.17 
Eight out of 227 (3.5%) babies with no antiepileptic drug exposure had major 
congenital malformations and the AAN review authors derived an unadjusted RR of 
0.92 (95% CI 0.41-2.05) indicating no difference in the rate of major congenital 
malformations between the two groups.   
 
Updated search 
A study of the Australian Pregnancy Registry focussed on lamotrigine monotherapy, 
comparing it with other antiepileptic drugs as well as no antiepileptic use in 
pregnancy19 Of 243 babies exposed to lamotrigine and 12 (4.9%) had major 
congenital malformations present within a year of birth. Compared with the 
unexposed group (3.4%, n = 4/118) this resulted in an unadjusted OR of 1.48 (95% 
CI 0.47-4.69) 
 
Section summary 
Both studies suggest that lamotrigine monotherapy does not pose any greater risk 
of major congenital malformations than no antiepileptic drug therapy. Although both 
studies agree, and both have reasonably large sample sizes, more studies are 
needed to verify the findings.  
 
6) Carbamazepine monotherapy versus sodium valproate monotherapy 
Summary of AAN review 
There were four studies which compared major congenital malformations in children 
with carbamazepine monotherapy exposure and those with sodium valproate 
monotherapy exposure. 
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Morrow et al found sodium valproate monotherapy exposure was associated with 
three-fold increase in risk of major congenital malformations compared to 
carbamazepine monotherapy (OR 2.97, 95% CI 1.65-5.35) after adjusting for 
maternal age, parity, family history of major congenital malformations, 
periconceptional folic acid use and sex of baby.17 Vajda et al found 19 in 113 (16.8%) 
babies with sodium valproate exposure, and 6 in 155 (3.9%) babies with 
carbamazepine monotherapy exposure to have major congenital malformations.18 
The AAN review authors derived an unadjusted RR of 4.34 (1.79-10.53). A 
population-based study of medical records in Sweden was conducted by Wide et al, 
comparing carbamazepine and sodium valproate.20 The Swedish Medical Birth 
Registry was used to identify children born between 1995 and 2001 whose mothers 
had reported antiepileptic drug use in pregnancy. Information on major congenital 
malformations was obtained from the birth registry and from the linked Swedish 
Register of Congenital Malformations. A total of 1398 children were exposed to 
antiepileptic drugs during early pregnancy, of which 268 exposed to sodium 
valproate monotherapy and 703 to carbamazepine monotherapy. Amongst those in 
the sodium valproate group, 26 (9.7%) had major congenital malformations whilst 28 
(4.0%) children in the carbamazepine group also had major congenital 
malformations, and this gave an adjusted OR of 2.51 (95% CI 1.43-4.86). The 
variables adjusted for were not given. Another study supported a greater risk 
associated with sodium valproate monotherapy exposure compared to 
carbamazepine monotherapy exposure.15 This was using data from the 
Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) investigation, which is a 
multicentre study with centres in the US and UK. The NEAD study was a prospective 
study enrolling women taking carbamazepine, sodium valproate, lamotrigine and 
phenytoin during the first trimester of pregnancy between 1999 and 2004.  The 
primary outcome of this study by Meador et al was serious adverse outcomes 
including foetal death and major congenital malformations.15 In 333 children, 110 
had carbamazepine monotherapy exposure and 69 with sodium valproate exposure. 
Five (4.5%) children in the carbamazepine group and four (5.8%) in the sodium 
valproate group had major congenital malformations and the AAN review authors 
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derived a RR of 3.83 (95% CI 1.41-10.39) indicating a higher rate of major congenital 
malformations in sodium valproate exposed children.  
 
Updated search 
Only one article was found which compared sodium valproate monotherapy with 
carbamazepine monotherapy, and that was an update on data from the UK Epilepsy 
and Pregnancy Register, presented in a conference abstract and hence details are 
limited.75 Data were captured up to 2009 which gave rise to 5,802 pregnancies of 
which 5,376 were treated with antiepileptic drugs during pregnancy.  The numbers 
in each exposure group are not given, but the relative risk of major congenital 
malformations in sodium valproate exposed babies compared to carbamazepine 
exposed babies was 2.35 (95% CI 1.57-3.57).   
 
Section summary 
There were in total five studies of four independent cohorts which compared major 
congenital malformation rates in sodium valproate exposed children with 
carbamazepine exposed children.  Two studies accounted for confounding variables 
and both found a two- to three-fold increase in major congenital malformation rates 
amongst children in the sodium valproate exposed children. The cohorts from the 
NEAD study and the Australian Pregnancy Registry found an increase of around four 
times associated with sodium valproate exposure compared to carbamazepine 
exposure, however both of these studies had much smaller samples and did not 
account for confounding. Findings from Kennedy et al reflect those from their earlier 
UK Epilepsy and Pregnancy Register study by Morrow et al, but have greater 
precision likely from an increase in numbers.17;75 Overall, the study findings indicate 
a higher risk associated with sodium valproate monotherapy compared to 
carbamazepine monotherapy.  
 
7) Carbamazepine monotherapy versus lamotrigine monotherapy 
Summary of AAN findings 
The AAN review does not cover the comparison between carbamazepine and 
lamotrigine, however one study in their review contained relevant details. Morrow et 
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al compared 647 babies with lamotrigine monotherapy exposure and 900 babies 
with carbamazepine monotherapy exposure and found 21 (3.2%) and 20 (2.2%) 
babies had major congenital malformations in the lamotrigine and carbamazepine 
group, respectively.17 They concluded no difference in rates of major congenital 
malformations between the two antiepileptic drugs groups (adjusted OR 1.71, 95% 
CI 0.88-3.32). 
 
Updated search 
My updated search found no studies making this comparison.  
 
Section summary 
Based on one study, we cannot be certain on the risk of lamotrigine monotherapy 
relative to carbamazepine monotherapy.  
 
8) Sodium valproate monotherapy versus lamotrigine monotherapy 
Summary of AAN findings 
Studies from the Australian Pregnancy Registry and the UK/US NEAD cohort 
compared major congenital malformations in children with sodium valproate 
monotherapy exposure to those with lamotrigine monotherapy exposure. In the 
study by Vajda et al, 19 in 113 babies (16.8%) with sodium valproate monotherapy 
exposure had major congenital malformations recorded, whilst none of the 61 
children with lamotrigine monotherapy exposure had major congenital 
malformations.18 The AAN review authors derived an unadjusted RR if 5.58 (95% CI 
2.06-15.09). Meador et al of the NEAD study found 12 out of 69 children (17.9%) 
with sodium valproate monotherapy exposure had major congenital malformations 
and one child had major congenital malformations out of 98 children (1.0%) with 
lamotrigine monotherapy exposure, giving a much higher RR of 17.04 (95% CI 2.27-
128.05).15 
 
Updated search 
The only article which reported results examining this area was the previously 
mentioned conference abstract by Kennedy et al of the UK Epilepsy and Pregnancy 
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Register.75 As mentioned before, the number of children in each antiepileptic drug 
group is not given, but they reported the RR of major congenital malformations in 
sodium valproate monotherapy exposed children compared to lamotrigine 
monotherapy exposed children was 2.40 (95% CI 1.57-3.68).  
 
Section summary 
There was a general consensus in that sodium valproate monotherapy is associated 
with a greater risk of major congenital malformations compared to lamotrigine 
monotherapy. However, the three studies disagree on the magnitude of increase in 
risk, and the confidence intervals suggest a lack of precision in the estimates except 
in the work by Kennedy et al.75 Further large studies need to be conducted to clarify 
the increase in risk.  
 
1.5.3. Discussion  
Summary 
There are 11 studies presented here which stem from nine independent cohorts. 
Unfortunately, not all 11 studies make the same comparison resulting in only three 
studies, on average, to draw conclusions for each comparison. The comparison 
between carbamazepine and sodium valproate monotherapy was conducted across 
the most studies, five studies in total. The conclusions made are limited by the small 
number of studies. Nevertheless, their strengths along with the weaknesses of these 
studies, should be borne in mind in interpreting the conclusions set out at the end of 
this section. 
 
Strengths & limitations 
Size 
The total number of children was over 200 in every study and there were over 1000 
antiepileptic drug exposed children in six studies. Even when specific monotherapies 
were examined, the number was mostly greater than 100. The largest study used 
data from the UK Epilepsy and Pregnancy Register.17 This was a good quality study 
with the highest number of foetuses exposed to specific monotherapies – 900 births 
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were exposed to carbamazepine, 715 to sodium valproate exposure and 647 to 
lamotrigine. The smallest numbers arose from the NEAD cohort in the study by 
Meador et al where around 100 babies were examined in each antiepileptic drug 
monotherapy group.15  
 
Setting 
Most studies were based on data from pregnancy registries, few from medical 
records, one from antenatal clinics and one from epilepsy clinics. Only one study 
was population based – Wide et al performed their study using data from the 
Swedish Medical Birth Register where it is compulsory for health care providers to 
submit data on deliveries, therefore capturing most of the population.20 Pregnancy 
registries on the other hand, have large numbers but are not necessarily 
representative of the population.  Self-enrolled or women who are referred may have 
been enrolled on the register because they have a prenatal diagnosis of a 
malformation, or they have reason to believe that their risk is high – for example, if 
previous pregnancies have been affected. In a similar manner, women from epilepsy 
clinics are not likely to be representative of the population as they may be those who 
suffer more severely from epilepsy compared to those whose conditions are 
controlled.  
 
Ascertainment of exposure 
The details on the type and timing of antiepileptic drug medication was mostly gained 
through interviews conducted in retrospect. Information gained in this way is biased 
because it depends on accurate recall – important in these studies for first trimester 
exposure to be attributed to major congenital malformations. Some studies also used 
medical records or contacted the woman’s health care professionals to support the 
details given in interview. However the accuracy of medical records also depends 
on the quality of recording. Furthermore, adherence to prescribed medication was 
rarely described – this may have been obtained through interviews but is unlikely to 
be ascertained in medical records. 
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Exposure definition 
The most conflicting results were amongst studies comparing any monotherapy and 
any polytherapy with no antiepileptic drug exposure. One study may have included 
mainly carbamazepine monotherapy exposed children in their “any” monotherapy 
group, whereas another may be dominated by a different drug e.g. sodium valproate. 
In the study by Holmes et al phenytoin was the common monotherapy, whereas in 
the study by Morrow et al the most common drug was carbamazepine, and this study 
was the only one to include newer antiepileptic drug lamotrigine.4;17 These two 
studies differed in their conclusions. Similarly with polytherapy, there is a suggestion 
that polytherapy with sodium valproate is associated with a higher risk of major 
congenital malformations – therefore risk of major congenital malformations in a 
group of “any” polytherapy exposure may depend on the presence of sodium 
valproate amongst the polytherapy regimens. Some studies analysed polytherapy 
with sodium valproate separately from polytherapy without sodium valproate, but to 
fully account for differing regimens, specific antiepileptic drug combinations should 
be examined.  
 
Outcome definition 
The primary outcome in almost all of these studies was major congenital 
malformations. One study pooled minor and major malformations, another included 
foetal death with major congenital malformations to create a composite outcome.15 
The latter study provided a breakdown so I was able to obtain results only for major 
congenital malformations, however the former study by Artama et al highlights one 
of the difficulties with using medical records in that it can be difficult to distinguish 
between minor and major malformations without a clinical review of the case.11  
 
The time limit for detecting major congenital malformations varied, and in some 
studies not specified. The longest was throughout an entire follow-up period of six 
years. The shortest was five days. In one study, major congenital malformations 
were counted twice - those recorded within one month of birth and  those within one 
year and in some cases, the number of children with major congenital malformations 
was doubled by extending time to one year.19 There is not a general consensus on 
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when a major congenital malformation should be detected, but this study shows that 
some may be missed if the cut-off is too short, hence the absolute risks would be 
underestimated.  
 
Where possible, studies have excluded women who have had prenatal scans 
showing evidence of malformations because these women could be more likely to 
participate in a study if they think they will receive more monitoring and care during 
pregnancy. However, this does exclude an important group of women – major 
congenital malformations can be detected early in pregnancy through such scans, 
some will not survive and some may be terminated. These may even be the most 
severe cases that will not be counted in these studies. Ideally, women should be 
enrolled into a study before any prenatal scans have taken place and all major 
congenital malformations detected through scans should be recorded.  
 
Birth outcome 
Similarly, all birth outcomes would ideally be known. Live births are generally a 
convenience sample since it is difficult to obtain data on some non-live births, 
particularly terminations. Some studies included pregnancies which had not ended 
in live birth, however little information was known on whether or not those babies 
suffered from malformations. This information is understandably difficult to gain, and 
impossible if no prenatal scans have been performed.  
 
Confounders 
Almost all studies collected data on potential confounders. However, only three 
studies adjusted for confounding. Even if the others  had done so, they  did not state 
this in their results 11;17;20 For some studies, the comparisons made in this current 
review were not the primary comparisons of the study hence confounding was 
neglected and although the AAN review authors derived some of the risk rates, they 
were unable to calculate adjusted risks. Potential confounding should be accounted 
for in observational studies because the exposed and unexposed groups are likely 
to unbalanced by factors which are related to the exposure and the outcome.  
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General findings 
One of the major conclusions drawn from this review is that on carbamazepine 
monotherapy versus sodium valproate monotherapy. The review suggest that there 
is a higher risk of major congenital malformations in babies born to women receiving 
sodium valproate monotherapy in the first trimester compared to those receiving 
carbamazepine monotherapy. The size of the increased risk not as clear from these 
studies but may be somewhere between two and five times.  
 
Sodium valproate monotherapy possibly also increases the risk of major congenital 
malformations in comparison to lamotrigine monotherapy and in comparison with no 
antiepileptic drug exposure in the first trimester.  
 
Carbamazepine and lamotrigine monotherapy possibly do not increase the risks of 
major congenital malformations compared to no antiepileptic drug treatment in the 
first trimester of pregnancy. 
 
No firm conclusions can be made with regards to major congenital malformation risks 
amongst any monotherapy or any polytherapy.  
 
These conclusions are limited by the few good quality controlled studies which 
examine major congenital malformations and antiepileptic drug exposure in 
pregnancy. Treatment decisions in pregnancy can have major consequences for the 
woman and her child therefore, in my view, recommendations and advice should be 
given based on large, well conducted studies which consistently agree in their 
findings. In this area, there is a need for more studies in general, but studies need 
to be large, preferably prospective and with accurate recording of medication details 
and major congenital malformations need to be well defined and diagnosed. Risk 
estimates for specific monotherapy and polytherapy regimens are more useful than 
broad groups of exposure such as “any” monotherapy. There is also an urgent need 
for studies examining newer antiepileptic drugs – lamotrigine is fast becoming a 
popular treatment, therefore its effect in pregnancy must be established. Ideally we 
should know about major congenital malformations which are detected at any stage 
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in pregnancy regardless of birth outcome, and it may be beneficial to extend the 
period of follow-up after birth to capture major congenital malformations not detected 
in the early months of life. Lastly, confounding variables should be considered in any 
observational study design, notably alcohol and tobacco use in pregnancy, maternal 
age and epilepsy type/severity.  
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Table 3 Summary of selected articles 
Authors Country Exposed Unexposed Outcome 
Comparisons with women with untreated epilepsy 
1) Any antiepileptic drug monotherapy  
Artama et al (2005) Finland 1231 939 All congenital malformations 
Holmes et al (2001) U.S 223 98 Major congenital malformations 
Morrow et al (2006) U.K 2598 227 Major congenital malformations 
Mawer et al (2010) U.K 185 46 Major congenital malformations 
Thomas et al (2008) India 262 75 Cardiac malformations 
2) Any antiepileptic drug polytherapy  
Artama et al (2005) Finland 180 939 All congenital malformations 
Holmes et al (2001) U.S 93 98 Major congenital malformations 
Morrow et al (2006) U.K 718 227 Major congenital malformations 
Mawer et al (2010) U.K 46 46 Major congenital malformations 
Thomas et al (2008) India 125 75 Cardiac malformations 
Veiby et al (2009) Norway 135 1900 Major congenital malformations 
3) Carbamazepine monotherapy 
Holmes et al (2001) U.S 58 98 Major congenital malformations 
Vajda et al (2006) Australia 155 40 Major congenital malformations 
Vajda et al (2010) Australia 302 118 Major congenital malformations 
4) Sodium valproate monotherapy 
Artama et al (2005) Finland 263 939 All congenital malformations 
Vajda et al (2006) Australia 113 40 Major congenital malformations 
Vajda et al (2010) Australia 224 118 Major congenital malformations 
5) Lamotrigine monotherapy 
Morrow et al (2006) U.K 647 227 Major congenital malformations 
Vajda et al (2010) Australia 243 118 Major congenital malformations 
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Authors Country Exposed Unexposed Outcome 
Comparisons between antiepileptic drug monotherapies 
6) Carbamazepine vs. sodium valproate 
Meador et al (2006) U.K & U.S 110 69 Major congenital malformations 
Morrow et al (2006) U.K 900 715 Major congenital malformations 
Vajda et al (2006) Australia 155 113 Major congenital malformations 
Wide et al (2004) Sweden 703 268 Major congenital malformations 
Kennedy et al (2010) U.K unspecified unspecified Major congenital malformations 
7) Carbamazepine vs. lamotrigine 
Morrow et al (2006) U.K 900 647 Major congenital malformations 
8) Sodium valproate vs. lamotrigine 
Meador et al (2006) U.K & U.S 69 98 Major congenital malformations 
Vajda et al (2006) Australia 113 61 Major congenital malformations 
Kennedy et al (2010) U.K unspecified unspecified Major congenital malformations 
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1.5. Summary 
The safety of drugs in pregnancy has been an ongoing concern since the 
thalidomide scandal highlighted the potential devastation that foetal exposure to 
maternal medications can cause. Antiepileptic drugs are teratogenic but some of 
the conditions for which they are prescribed are difficult to manage without drug 
treatment. Thus, a clearer understanding of the safety of antiepileptic drugs in 
pregnancy is much sought after. Decades of research have suggested increased 
risks associated with certain antiepileptic drugs – namely sodium valproate – but 
there are unknowns with respect to the magnitude of risk for different antiepileptic 
drug regimens. This paucity of knowledge was highlighted in the literature review 
which furthermore showed that there are only a handful of studies which have 
compared the risk between different antiepileptic drug treatments – information 
which clinicians can use to provide a quantitative framework around the advice 
given to women about the risks and benefits of antiepileptic drugs in pregnancy.  
 
The main research question in this thesis will focus on the relative risk of major 
congenital malformations associated with different antiepileptic drug regimens in 
pregnancy. This PhD study provides access to a large clinical database of 
routinely collected UK primary care data, known as The Health Improvement 
Network (THIN) which contains historical medical records for a large number of 
patients from 1994 onwards. In the forthcoming chapters, I describe why THIN is 
an ideal data source for this research by exploring the recording of information 
pertinent to conducting this research.  
 
1.6. The next chapter 
The limitations in the studies discussed in this chapter emphasise the difficulty in 
conducting drug safety in pregnancy studies. In the next chapter, an overview is 
given of the typical study design adopted in such studies explaining their 
strengths and limitations. The chosen data source for this research project is then 
introduced and described in the context of these relative strengths and 
weaknesses to demonstrate the appropriateness of THIN data for this study.  
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Chapter 2 
Methodological challenges of studying teratogenicity 
 
2.1. Aim of the chapter 
At the end of Chapter 1, several challenges in studying teratogenicity were raised 
through the literature review. In this Chapter, I give an overview of how the choice 
of study design and data source can overcome some of these challenges. More 
specific to this project, I describe examples of different data sources that have 
been used in the study of antiepileptic drugs in pregnancy. This demonstrates the 
variety of sources of available and their relative strengths and weaknesses. This 
leads to an introduction of the data source chosen for this PhD which is The 
Health Improvement Network.  
 
2.2. Background 
Studies examining adverse effects of medication given in pregnancy are 
conducted post marketing i.e. after the drug has been licensed for use and is 
prescribed in the general population. In an ideal world, all side effects would be 
known prior to licensing, in the development stages of a drug. However, some 
side effects are rare and would require a very large group of volunteers to be 
involved in testing in order that the effect is observed in pre-clinical trials. 
Furthermore, if studying the side effects of drugs in pregnancy, one would need 
pregnant women to participate in clinical trials. The repercussions of the 
thalidomide disaster make it undesirable to involve pregnant women in clinical 
trials, from both the pharmaceutical and the woman’s point of view.  
 
Our knowledge of a drug’s teratogenic potential is therefore derived from animal 
studies and post marketing observational studies. Animal studies are commonly 
used to flag possible human teratogens; however, animal models are not 
perfectly representative of humans thus it is possible for humans to be affected 
but not animals. Reliance is therefore placed on observational studies to uncover 
drugs which may elevate the risk of major congenital malformations if taken in 
pregnancy. 
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2.3. Observational study designs 
The studies in Chapter 1 show that teratogenic effects are mostly examined after 
the drug has been marketed. These are observational studies – studies which 
examine populations of interest in their natural course without intervention from 
the researcher. The next section describes the commonly used observational 
study designs, particularly for investigating antiepileptic drugs in pregnancy. 
 
Cohort study 
In a cohort study, a group of people are observed either forwards (prospectively) 
or backwards (retrospectively) over time. The group are divided into natural sub 
groups according to their levels of exposure – e.g. whether or not they are on 
antiepileptic drug medication. The outcome is measured in each group, 
information on confounders collected and analysed using various methods. One 
major advantage of cohort studies is that they involve a population at risk of an 
outcome, and therefore incidence and prevalence rates of the outcome can be 
obtained and absolute risks can be estimated  
 
A cohort study design is useful when one wishes to examine multiple outcomes 
from a single exposure, particularly if the exposure is rare, and is therefore a 
common choice of design for newly marketed drugs since it may take some time 
for these drugs to become commonly prescribed.  
 
Case-control studies  
Case-control studies are retrospective studies examining a group of individuals 
with an outcome (i.e. cases) and a group of individuals without the outcome (i.e. 
controls) back in time, looking for differences in exposures. Particular situations 
lend themselves well to case-control studies - studying multiple exposures to a 
single outcome, rare outcomes and if there is an urgent need for a study – say in 
an outbreak situation – because there are a fixed number of cases made 
available at the beginning of the study. However, the total population at risk of an 
outcome is not available absolute risks cannot be obtained. Odds ratios are 
59 
 
instead reported which are a close estimate of the relative risk if the outcome is 
rare. 
 
Neither study design perfectly addresses all challenges in studying teratogenicity. 
Below, I outline some of the shortfalls of observational study designs.  
- Both designs are subject to confounding. Measured confounders can be 
accounted for, but unmeasured and unknown confounding is always an 
issue in any type of observational study. 
- Selection bias – where the study population is not representative of the 
general population – is potentially an issue for both designs but depends 
on the data source, which is discussed next. 
- Recall bias affects either study design, but is more commonly an issue in 
case-control studies. If information on exposure and risk factors is 
ascertained retrospectively after the outcome is known – the knowledge of 
the outcome may affect the level and/accuracy of recall.  
- Observer bias also affects studies if the observer expresses a differential 
effort to obtain data on exposure and risk factors depending on the 
outcome.  
These are only some of the major challenges – more are discussed in the next 
section on data sources. Table 4 summarises the main strengths and limitations 
associated with cohort and case-control studies.  
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Table 4 Advantages and disadvantages of study designs 
 Advantages Disadvantages 
C
o
h
o
rt
 d
e
s
ig
n
 
 
 Can examine multiple 
outcomes 
 Ideal for rare exposures  
 Wide range of risk estimates 
can be calculated 
 Prospective studies 
minimise recall bias 
 No additional selection of a 
control group as there is 
with case-control studies 
 
 Can be large, expensive 
and labour intensive 
 Loss to follow up can 
invalidate results 
 Open to selection bias 
 Open to recall bias if 
retrospective 
 Not ideal for rare outcomes 
 Prone to confounding 
 Open to exposure 
misclassification 
 Open to observer bias if 
retrospective 
C
a
s
e
-c
o
n
tr
o
l 
d
e
s
ig
n
 
 
 Can examine more than one 
exposure to a single 
outcome 
 Ideal for rare outcomes 
 Ideal for generating 
hypotheses for further larger 
studies 
 Ideal for urgent studies (e.g. 
outbreaks) 
 Ideal for delayed outcomes  
 
 Open to recall bias if 
information obtained 
through retrospective 
interviews or questionnaires 
 Can be difficult in selecting 
a control group 
 Estimates are limited to 
odds ratios  
 Prone to confounding 
 Open to exposure 
misclassification 
 Open to observer bias 
 Limited to one outcome 
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2.4. Observational sources of data 
The choice of study design can be informed by the available sources of data. In 
studies of medication safety in pregnancy, there are some common types of data 
sources used in research.  
 
2.4.1. Pregnancy registry 
A pregnancy registry is usually established to monitor adverse outcomes 
associated with the use of specific drugs, or a class of drugs, in pregnancy. 
Pregnant women are enrolled if they have a certain condition or are prescribed 
certain drugs in pregnancy. Data is generally on pregnancy, delivery and post-
natal states and events in the mother and baby. This is usually collected in a 
prospective manner throughout their pregnancy and for some length of time after 
the birth of the baby, depending on the outcome of interest (e.g. an interest in 
child development might necessitate years of follow up). The exact methods of 
data collection vary between registries but can involve telephone interviews, 
questionnaires and access to medical records. 
 
Registries can be established by any interested party (e.g. industry, academic 
research group, independent physician) though participation is always voluntary. 
It is sometimes made mandatory for the manufacturer of a new drug to establish 
a pregnancy registry as a “post–marketing requirement” or “commitment” - written 
agreements between the manufacturer and the regulatory agency made before 
or after marketing approval.  
 
Example: The UK and Ireland Epilepsy and Pregnancy Register  
 
As was evident from the literature review in Chapter 1, there are several epilepsy 
and pregnancy registries around the world. The prominent ones which have made 
major contributions to our understanding of the teratogenic effects of antiepileptic 
drugs include: 
- the International Registry for Antiepileptic Drugs in Pregnancy (EURAP), 
- the North American Antiepileptic Drugs in Pregnancy Registry, 
- the Australian Pregnancy Registry,  
- the UK and Ireland Epilepsy and Pregnancy Registry, and  
62 
 
- the Lamotrigine Pregnancy Registry.  
 
I describe in more detail the UK Epilepsy and Pregnancy Register which has 
published several studies in this area since its initiation. The UK arm of the UK 
Epilepsy and Pregnancy Register was first established in 1996 and was joined 
with the Irish Epilepsy and Pregnancy Register in 2007 to form the registry as it 
stands today.81 The aim is to observe which antiepileptic drugs are used in 
pregnancy and to determine their relative safety.81;82 Women are referred to the 
register by themselves or through a health care professional and included if they 
are pregnant with epilepsy regardless of whether or not they are taking 
antiepileptic drugs, and before the pregnancy outcome is known. They are 
excluded if: 
o prenatal tests have found any major congenital malformations, or 
o they did not take antiepileptic drugs in the first trimester but did take 
them in the subsequent trimesters.17 
 
Baseline and exposure information is collected from the referring source (i.e. the 
woman herself or the health care professional), medical records and liaison with 
other health care professionals. Outcome data is collected three months after the 
expected delivery date via a questionnaire to the woman’s general practitioner.17 
In August 2013, over 10,000 women had joined the register which is funded by 
UCB Pharma Ltd.17;82  
 
A recent study 
In January 2014, Campbell et al published recent findings from the UK Epilepsy 
and Pregnancy Register.81 They conducted a retrospective cohort study of 5,206 
pregnancies observed between 1996 and 2012, in which women took one of 
three monotherapies in the first trimester (sodium valproate (n = 1,290), 
carbamazepine (n = 1,718) or lamotrigine (n = 2,198)). The outcome of interest 
was a major congenital malformation which they defined as “an abnormality of an 
essential embryonic structure requiring significant treatment and present at birth 
or discovered in the first six weeks of life according to the definitions and list of 
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disorders in the EUROCAT *  registry.” The outcome was ascertained three 
months after birth using information gathered from health care professionals 
associated with the woman’s care. One of the study authors classified 
pregnancies according to outcomes as: 
- without congenital malformations,  
- with major malformations, or 
- with other malformations.  
The major malformation rate in each of the three antiepileptic drug exposed 
groups was compared to generate odds ratios. Logistic regression methods were 
used to account for a number of potential confounders. As a sub study, they also 
reported odds ratios comparing the rate of specific malformations between 
different exposures – for example, one of their findings was that neural tube 
defects and facial clefts were more likely in babies exposed to sodium valproate 
compared to carbamazepine. 
 
Strengths and weaknesses of pregnancy registries 
A large sample size is advantageous in studying teratogenicity due to the rare 
incidence of major congenital malformations. A larger sample is more likely detect 
moderate differences in risk of major congenital malformations between groups 
and may also allow confounding to be examined in more detail. Pregnancy 
registries have provided large samples – UK Epilepsy and Pregnancy Register is 
the largest national registry in the UK and in the latest study, analysed over 5,000 
pregnancies. This is a major strength, however, the downside is that for a 
condition such as epilepsy which affects around 1% of the UK population, it can 
take a long time to accumulate such numbers, which may have cost implications.  
 
Pregnancy registries are usually set up with a research question in mind. This 
means that risk factors of interest can be captured and measured appropriately 
for analysis unlike in administrative databases where analysis is limited to data 
                                            
 
 
* EUROCAT is a European surveillance system  of congenital anomalies collecting data from 43 
countries on approximately 30% of all cases of major congenital malformations 
(http://www.eurocat-network.eu/). 
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which has already been collected. Data is mostly captured prospectively if 
possible, though some registries will enrol patients in retrospect (and therefore 
ascertain some details after the event). Where this occurs, some registries 
acknowledge potential differences between prospectively and retrospectively 
enrolled women by presenting separate analyses.  
 
The main drawback of pregnancy registries is the potential for selection bias, 
although this limitation is not restricted to pregnancy registries. Firstly, women 
enrolled in a registry may be different from those who do not enrol. Secondly, if 
pregnancy losses are not collected, the registry may underestimate the rates of 
major congenital malformations as some, but not all losses may associated with 
these.  
 
2.4.2. Congenital malformation registry 
A congenital malformation registry collects data on the women whose babies are 
diagnosed with a major congenital malformation. Many countries have these 
registries for surveillance purposes so that, should there ever be another drug 
like thalidomide, these registers can provide valuable early signals. However, the 
breadth of information in these registries has meant that over time, they have also 
been used to inform planning of health services and conduct epidemiological 
studies to help understand the causes and consequences of major congenital 
malformations.83  
 
Notifications to a congenital malformations registry are either through self-
enrolment or from clinical sources including pathology labs, ultrasound labs and 
delivery suites. Notifications are made retrospectively after a pregnancy has 
ended and a major congenital malformation diagnosed, or when diagnosis has 
been made following a prenatal scan.  
 
Once a registry is notified of a case, further data can be collected from medical 
records and through questionnaires and interviews. The information collected is 
broader in terms of exposures compared to pregnancy registries because the 
goal is to identify potential teratogens (as opposed to pregnancy registries where 
the goal is to identify outcomes associated with specific drug exposure in 
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pregnancy). For comparisons, some registries also collect data on “healthy” 
babies - a group of unaffected babies to compare exposures against.  
 
National congenital malformation registries can also contribute to international 
collaborations, such as EUROCAT which collects data on congenital 
malformations from 43 registries in 23 countries. This pooled dataset greatly 
increases the size of studies conducted using this data, which for studying rare 
outcomes is a strong advantage. However, there is likely to be heterogeneity 
between different countries and possibly different registries which have to be 
considered in analyses.  
 
Example: Spanish Collaborative Study of Congenital Malformations 
(ECEMC) 
In antiepileptic drug research, congenital malformation registries have been less 
often used than pregnancy registries. However, congenital malformations 
registries have their strengths – described below is a case-control study from the 
Spanish Collaborative Study of Congenital Malformations (ECEMC) who have 
addressed some of the major issues usually associated with congenital 
malformations registries.  
 
Established in 1976, the ECEMC is a hospital based registry of congenital 
malformations across Spain. The objective of the registry is surveillance of 
congenital malformations in Spain and epidemiological research to understand 
the characteristics, clusters and causes of congenital malformations.73;84 The 
network involves over 400 paediatricians working in one of 80 participating 
hospitals.84 They are trained to follow strict methodology to examine new born 
babies within three days of birth and assess whether or not there are major or 
minor malformations. Control babies born without any congenital malformations 
are also recruited at this time by the same set of paediatricians. Once the status 
of a case is determined and data on the infant has been collected, the 
paediatrician interviews the mother using a predefined protocol to collect the 
same data from both the cases and the controls.  The data are then sent to and 
analysed by a separate, central co-ordinating group of experts in congenital 
defects epidemiology, clinical teratology, dysmorphology, clinical genetics and 
cytogenetics.73 They are responsible for performing diagnostic tests to confirm 
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the initial diagnosis made by the local paediatrician as well as conducting 
research studies. The registry captures between 20 and 25% of all births in 
Spain.84 
 
A recent study  
The ECEMC published a case-control study looking at a specific type of major 
congenital malformation – hypospadia – and its association with specific 
antiepileptic drug exposure – valproic acid (a form of sodium valproate) - in the 
first trimester.73   
 
Hypospadia is a rare malformation which affect males – it is the incorrect 
positioning of the opening of the urethral tube in the penis. According to 
EUROCAT, it is estimated to affect approximately 13 per 10,000 births in the UK 
http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. The 
ECEMC identified 2,393 babies with hypospadia (cases) and 12,465 males 
without (controls). Cases were initially identified by the paediatrician, and 
confirmed using other methods which include blood samples, photos, imaging 
studies and pathology reports. Controls were selected as the next male infant 
born in the same hospital but without any congenital malformations. Exposure 
information was ascertained via structured interview, gathering information on 
timing, dose, and type of drug use as well as risk factors information. Exposure 
was defined as use of valproic acid in the first trimester of pregnancy – an infant 
was unexposed if valproic acid was not taken in this time period. Odds ratios were 
calculated and conditional regression analysis used to control for confounders. 
The results of the study suggested a substantial increased risk of hypospadias.  
 
Strengths and weaknesses of congenital malformation registries 
One advantage which is made clear in this study is that congenital malformations 
registries can be ideal if one wishes to examine specific major congenital 
malformations. Hypospadias are one of the most common types of major 
congenital malformations, but are rare in the population. This study identified over 
2,000 cases – using a registry which is based on the outcome of an event, one is 
more likely to ascertain large numbers of outcomes.  
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The ECEMC also show how a congenital malformation registry can capture an 
internal control group of babies without major congenital malformations. Other 
congenital malformations studies have used external reference populations in 
order to make comparisons with a group of “healthy” controls. But these have 
questionable comparability since they are usually selected in a different setting 
or location and they are not assessed by the same paediatrician or other persons 
diagnosing major congenital malformations potentially introducing information 
bias.  
 
A strength specific to the ECEMC is that they have tried to reduce outcome 
misclassification by conducting diagnostic tests as well as training a paediatrician 
to use standardised methodology to diagnose the condition themselves.  
 
In general for congenital malformations registries, steps to reduce exposure 
misclassification should be taken since this is always information collected 
retrospectively. The use of medical records, although collated retrospectively, 
can offer a method which has a lower likelihood of misclassification if the records 
were made prospectively. However, women interviewed after the birth of their 
child, and after they join the registry, may report details of drug use in pregnancy 
differently depending on the whether or not their baby was affected i.e. recall bias 
may have been an issue.  
 
Congenital malformation registries are restrictive in that only case-control studies 
can be performed using their data. However, the ECEMC have shown how 
rigorous methodology can be used to conduct case-control studies that provide 
valuable observations. 
 
2.4.3. Population based birth registers 
National birth registers exist in a number of countries – they collect information 
on nearly all births in hospital and at home. Similar to congenital malformation 
registries, they were first established in the wake of the thalidomide disaster as a 
means of surveillance of major congenital malformations and other perinatal 
health problems, but are now commonly used for research purposes.  
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The registers collate information from medical records, antenatal forms and 
maternity wards and are usually notified to the registry by the midwife or other 
health care personnel as part of their duties. Data is collated retrospectively, but 
it is prospective in that the data was recorded before the outcome is likely to have 
been known (e.g. antenatal information is filled out on forms during antenatal 
visits prior to pregnancy outcome).  
 
Information is obtained on mothers and fathers, demographics, health of parents, 
health in pregnancy, complications in pregnancy and delivery and information on 
the baby including major congenital malformations and perinatal health 
problems.85 
 
Example: Danish Medical Birth Registry (DMBR) 
Described here is an example of a study from the Danish Medical Birth Registry 
(DMBR). Established in 1968, the DMBR was set up to monitor perinatal health 
and the quality of antenatal and delivery services in Denmark.86 All births in 
hospital and at home are recorded making the registry representative of the 
population. The information is made available to the registry via the midwife at 
the point of delivery, or by the doctor when the mother is discharged from hospital, 
using a standard form.87 The data is typical of other birth registries – 
demographics, reproductive history, health in pregnancy and delivery details,87 
along with a unique identifier which allows the registry information to linked across 
to other national registers.  
 
A recent study 
In 2011, Molgaard-Nielsen et al used data from the DMBR to examine first 
trimester use of newer antiepileptic drugs in relation to the risk of major congenital 
malformations. A retrospective cohort study was performed using 837,795 live 
births from 1996 to 2008. Births were linked to another national registry, the 
Registry of Medicinal Products Statistics, which provides information on all 
prescriptions in Danish pharmacies since 1994. Women prescribed antiepileptic 
drugs in the first trimester of pregnancy were defined as exposed. Further linkage 
was made to the National Patient Registry which contains individual level data on 
inpatient stays and outpatients visits at hospitals. This was used to identify cases 
of major congenital malformations, which were defined according to EUROCAT 
69 
 
guidelines and had to be recorded within a year since birth. Information on several 
confounding variables was obtained through linkage with other national registers. 
Odds ratios were calculated comparing the antiepileptic drug groups with a group 
of births for without antiepileptic drug exposure in the first trimester of pregnancy.  
 
Strengths and weaknesses of birth registers 
One of the main strengths of birth registries is that some countries are able to link 
their birth registry data to a number of other national registries – for example, 
hospital discharge data. This additional resource can be used to validate 
diagnoses, increase sample sizes and simply to provide additional factors of 
interest. The linkage to pharmacy data is major advantage since the details are 
an accurate copy of the filled prescription providing information on the type of 
drug, its strength and daily dose as well as providing a point in time which is a 
close proxy for when the dispensed drugs should have been consumed.  This is 
a more reliable source of pharmacological information than interviews with the 
mother who may be biased or may not remember all of the details correctly.  
 
However, questions have in the past been raised over the quality of the data from 
some birth registries.87 It has been suggested that there poorer accuracy if those 
inputting the data have little knowledge of how the data is used for research.87  
Usually, data is routinely entered by personnel who have no involvement in the 
secondary uses of the data, some seeing it as a burden.88 The lack of inclusion 
may lead to disinterest in the importance of accuracy of details. By involving the 
staff who routinely collect the data in research, a better quality of data is 
possible.88 
 
Selection bias can continue to be a challenge in birth registry data if there is a 
lack of information on non-live outcomes in pregnancies.  
 
2.4.4. Administrative databases  
These are databases which hold routinely collected health care data and whose 
primary purpose is administrative - not for research. However, the data are 
increasingly being used for research purposes primarily due to large sample sizes 
held in such databases, and the relatively faster speed at which studies can be 
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conducted compared to studies which involves data collection. They have been 
valuable for research into health service planning and monitoring, economic 
analyses as well as epidemiological research.89  I describe here two types of 
administrative databases – insurance claims databases and electronic medical 
records.  
Claims databases 
Claims databases provide a longitudinal record of billable health interactions with 
medical services and pharmacy. Information is collected by submission of claims 
from the care provider (e.g. hospital or pharmacy) to the insurer. Details can 
include information on diagnoses, operations, inpatient stays, the care provider, 
treating physician’s profile, and prescriptions. These databases are a popular 
choice for research studies in the United States since healthcare is not free but 
paid for through health insurance plans. Some are state funded, while others are 
private insurance plans paid for by individuals themselves or possibly employers 
who offer health insurance as employee benefits. This diversity in health plans 
means there are likely to be differences in the type of people enrolled in different 
health plans, and therefore the use of data from just one health plan may not 
reflect the population. For example, Medicaid is a government funded health plan 
in the U.S for those on low income, while Medicare is another government funded 
plan aimed specifically at those over 65 years of age – thus there are at least 
differences in age and wealth between the members of these two plans.  
 
Example of claims databases in the U.S. 
Described here is a recent study which used insurance claims data to study the 
specific relationship between topiramate, a newer antiepileptic drug, and the risk 
of oral clefts.90 This was a retrospective cohort study was carried out on 
pregnancies linked to a child who was born in the period 1997-2010. The data 
was collated from across four databases – three were insurance claims, the 
remainder was an electronic health record system. Two of the claims databases 
used in this study are derived from private health insurance claimants, whilst 
another used claims data from a government funded health insurance plan for 
people on low incomes (Medicaid). The remaining database contained the 
medical records of members who receive private health care through Kaiser 
Permanente Northern California health plan. Each of the data sources followed a 
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standardised protocol to collect the same information which was pooled and 
analysed centrally. However, the methods for identifying the study population 
varied with each data source, due to differences in the information captured on 
the linkage between a mother and baby.  
 
The authors compared the prevalence of oral clefts between three cohorts – 
women with first trimester topiramate use, women with any antiepileptic drug use 
prior to pregnancy but not during the first trimester or the four months before 
conception, and women with similar medical indications for topiramate to the first 
cohort but with no use of topiramate in the first trimester or four months prior to 
conception.  
 
The dates of the first trimester in this study were derived from the date of delivery, 
gestational age at birth and the number of babies born. Prescription claims and 
dispensing data was used to identify exposure, and timing of exposure, to 
topiramate. Oral clefts were searched for using diagnosis codes and those 
identified in the claims databases were further verified by two paediatricians, 
whilst those found in the medical records were assumed valid. To build a 
longitudinal medical profile of the cases, medical records of the cases found in 
the claims databases were requested and these claims were joined together to 
track the medical history of the mother and her pregnancy.   
 
Strengths and limitations of claims databases 
One of the strengths of claims databases, is that most offer accurate reporting of 
dispensing data – claims from pharmacies for reimbursements are generally 
accurate due to government audits which are regularly carried out to prevent 
fraudulent claims being made. 
 
Claims databases offer information on the health of a large number of individuals, 
but their data quality has been questionable in the past.89;91-94 Below I outline 
some of the criticisms. Diagnoses made in hospitals use the International 
Classification of Diseases (ICD) to code symptoms and diagnoses. For a claim, 
these ICD codes have to be translated to Diagnosis Related Group (DRG) codes. 
Hospitals have been known to use the DRG code which offers the highest 
financial reimbursement, rather the most clinically important.95 This highlights 
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another general weakness of administrative databases, in that they are not 
designed for specific research questions. A researcher is limited to the 
information which is available. In this study the authors requested medical 
records to supplement the information available from claims data, however even 
this combined administrative data may not provide all of the desired information.  
 
Further limitations to claims data include the need for extensive data cleaning, 
the need to understand recording behaviour (e.g. what does a missing smoking 
status mean? Is recording of certain information such as BMI only given if the 
claimant has a particular condition?) and therefore whether or not the claimant 
population is representative of the general population. 
 
Electronic medical records 
Electronic medical records provide a history of interactions with the healthcare 
system such as prescribing and diagnosis information, test results and referrals, 
as well as a demographic profile of the individuals held on the database. The aim 
of the database is to provide a complete picture of the health of an individual in 
order to promote the correct course of care for that individual.  
 
Described next is an example of an electronic medical records database, The 
Health Improvement Network (THIN). This is the data source which is used in the 
studies contained in this PhD, and here I provide details on the database itself as 
well as its strengths and weaknesses. 
 
2.5. The Health Improvement Network  
2.5.1. Background 
In the UK, primary care is the first point of contact for medical care (unless in an 
emergency situation). The general practitioner (GP) can conduct or order tests, 
prescribe drugs and provide some diagnoses, although many diagnoses may 
require confirmation from specialists. They also act as the gatekeeper to further 
specialist care – for example – if an individual presents with symptoms of epilepsy 
(e.g. recent seizures), the GP may refer the individual for further tests to be 
performed in a hospital setting (such as an EEG and MRI scan) and refer them 
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to a neurologist for specialised consultation.  Generally, a specialist can only be 
seen through a referral from primary care (the exception being through 
emergency care) and therefore primary care data should at least capture the 
initial consultation from which a referral was made. 
 
The Health Improvement Network (THIN) is one of the UK’s largest primary care 
databases. In 2014, the database contained information on over 12 million 
patients attending 587 practices (http://csdmruk.cegedim.com/). Data in THIN is 
collected through an interface (provided by Vision software) which is used by the 
GP practice to input medical information. When the data is collected out of the 
system every quarter, it is anonymised to protect patient confidentiality. The data 
are extracted, cleaned and then structured into tables ready for researchers to 
analyse. Updates on THIN data are available twice a year.  
 
Researchers receive THIN data in four main data blocks – patient, therapy, 
medical and additional health data (Figure 1) which collate information recorded 
during a patient’s visit to their GP as well as information received from other parts 
of the health system e.g. hospital discharge letters. This includes medical 
diagnoses and symptoms (based on the hierarchical Read code system),96;97  
additional health data on health measures, test results and immunisations, 
prescriptions, referrals to secondary care and free text information. It also 
includes demographic information such as the patient’s year of birth and sex, and 
a marker of social deprivation, the Townsend score. The Townsend score is a 
postcode based index of deprivation which uses information from the 2001 
Census. The score is based on the percentage of unemployment, overcrowded 
households, no car/van ownership and non-home owners.98;99 The THIN data 
files are linked by an anonymous patient identifier. The database also includes a 
family identifier as well as dates on registration, death and transfer to another 
practice. 
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Figure 1 THIN data structure (Redrawn from Source: CSD-EPIC Research Format THIN data (Version 
2.0), 2010) 
 
  
Data quality indicators have been created which help researchers determine 
when practices were providing good quality data. The Acceptable Mortality Rate 
(AMR) date was developed by Maguire et al in 2009 after it was observed in that 
data that some GP practices had low mortality rates indicating that mortality was 
not being adequately recorded.100 The AMR date measures the year in which the 
death rate in the practice was deemed acceptable in comparison with age/sex 
adjusted national rates. For research purposes, the use of data only from this 
date onwards removes under-reporting of deaths and other biases associated 
with record updating.100 A further measure was derived by Horsfall et al - the 
Acceptable Computer Usage (ACU) date which defines when the practice on 
average was entering at least two therapy records, one medical record and one 
additional health data record per patient per year.101 Both dates can be used to 
define a point in time from which good quality data is likely to have been recorded 
in a practice. 
 
Research studies using THIN data cover a broad range of conditions, drugs and 
epidemiology. Studies have included estimation of incidence rates such as for 
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pancreatic and biliary tract cancer, description of prescribing patterns such as 
mood stabiliser treatment in people with bipolar disorder, and studies of 
association such as serum bilirubin and the risk of respiratory disease and 
death.34;102-105 Other uses of THIN data have been in health care planning, 
assessment of current clinical practices, and for methodological research.106;107  
Outlined below are the general strengths of THIN data for research, and in 
balance to this, some of its limitations, which have to be borne in mind and 
addressed in any research study. As THIN is the data source chosen for use in 
this PhD, the further details of advantages and disadvantages specific to studying 
medication safety in pregnancy are covered in the next chapter which presents 
how THIN can be used to identify a mother-child cohort.  
 
2.5.2. Strengths of THIN data for research 
 
 Designed for research 
One of the major differences between THIN and insurance claims 
databases is that THIN is intended for use in clinical research, secondary 
to clinical management. Thus the data captured is designed to benefit and 
inform primary care research. Furthermore, the providers of THIN data are 
continually improving their data and consulting both GP practice users and 
researchers on how the system and the data can be improved to meet 
their needs.  
 
 Large sample size 
As mentioned, the database holds information for 12 million patients 
across the UK providing access to potentially large sample sizes for study.   
 
 Representative of general population 
All data are anonymised, and are broadly representative of the UK 
population in terms of sex, age, size of practice and geographic 
distribution.108 
 
 Prospective data collection 
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Studies of routinely collected data are retrospective however, more 
importantly, they use prospectively recorded data. This reduces the 
potential for recall bias whereby the level of exposure information recalled 
differs depending on whether or not an outcome occurred. 
  
 Real world clinical data 
The data is a reflection of clinical practice in the real world amongst a 
population of individuals who differ in all manners of their health and socio-
demographic factors. It reflects real GP behaviours which are also likely to 
differ but are a true representation of medical care in real time - a stark 
contrast to the regimented medical care recovered in clinical trials where 
participants are tended to at specific time points.   
 
2.5.3. Weaknesses of THIN data for research 
 
 Uncollected or poorly recorded information 
The main disadvantage in using a database of retrospectively collected 
routine data is that the data is not collected for a specific research study. 
Thus, there may be factors which are of interest to a study which are not 
collected, or are poorly measured. For example, there is limited 
information on severity the underlying conditions associated with 
prescribing of antiepileptic drugs.  
 
 Lack of information outside of primary care 
Despite the breadth of clinical information collected in THIN, any events 
such as prescriptions, diagnoses, inpatient stays, which happen outside of 
primary care may not be well-recorded although discharge letters are sent 
from hospitals to GPs. This depends on efficient communication of such 
information to primary care and further accurate input of relevant clinical 
details into the computer system.  
 
Electronic medical records databases are a powerful source of real world clinical 
data due to the large number of patients and wide breadth of clinical information 
contained in such databases.  THIN is an excellent example, and furthermore 
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shows how routinely collected electronic medical records can serve both as a 
clinical management system and for use in research.  
 
2.6. Summary 
Designing a study to examine the teratogenicity of drug is challenging. 
Randomised controlled trials are not a favourable design for concerns over the 
involvement of pregnant women and the study sample required to study rare 
outcomes, meaning that research must depend on observational studies. Despite 
having to address issues around bias, confounding, and access to relevant 
information, observational data has the capability to provide large samples of 
women taking drugs in pregnancy, as well a wide range of other health and 
clinical information. Every observational study has to consider the 
aforementioned issues and additionally other issues specific to the research 
question in mind. In this PhD, I will conduct a retrospective cohort study of 
pregnant women using data from The Health Improvement Network primary care 
database. Some of the reasons for this choice have been alluded to in the above 
section on the general merits of THIN. The next chapter expands on why THIN 
was chosen specifically for this study of pregnant women.  
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Chapter 3 
Using The Health Improvement Network to Identify a Mother – 
Child cohort 
 
3.1. Aim of chapter 
The previous chapter introduced the various data sources which can be used to 
study major congenital malformations and their association with in utero exposure 
to medication. The chapter concluded with the introduction of The Health 
Improvement Network (THIN) as the selected data source or this PhD. In this 
chapter, I discuss The Health Improvement Network in greater detail, with 
particular emphasis on how the data is used to create a cohort of pregnancies 
which can be linked to a child. Finally, a further review of THIN in terms of its 
strengths and limitations specific to this research study is given, justifying the 
decision to use this data source.  
 
3.2. Cohort of pregnancies in THIN 
In the UK, primary care is often the first point of contact for pregnant women for 
advice and referral to antenatal services.109 Thus, a large number of pregnancies 
are recorded in primary care databases such as THIN which are likely to be 
representative of the UK population. The cohort of pregnancies derived from 
THIN is described in the next section. Firstly, the algorithm used to extract 
pregnancy data and link the pregnancy to the subsequent child’s medical record, 
and secondly a summary of the characteristics of the cohort.  
 
3.2.1. Method 
The algorithm for identifying pregnancy information in THIN has been developed 
by Dr Irene Petersen (University College London) in her research on 
antidepressants in pregnancy.110 Further validation techniques were developed 
Dr Rachel McCrea (University College London).111;112 The pregnancy cohort and 
linked mother-child cohort created from these methods were used in the studies 
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for this PhD. Below is a brief description of how these cohorts were extracted 
from primary care data. 
 
The pregnancy cohort captures women aged 13-55 years who were pregnant 
and registered at a GP practice contributing data to THIN between 1994 and 
2012. A pregnancy was indicated in THIN if there was a Read code in the 
woman’s medical records or additional health data pertaining to the delivery of a 
baby or an antenatal event. For example, “Z257.11 Normal delivery”. Pregnancy 
start dates were ascertained from the date of the last menstrual period, 
gestational age of the baby at birth, preterm birth, and free text data. Delivery 
dates were determined using the date of the record if there was a delivery Read 
code in the data or derived from Read codes for postnatal visits such as “62R1.00 
P/N - first day visit”. Otherwise, a record of the estimated delivery date was used. 
If no information could be found on delivery, then it was assumed to be 280 days 
after the pregnancy start date (i.e. full term) if present. Similarly, if there was no 
start date information, and only delivery information, then the start was assumed 
as 280 days prior to delivery. Pregnancies where no start or end date could be 
found or estimated were excluded. Pregnancies were included if there was at 
least six months of acceptable quality data in the woman’s records prior to the 
start of pregnancy – this was needed to determine who was prescribed 
antiepileptic drugs prior to pregnancy – and similarly, at least six months of follow 
up after delivery was required to determine who had the relevant outcomes.  
 
A mother-child linkage algorithm links a child in THIN to the pregnancy, thus 
providing information on child outcomes. The existing THIN variable “famnum” is 
a family number and is derived based on matching addresses. This is how the 
initial link was made between mother and child within the same general practice. 
Further, a mother-child linkage was created associating a child with a pregnancy 
based on matching the child’s month of birth to the date of delivery in the mother’s 
records. As the exact date of birth is not known and some children may be 
registered sometime after birth (for example if they had been in hospital) children 
were considered if they were registered from birth up to least six months of age. 
The family number, however, also capture individuals within the same “famnum” 
if they lived in a block where the postcode was the same for all residents. 
Therefore individuals were excluded if there were more than four children 
80 
 
identified in the same household, or more than one mother linked to the same 
child. 
 
Drs Petersen and McCrea conducted further work on the pregnancy cohort to 
improve the validity of the identified pregnancies. An algorithm was implemented 
which extracted five key types of evidence of pregnancy. These were: 
 last menstrual period,  
 antenatal data, 
 delivery data, 
 postnatal data, and 
 linkage to a child. 
If there were at least two different types of evidence from the list above, a 
pregnancy was deemed valid. An exception was if the pregnancy had only 
evidence of the last menstrual period and an antenatal record. Here, it was 
required that the antenatal record was at least 105 days after the date of the last 
menstrual period so that the pregnancy had at least completed  the first trimester. 
A further exclusion was made if subsequent or previous pregnancies were found 
to be less than 280 days apart. There is the possibility that this removes valid 
pregnancies which have ended prematurely.  However, the decision to exclude 
this was based on previous observations that suggest that the outcome for many 
of these pregnancies were unreliable.  
 
3.2.2. Summary of characteristics 
Between 1994 and 2012, there were 353,171 pregnancies belonging to 256,026 
women identified using the above method, of which 82% (n = 288,281) could be 
linked to a child’s medical record in THIN. The majority of the pregnancies – over 
80% - were recorded from 2000 onwards (Table 5).  Around 30% of women had 
more than one pregnancy recorded in THIN. Women were, on average, 30 years 
old at the time of delivery (IQR = 26-40). The distribution amongst the five levels 
of social deprivation measured by the Townsend score fell slightly biased to the 
lesser deprived groups. Amongst the children identified using the mother-child 
linkage, the median follow-up time for the child was 4.6 years (IQR= 2.1-8.2) and 
just over half of the children were boys (Table 5).  
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Table 5 Characteristics of pregnancies recorded between 1994 and 2012 
 Number of pregnancies  
(N = 353,171) 
n (%) 
Maternal age band (years) 
<20 
20-24 
25-29 
30-34 
35-39 
40-44 
45+ 
 
18,095 (5.1) 
53,426 (15.1) 
92,482 (26.2) 
112,040 (31.7) 
63,679 (18.0) 
12,853 (3.6) 
596 (0.2) 
Year of delivery 
1994-1999 
2000-2004 
2005-2009 
2010-2012† 
 
46,032 (13.0) 
92,958 (26.3) 
140,835 (39.9) 
73,346 (20.8) 
Townsend 
1 (least deprived) 
2 
3 
4 
5 (most deprived) 
Missing 
 
81,256 (23.0) 
66,691 (18.9) 
69,195 (19.6) 
64,902 (18.4) 
48,620 (13.8) 
22,507 (6.4) 
Number of pregnancies in THIN‡ 
1 
2 
>2 
 
188,862 (71.3) 
63,258 (23.9) 
12,906 (4.9) 
Linked to a child in THIN 
Yes 
No 
 
288,281 (81.6) 
64,890 (18.4) 
Length of follow up time in child 
(years)  
(median [interquartile range]) 
 
 
4.6 [2.1-8.2] 
Sex of child§ 
Male 
Female 
 
147,766 (51.3) 
140,515 (48.7) 
 
                                            
 
 
† This is smaller than previous years due to the requirement that pregnancies needed six 
months of data after delivery – pregnancies delivered in the second half of 2012 would therefore 
not have sufficient data in the current dataset. 
‡ Denominator is the number of women (n=265,026), not number of pregnancies 
§ Denominator is the number of pregnancies linked to a child (n=288,281) 
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3.3. Antiepileptic drugs, pregnancy and major congenital 
malformations recording in THIN 
As Table 5 shows, THIN data is a useful resource for providing a large sample of 
population based pregnancies. The decision to use THIN data for this research 
study was based on this and a number of other strengths that are outlined below.  
 
 Well reported prescription data 
In the UK, the majority of prescribing is conducted through primary care 
and hence is captured in a primary care database such as THIN. 
Moreover, the Vision software which collects data for THIN, is devised 
such that the information entered by the GP onto a computer system to 
generate a prescription for the patient to take to the pharmacy, is directly 
captured i.e. not re-entered after the consultation. This reduces the 
likelihood of errors in reporting the details of the prescription.  
 
 Minimal recall bias for drug exposure 
Many studies which examine the use of drugs in pregnancy rely on 
retrospective methods of exposure status ascertainment. As discussed in 
Chapters 1 and 2, this can lead to issues around recall bias whereby 
women recall the exposure details differently depending on outcome 
status. By prospectively collecting data on exposure before outcome is 
known, recall bias is minimised.  
  
 Ideal for rare exposures and outcomes 
Antiepileptic drug exposure in pregnant women is relatively rare. Holmes 
et al estimated this to be around 1 in 250 pregnant women.4 Major 
congenital malformations are also rare – 1-3% in the general population, 
although possibly as high as 10% in certain antiepileptic drug exposed 
groups. This is compounded if investigating specific antiepileptic drug 
exposures, and therefore a large sample size is needed to ascertain 
sufficient numbers of exposures and outcomes.  
 
 Comparison to women with untreated conditions 
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Comparisons of outcomes with similar individuals is needed is order to 
attribute an association with the exposure of interest and not a 
confounding variable. Studies which have used the general population as 
an unexposed comparison group (i.e. pregnancies in the general 
population where antiepileptic drugs were not taken in pregnancy) fail to 
account for the possibility that the underlying condition, such as epilepsy 
or bipolar disorder and factors associated with these may be confounding 
the association. Primary care databases are population based, thus 
enabling a sample of antiepileptic drug unexposed pregnancies to be 
gathered amongst women with similar conditions as those in the exposed 
groups. These unexposed pregnancies may, however, be different in that 
the severity of the underlying condition is milder, allowing them to be 
untreated – this limitation to the data is referred to later. 
 
 Validation of primary care data 
There are several validation studies which have examined aspects of THIN 
data to see how well recorded particular events are. THIN data has good 
generalisability to the UK for demographics, diagnoses (including epilepsy 
and mental illness) and death recording.108;113;114 THIN has also been used 
for studies in pregnancy and studies involving antiepileptic drug use. 110;115-
117 
 
Along with the knowledge that pregnancies and prescribing are well recorded, the 
above strengths justify the choice in selecting THIN to study antiepileptic drug 
use in pregnancy and the risk of major congenital malformations as part of this 
PhD. Limitations must, however, be borne in mind throughout the study and in 
the overall conclusions in this thesis. Some of these are outlined below and will 
be further discussed in Chapter 8. 
 
 Adherence to prescribed medication 
The prescribing of a drug does not necessarily mean that the drug is taken 
or if the drug is dispensed and therefore we cannot be certain of foetal 
exposure. A true effect would therefore be diluted as patients who did not 
consume the prescribed drug would be misclassified as exposed. 
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 Lack of information on disease severity 
Disease severity may not be well recorded for the underlying conditions of 
women receiving antiepileptic drugs in THIN. For example, epilepsy has a 
broad scope of severity with some women having many tonic-clonic 
seizures every day to those who have milder forms with fewer and less 
intensive seizures. This is important if disease and its severity are 
confounders i.e. they are associated with both antiepileptic drug exposure 
and the risk of outcomes. Few studies have captured such information in 
the past and as such it is unknown the extent of confounding if any.  
 
 Prescribing outside of primary care 
Although GPs in the UK are responsible for the majority of prescribing, 
medication initiated  in secondary care (e.g. accident and emergency) or 
in tertiary care (e.g. neurologist, psychiatrist etc.) will not be present in 
primary care records unless they are entered appropriately into the 
computer system by the GP practice in retrospect.  
 
 Possible under recording of non-live births 
Table 5 showed that around 80% of the identified pregnancies could be 
linked to a child. These are children who have been registered at a GP 
surgery, therefore they were live born babies. The 20% of pregnancies 
which could not be linked to a child will include women who transferred to 
a new GP practice shortly after delivery of a live born baby, (thus the baby 
would be registered at a new practice and could not be linked), and also 
women whose pregnancies ended in a non-live birth (i.e. miscarriage, 
termination, stillbirth, neonatal death). These are potentially under 
recorded in primary care due to them being largely diagnosed outside of 
primary care and in hospital.  
 
 Retrospective case ascertainment 
In this study, major congenital malformations need to be distinguished 
from minor congenital malformations – for some malformations, it is clear 
whether or not they are major or minor (e.g. a birth mark is generally 
minor), however the severity of some and therefore whether or not they 
are major can be difficult to ascertain from a medical record alone.  
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3.4. The next chapter 
There are limitations to every study design, and there is not one correct method 
for studying medication use in pregnancy. Primary care data is a useful resource 
which has been underutilised in the study of antiepileptic drugs in pregnancy 
despite the strengths it offers.  In this thesis, I plan to use to use UK primary care 
data to conduct three studies on antiepileptic drugs in pregnancy and major 
congenital malformations. In the next chapter, an overview of these studies is 
presented. 
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Chapter 4 
Overview of three research studies 
 
4.1. Aim of chapter 
The first chapter of this thesis showed there is a current need to continue 
research into the teratogenic effects of antiepileptic drugs in pregnancy, largely 
to establish drug specific risks using large samples. The second chapter 
described various ways of conducting such a study using different designs and 
data sources, whilst the third chapter focussed on the use of one data source – 
The Health Improvement Network (THIN) – and its strengths specifically for 
studying the risk of antiepileptic drug use in pregnancy. Primary care data from 
THIN was therefore chosen to conduct a cohort study of women taking 
antiepileptic drugs in pregnancy, and this study is presented later in this thesis. 
However, prior to that, there are two studies which were conducted and are also 
presented in this thesis. These studies are an exploration and validation of data 
that is required from THIN for the main study. In this current chapter, a brief 
outline of the aims and objectives of each of these studies and the main cohort 
study is given. More detailed methods, results and discussions relating to each 
of the three studies are presented in later chapters.  
 
4.2. Study 1: Antiepileptic drug prescribing in pregnancy in 
primary care 
The aim of this study was to understand patterns of antiepileptic drug prescribing 
in pregnancy in primary care. This helped to verify whether sufficient information 
on antiepileptic drug prescribing was captured in THIN.  
 
The specific objectives were to: 
1. Examine secular trends in the prescribing of antiepileptic drugs during 
pregnancy; 
2. Explore changes to prescribing, specifically discontinuation of antiepileptic 
drugs, soon after a woman becomes pregnant; 
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3. Identify factors associated with antiepileptic drug discontinuation in 
pregnancy.  
 
4.3. Study 2: Prevalence of major congenital malformations 
and perinatal death in primary care 
The aim of this second study was to describe the outcomes of interest for the 
main study: major congenital malformations and perinatal death using THIN data.  
 
The specific objectives were to: 
1. Estimate the birth prevalence of each outcome in the general 
population using primary care data; 
2. Examine secular changes and associated demographic factors. 
 
4.4. Study 3: Antiepileptic drugs in pregnancy and the risk of 
major congenital malformations or perinatal death in primary 
care 
This is the main cohort study in this thesis which aims to answer the question - 
what is the risk of major congenital malformations or perinatal death associated 
with first trimester use of antiepileptic drugs in pregnancy?  
 
The objectives were as follows: 
1. In women who were prescribed antiepileptic drugs before pregnancy, 
determine the absolute risk of major congenital malformations or perinatal 
death for: 
a. each group of pregnancies prescribed individual antiepileptic drug 
monotherapy in the first trimester of pregnancy. 
b. pregnancies prescribed sodium valproate polytherapy in the first 
trimester of pregnancy. 
c. pregnancies where no antiepileptic drug therapy was prescribed in 
the first trimester of pregnancy. 
 
2. In women who were prescribed antiepileptic drugs before pregnancy, 
conduct pairwise comparisons of the risk of the major congenital 
malformations or perinatal death between each of the following first 
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trimester regimens, adjusting for differences in demographic and clinical 
characteristics: 
a. Lamotrigine monotherapy 
b. Carbamazepine monotherapy 
c. Sodium valproate monotherapy 
d. Sodium valproate polytherapy 
e. No therapy 
 
4.5. The next chapters 
Studies 1, 2 and 3 are described in full in Chapters 5, 6 and 7 respectively. The 
thesis concludes with an overall discussion of the collective findings in these 
studies and how this informs the research area with recommendations for clinical 
practice and further research.  
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Chapter 5 
Antiepileptic drug prescribing in pregnancy in primary care 
 
5.1. Aim and objectives of the chapter 
The aim of this chapter is to gain a broad understanding of antiepileptic drug 
prescribing in pregnancy in primary care.  Antiepileptic drug use in pregnancy is 
the exposure of interest in the main research study presented later in this thesis. 
Therefore, it is necessary to explore the recording of such information in the data 
source which I plan to use. In this exploration, I look at which drugs are prescribed 
to pregnant women and whether or not women continue to be prescribed 
following the start of pregnancy.  
 
As set out in the previous chapter, the specific objectives were to: 
1. Examine secular trends in the prescribing of antiepileptic drugs during 
pregnancy;  
2. Explore changes to prescribing, specifically discontinuation of antiepileptic 
drugs, soon after a woman becomes pregnant;  
3. Identify factors associated with antiepileptic drug discontinuation in 
pregnancy. 
 
5.2. Introduction 
Women in pregnancy generally seek support from their GP or local midwife 
service to provide antenatal care. As part of this care, women with chronic 
conditions may need further support to manage their condition throughout the 
course of pregnancy, which includes discussions on the use of drugs in 
pregnancy. Epilepsy and bipolar disorder are chronic conditions that can be 
treated with antiepileptic drugs and women with these conditions need to be 
aware of the risks and benefits of continued therapy in pregnancy, ideally before 
pregnancy occurs.118;119 
 
The National Institute of Health and Clinical Excellence (NICE) advise against the 
use of one specific antiepileptic drug, sodium valproate, in pregnancy if possible 
because of its teratogenic risk.24;31 In previous UK guidelines, health care 
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professionals were advised that women with bipolar disorder should avoid, 
carbamazepine and lamotrigine if possible.24 New guidelines published in 2014 
go further to state that pregnant women with mental health conditions should 
cease sodium valproate in pregnancy, consider ceasing carbamazepine and 
monitor blood serum levels of lamotrigine in pregnancy.120 These three drugs are, 
however, popular drugs for treating epilepsy and bipolar disorder,34;121 thus the 
dilemma of using these drugs in pregnancy affects many women. A recent survey 
of women with epilepsy found many of the women did not discuss the risks and 
benefits of antiepileptic drugs in pregnancy with their GP/neurologist.118 Women 
and their health care professionals are hence, forced to face treatment dilemmas 
in pregnancy, rather than before.122 Coupled with the misperception of the actual 
teratogenic risk of drugs,9 women may be more inclined to stop treatment or 
switch treatments abruptly in pregnancy, possibly resulting in inadequate 
management of their underlying epilepsy or bipolar disorder which in itself places 
the woman at risk during their pregnancy.51  
 
There is a clear need for more information on the risks and benefits of 
antiepileptic drugs in pregnancy. However, the first step is to explore which 
antiepileptic drugs are commonly prescribed. Treatment choices in pregnancy 
are likely to have changed in the last 20 years due to the known teratogenicity of 
older antiepileptic drugs such as sodium valproate and the introduction of newer 
antiepileptic drugs such as lamotrigine which are favoured on account of their 
limited side effects profile and  better tolerability. Previous studies highlight 
sodium valproate, carbamazepine and lamotrigine as commonly prescribed 
antiepileptic drugs in pregnancy. In this chapter, I present my study which aims 
to further evaluate prescribing of antiepileptic drugs in pregnancy in general 
practice and furthermore, to examine the influence of pregnancy on 
discontinuation of antiepileptic drugs.  
 
5.3. Methods 
5.3.1. Secular trends in antiepileptic drug prescribing in pregnancy 
Using the pregnancy cohort of 353,171 pregnancies described in Chapter 3, the 
therapy records for each pregnancy were investigated for prescriptions of 
antiepileptic drugs made during pregnancy. A list of drug ID codes relating to 
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antiepileptic drugs listed in Chapter 4.8.1 of the British National Formulary (BNF) 
was created and used to identify the relevant prescriptions of antiepileptic drugs 
(carbamazepine, ethosuximide, gabapentin, pregabalin, lamotrigine, 
levetiracetam, phenobarbital, primidone, phenytoin, topiramate, valproate, 
vigabatrin, lacosamide, rufinamide, oxcarbazepine, tiagabine, valproic acid, 
clobazam, clonazepam, piracetam, acetazolamide). 
 
For each year between 1994 and 2012, the prevalence of antiepileptic drug 
prescribing in pregnancy was calculated as the number of pregnancies where two 
or more prescriptions were given within any three month period in pregnancy 
divided by the total number of pregnancies delivered in the given year.  This 
attempts to capture repeat users of antiepileptic drugs and thus exclude 
individuals with just one-off prescriptions. Secular trends are observed for overall 
antiepileptic drug prescribed, and for individual antiepileptic drugs.  
 
5.3.2. Discontinuation of antiepileptic drugs in pregnancy 
Pregnant women prescribed antiepileptic drugs at least once in the three months 
before pregnancy were identified and stratified into three groups based on the 
indication for prescribing antiepileptic drugs. These indications were epilepsy, 
bipolar disorder or depression (identified using Read code lists found in Appendix 
2) and no/other indication (for example the treatment of neuralgia) for antiepileptic 
drugs. Read code lists were derived based on searches for key words, 
examination of relevant hierarchies and clinical review - a method which has been 
widely used in other epidemiological studies of THIN data.96 The prescriptions 
were traced from three months before pregnancy to their last consecutive 
prescription. This last prescription was assumed when no other antiepileptic 
drugs were prescribed within the subsequent three months of the previous 
prescription. The period of follow-up was from three months before the pregnancy 
start date and ended at the earlier of the last prescription date or the delivery date 
if the birth was premature, or two months before the delivery date if the birth was 
full term. 
 
A group of non-pregnant women prescribed antiepileptic drugs was selected for 
comparison with pregnant women prescribed antiepileptic drugs. This included 
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women who had never been pregnant as well as women who had had one or 
more pregnancies. For the latter group I excluded periods where they were 
pregnant and excluded periods from two years before pregnancy to one year after 
a delivery. These periods were designed to exclude the time where planning 
pregnancy, pregnancy itself or breastfeeding may have an impact on choice of 
drug treatment. One non-pregnant period per woman was chosen at random. A 
random index date was assigned in the non-pregnant period as a comparative 
pregnancy start date. Non-pregnant women were also stratified by the indication 
for antiepileptic drugs and randomly selected within five year age bands so that 
the age distribution was similar to that of pregnant women. Two women for every 
one pregnant woman taking antiepileptic drugs were selected. For non-pregnant 
women, follow-up started three months before the index date and ended at the 
earlier of the last prescription date or 280 days after the index date.  
 
Cox’s proportional hazards regression model was used to estimate hazard ratios 
(HRs) comparing the time to last prescription between pregnant and non-
pregnant women, stratified by indication for antiepileptic drugs. The proportion of 
women continuing to receive antiepileptic drug prescriptions was identified at 92 
days follow-up (i.e. the approximate start of pregnancy), 134 days (i.e. 
approximate point of six weeks gestation), and at 288 days follow-up (i.e. 
approximately beginning of the third trimester). Amongst the women with no or 
other indication for antiepileptic drugs, it was not possible to select a similar non-
pregnant group of women, thus HRs were not estimated for this group. 
 
The following factors were examined using Cox’s regression to build a model for 
the discontinuation of antiepileptic drugs in pregnancy, stratified by indication. 
 Maternal age was categorised as younger than 25, 25-34 and 35+ years 
 Social deprivation was measured using the Townsend quintile (described 
in Chapter 2)  
 The number of times antiepileptic drugs were prescribed prior to the 
initiation of follow-up, i.e. in the three to six months before pregnancy, was 
counted and categorised as 0, 1 or 2+  
 Co-medication was measured as the number of different types of drugs 
prescribed for treatment of conditions affecting the central nervous system 
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(BNF Chapter 4), excluding antiepileptic drugs and was categorised as 0, 
1 and 2+, and measured in the three months before pregnancy  
 Amongst women with epilepsy, co-morbidity with bipolar disorder or 
depression was also analysed as a risk factor.  
Univariable analyses of each of these factors and adjusted analyses including all 
factors in the regression model were performed. The reference category was the 
largest group for maternal age, number of co-medications, and frequency of 
antiepileptic drug prescribing prior to pregnancy. Townsend score 1 (least 
deprived) formed the reference group for examining social deprivation. 
 
As a secondary analysis, the discontinuation rate in pregnant women was 
compared between pre-pregnancy antiepileptic drugs. Women prescribed 
sodium valproate in the three months before pregnancy were compared to 
women prescribed lamotrigine and carbamazepine separately. Hazard ratios 
were estimated comparing the time to last prescription with sodium valproate as 
the reference group.  
 
5.4. Results 
5.4.1. Secular trends of antiepileptic drug prescribing prevalence  
Antiepileptic drugs were prescribed in pregnancy for 1,620 (0.5%) out of 353,171 
pregnancies in the cohort. Lamotrigine (0.2%; n = 573), carbamazepine (0.2%; n 
= 560) and sodium valproate (0.1%; n = 342) were the three most commonly 
prescribed antiepileptic drugs in pregnancy over the study period (Table 6). 
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Table 6 Antiepileptic drugs prescribed in pregnancy 
Women prescribed antiepileptic drugs in pregnancy 
(N=353,171) 
 
n (%) 
Any 1,620 (0.46) 
Lamotrigine 573 (0.16) 
Carbamazepine 560 (0.16) 
Sodium valproate 342 (0.10) 
Levetiracetam 106 (0.03) 
Phenytoin 65 (0.02) 
Gabapentin 61 (0.02) 
Clonazepam 53 (0.02) 
Clobazam 44 (0.01) 
Topiramate 42 (0.01) 
Pregabalin 17 (<0.01) 
Phenobarbital 10 (<0.01) 
Oxcarbazepine 7 (<0.01) 
Ethosuximide 7 (<0.01) 
Acetazolamide 5 (<0.01) 
Vigabatrin 5 (<0.01) 
Zonisamide 3 (<0.01) 
Primidone 3 (<0.01) 
Lacosamide 2 (<0.01) 
 
Figure 2 below shows the secular changes in antiepileptic drug prescribing in 
pregnancy for five categories – pregnant women prescribed any antiepileptic drug 
in pregnancy, and pregnant women prescribed one of four most common 
antiepileptic drugs in pregnancy - lamotrigine, carbamazepine, sodium valproate 
and levetiracetam. Between 0.3% and 0.6% of pregnancies delivered each year 
from 1994 to 2012 were exposed to antiepileptic drugs. Amongst these, 
carbamazepine was the most commonly prescribed antiepileptic drug in 
pregnancy in the 1990’s; however its use fell from around 0.4% in 1994 to 0.1% 
in 2012. Sodium valproate use rose for a short period between 1994 and 1998 
when it reached its peak (0.2% of pregnancies) before declining to being 
prescribed in less than 0.05% of pregnancies in 2012. Prescribing of these older 
antiepileptic drugs was surpassed in 2004 when lamotrigine rose to be the most 
commonly prescribed antiepileptic drug. In 2012 it was prescribed in 0.3% of all 
pregnancies.  
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Newer antiepileptic drug, levetiracetam, was the fourth most commonly 
prescribed antiepileptic drug in pregnancy, prescribed to 0.03% of all pregnancies 
and a look at its secular changes shows a slow increase in its use in pregnancy 
since its introduction to the market in 2000. By 2012 it was as commonly 
prescribed as carbamazepine in 0.01% of all pregnancies.  
 
Figure 2 Secular changes in prescribing prevalence of antiepileptic drugs in pregnancy 
 
 
5.4.2. Discontinuation of antiepileptic drugs 
5.4.2.1. Pregnant vs. non-pregnant women 
Of the 353,171 pregnant women, there were 1,911 (0.5%) who had received an 
antiepileptic drug prescription in the three months before pregnancy. Of these 
1,329 (69.5%) had a clinical record of epilepsy and 166 (8.7%) of bipolar disorder 
or depression. The remaining 416 (21.8%) had no indication or other indications 
for the prescribing of antiepileptic drugs.   
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Women with epilepsy 
Figure 3 shows the discontinuation rate between 1,329 pregnant women and 
twice as many non-pregnant women (n = 2,658) who were prescribed 
antiepileptic drugs for epilepsy. After 92 days follow-up (i.e. beginning of 
pregnancy in pregnant women), 79.6% (n = 1,059) of pregnant women and 86.8% 
(n = 2,307) of non-pregnant women continued to receive antiepileptic drugs.  After 
134 days (i.e. six weeks gestation in pregnant women) this fell to 72.7% (n = 967) 
of pregnant women and 83.7% (n = 2,227) of non-pregnant women. After 288 
days (i.e. beginning of third trimester in pregnant women), 61.4% (n = 816) of 
pregnant women continued to receive antiepileptic drug prescriptions, compared 
to 73.9% (n = 1,965) of non-pregnant women. Overall, pregnant women with 
epilepsy were found to be more likely to discontinue antiepileptic drugs in 
pregnancy compared to non-pregnant women with epilepsy (HR 1.63, 95% CI 
1.46-1.83). 
 
Figure 3 Antiepileptic drug discontinuation in women with epilepsy 
 
 
Women with bipolar disorder or depression 
Compared to 332 non-pregnant women taking antiepileptic drugs for bipolar 
disorder or depression, the rate of discontinuation of antiepileptic drugs was much 
faster in 166 pregnant women (Figure 4). After 92 days follow-up, just over half 
(n = 89) of the pregnant women continued to be prescribed compared to 74.7% 
(n=248) of non-pregnant. There was a rapid decline for pregnant women - only 
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26.5% (n = 44) remained to be treated at 134 days follow-up, compared to 68.4% 
(n = 227). By the beginning of the final trimester, 12.7% (n = 21) and 53.9% (n = 
179) of pregnant and non-pregnant women respectively were prescribed. Overall, 
pregnant women with bipolar disorder or depression were three times more likely 
to cease antiepileptic drugs compared to non-pregnant women (HR 3.03, 95% CI 
2.45-3.83).  
 
Figure 4 Antiepileptic drug discontinuation in women with bipolar disorder/depression 
 
A review of the therapy records of the 122 women who had ceased receiving 
prescriptions for antiepileptic drugs six weeks into the pregnancy found 66 (54%) 
women continued on alternative antidepressants/antipsychotics in the first 
trimester, leaving 56 (46%) women who did not. Only 14 women were found to 
restart antiepileptic drugs later in pregnancy.  
 
Women with other indications for antiepileptic drugs 
A total of 416 women were prescribed antiepileptic drugs in the three months 
before pregnancy where an indication of epilepsy, bipolar disorder or depression 
was not entered in the medical records. Figure 5 shows that there is a dramatic 
decline in the use of antiepileptic drugs in pregnancy for this group. By the start 
of pregnancy, just under half continue to be treated with antiepileptic drugs 
(42.8%; n = 178), and falling to 20.0% (n = 83) by six weeks gestation. By the 
beginning of the third trimester, 90.4% (n = 376) had ceased being prescribed 
antiepileptic drugs.  
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Figure 5 Antiepileptic drug discontinuation in women with no/other indications 
 
 
5.4.2.2. Discontinuation rates by specific antiepileptic drugs in 
pregnancy 
Pregnant women with epilepsy 
Of 1,329 pregnant women with epilepsy who were receiving antiepileptic 
prescriptions in the three months preceding pregnancy, 409 (30.8%) were 
prescribed lamotrigine, 408 (30.7%) prescribed carbamazepine and 270 (20.3%) 
prescribed sodium valproate.  
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Figure 6 Antiepileptic drug discontinuation in pregnant women with epilepsy by drug 
 
Figure 6 shows that the most marked decline in continuation of antiepileptic drugs 
was amongst women who were prescribed sodium valproate before pregnancy. 
After six weeks gestation, 59.3% (n = 163) of the sodium valproate users 
continued therapy, whilst 79.7% (n = 326) of the lamotrigine group and 73.5% (n 
= 300) of the carbamazepine group continued. By the end of the second trimester, 
less than half of the sodium valproate group were still receiving antiepileptic drug 
treatment (n = 128) compared to 68.9% (n = 282) of lamotrigine and 63.0% (n = 
257) of carbamazepine users. 
 
Overall, women prescribed lamotrigine before pregnancy were 50% less likely to 
stop antiepileptic drugs in pregnancy compared to women prescribed sodium 
valproate (HR 0.50, 95% CI 0.40-0.64). For women prescribed carbamazepine 
before pregnancy, the likelihood of stopping was 38% less than that of women 
prescribed sodium valproate (HR 0.62, 95% CI 0.50-0.78). 
 
Pregnant women with bipolar disorder or depression 
Of 166 pregnant women with bipolar disorder or depression prescribed 
antiepileptic drugs in the three months prior to pregnancy, 39 (23.5%) were 
receiving sodium valproate, 14 (8.4%) lamotrigine and 45 (27.1%) 
carbamazepine (Figure 7). At six weeks gestation, 23.1% (n = 9) of sodium 
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valproate users, 42.9% (n = 6) of lamotrigine users and 24.4% (n = 11) of 
carbamazepine users continued on therapy. By the beginning of the third 
trimester, 4 (10%) 2 (14%) and 6 (13%) of sodium valproate, lamotrigine and 
carbamazepine users, respectively, were continuing antiepileptic drugs.  
 
Figure 7 Antiepileptic drug discontinuation in pregnant women with bipolar disorder/depression by 
drug 
 
 
5.4.2.1. Factors predicting discontinuation of antiepileptic drugs in 
pregnancy 
Pregnant women with epilepsy  
In univariable analyses, all five examined factors were associated with the 
likelihood of antiepileptic drug discontinuation in pregnancy amongst women with 
epilepsy. A full model (maternal age, Townsend score, frequency of antiepileptic 
drug prescribing before pregnancy, co-medication use and, in women with 
epilepsy, co-morbidity with depression) was therefore analysed, and after 
adjusting, the variables which predicted discontinuation were age, previous 
prescriptions of antiepileptic drugs before pregnancy and use of co-medications. 
Table 7 displays the HRs for the full model. 
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Most pregnant women with epilepsy were aged between 25 and 34 years, thus 
this group were the baseline for comparison between age bands. Hazard ratios 
indicate that pregnant women who were younger than 25 years at the start of 
pregnancy were slightly more likely to discontinue (HR 1.20, 95% CI 0.99-1.47), 
and that women older than 35 years were less likely to discontinue (HR 0.77 95% 
CI 0.59-1.01). While the confidence intervals for these estimates includes 1 the 
overall p-value (0.012) suggests that, overall, there was a significant effect of age.  
 
The majority of women had received two or more prescriptions of antiepileptic 
drugs in the three to six months prior to pregnancy and, compared to this group, 
those women prescribed antiepileptic drugs only once were three times more 
likely to stop being prescribed antiepileptic drugs in pregnancy (HR 3.46, 95% CI 
2.85-4.20). Women with no antiepileptic drugs prescribed in this period were 
nearly six times more likely to stop being prescribed in pregnancy (HR 5.81, 95% 
CI 4.59-7.35). 
 
Most women were not prescribed other drugs treating the central nervous system 
(CNS) (e.g. antidepressants or antipsychotics). The overall p-value (0.019) 
suggests there is a significant effect of co-medication with CNS drugs – those 
prescribed CNS drugs are more likely to discontinue (Prescribed one other CNS 
drug - HR 1.32 (95% CI 1.06-1.65); prescribed more than one other CNS drug – 
HR 1.37 (95% CI 0.98-1.91)). 
 
Pregnant women with bipolar disorder or depression 
The Townsend score of social deprivation did not affect the likelihood of 
discontinuation of antiepileptic drugs in pregnancy. All other factors did and were 
entered into a multivariable model. Adjusted HRs are displayed in Table 7. 
  
The most common age band was 25-34 years of age forming the comparison 
group. Those older (35 years or more) were less likely to stop antiepileptic drugs 
in pregnancy (HR 0.55 95% CI 0.36-0.85), but for those younger (under 25 years) 
were no different (HR 0.88, 95% CI 0.54-1.42).  
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There was an overall significant effect of the frequency of antiepileptic drug 
prescribing before pregnancy on the likelihood of discontinuation in pregnancy. 
Those who had no prescriptions of antiepileptic drugs before pregnancy were 
twice as likely to discontinue in pregnancy, compared to those who had received 
more than one prescription before pregnancy (HR 2.02, 95% CI 1.33-3.07). 
Those with just one prescription were slightly more likely than those with more 
than one prescription to discontinue treatment in pregnancy (HR 1.31, 95% CI 
0.83-2.08). 
 
Overall, the p-value suggest that there is a difference in the likelihood of 
antiepileptic drug discontinuation in pregnancy depending on the number of other 
co-medications the woman receives. Compared to women with more than one 
other co-medication, those who none were twice likely to stop antiepileptic drugs 
in pregnancy (HR 2.20, 95% CI 1.29-3.77). Women with only one other co-
medication were also more likely than those receiving more than one to cease 
treatment in pregnancy, however to a lesser extent (HR 1.36, 95% 0.95-1.95).
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Table 7 Risk factors for discontinuation of antiepileptic drugs in pregnant women 
 Pregnant women with epilepsy (N = 1329) Pregnant women with bipolar disorder (N = 166) 
  Unadjusted Adjusted  Unadjusted Adjusted 
 N HR (95% CI) p-value HR (95% CI) p-value N HR (95% CI) p-value HR (95% CI) p-value 
Age (years)   
<0.001 
 
0.012 
  
0.004 
 
0.024 
<25 326 1.39 (1.15-1.69) 1.20 (0.99-1.47) 26 1.06 (0.68-1.65) 0.88 (0.54-1.42) 
25-34 809 1 1 99 1 1 
35+ 194 0.84 (0.65-1.10) 0.77 (0.59-1.01) 41 0.50 (0.33-0.77) 0.55 (0.36-0.85) 
Depression/ bipolar disorder 
<0.001 
 
0.10 
     
No 1183 1 1      
Yes 146 1.56 (1.23-1.98) 1.24 (0.96-1.61)      
Townsend   
0.011 
 
0.24 
  
0.248 
  
1  245 1 1 24 1   
2 203 1.36 (1.00-1.86) 1.31 (0.96-1.79) 24 1.14 (0.62-2.08)   
3 246 1.36 (1.01-1.82) 1.23 (0.91-1.66) 22 0.87 (0.46-1.62)   
4 294 1.46 (1.10-1.94) 1.24 (0.93-1.66) 50 1.40 (0.84-2.34)   
5 252 1.68 (1.26-2.24) 1.44 (1.07-1.94) 33 0.87 (0.49-1.54)   
Missing 92 1.19 (0.79-1.78) 1.06 (0.71-1.61) 13 1.31 (0.63-2.73)   
Previous antiepileptic drugs 
<0.001 
 
<0.001 
  
0.001 
 
0.004 
0 140 6.24 (4.95-7.88) 5.81 (4.59-7.35) 48 2.08 (1.43-3.04) 2.02 (1.33-3.07) 
1 361 3.26 (2.70-3.95) 3.46 (2.85-4.20) 28 1.56 (1.00-2.44) 1.31 (0.83-2.08) 
2+ 828 1 1 90 1 1 
Co-medications   
0.008 
 
0.019 
  
0.021 
 
0.011 
0 1011 1 1 18 2.09 (1.24-3.52) 2.20 (1.29-3.77) 
1 235 1.32 (1.07-1.63) 1.32 (1.06-1.65) 63 1.23 (0.87-1.75) 1.36 (0.95-1.95) 
2+ 83 1.41 (1.03-1.93) 1.37 (0.98-1.91) 85 1 1 
104 
 
5.5. Discussion 
Key findings 
Approximately 1 in 200 pregnancies in primary care between 1994 and 2012 were 
prescribed antiepileptic drugs during pregnancy. There has been a decline in 
prescribing of the older antiepileptic drugs in pregnancy namely carbamazepine 
and sodium valproate since 1994 whereas prescribing of lamotrigine, a newer 
antiepileptic drug, has increased five-fold since 2000. Pregnancy was a 
determinant for the discontinuation of antiepileptic drugs particularly for women 
with bipolar disorder/depression. Furthermore, fewer prescriptions of antiepileptic 
drugs before pregnancy and fewer co-medications were associated with the 
likelihood of discontinuation in pregnant women. Finally, older women were more 
likely to continue treatment than younger women. 
  
Secular trends in antiepileptic drugs prescribing in pregnancy 
Secular changes in the prescribing of antiepileptic drugs in pregnancy have been 
analysed in other countries.  The Australian Register of Antiepileptic drugs in 
Pregnancy found similar patterns with regards to specific antiepileptic drugs – 
decreases in sodium valproate and carbamazepine, and increases in the use of 
lamotrigine and levetiracetam.123 The US based Medication Exposure in 
Pregnancy Risk Evaluation Program (MEPREP) examined trends in antiepileptic 
drug prescribing in pregnancy between 2001 and 2007, and although specific 
antiepileptic drugs were not examined, they found prescribing of older 
antiepileptic drugs as a group, did not vary much over the study period, whereas 
newer antiepileptic drugs increased by five-fold.124  The European and 
International Registry of Antiepileptic Drugs in Pregnancy (EURAP) used pooled 
data from 38 countries to examine the utilisation of antiepileptic drugs in 
pregnancy, and assessed secular trends for common antiepileptic drugs which 
included carbamazepine, sodium valproate and lamotrigine. Again, 
carbamazepine use declined and lamotrigine rose, but sodium valproate fell only 
slightly.125 These studies combined with the results from my study show a 
consistent pattern in that carbamazepine prescribing has fallen whilst lamotrigine 
use in pregnancy is becoming more common. There are some differences 
between these studies on the secular changes in sodium valproate use; however, 
one must bear in mind country specific differences in prescribing practices for 
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epilepsy and bipolar disorder, as well as for pregnant women in general, and to 
my knowledge, this is the first study to look at secular changes in antiepileptic 
drug prescribing in pregnancy in the UK.  
 
Sodium valproate is generally not recommended for use in pregnancy because 
of its teratogenicity,24;31  and the results of my study reflect this guidance being 
implemented. Carbamazepine has also been associated with a higher risk of 
major congenital malformations in some studies.4;5;126-128 Whilst studies on 
lamotrigine have been few in numbers and small in scale, results have been 
promising in terms of risk of major congenital malformations.5;18;129-131 The 
awareness of these studies may be contributory to the changes observed in the 
prescribing of antiepileptic drugs in pregnancy over time.  In the general 
population, there has been a general increase in the use of newer antiepileptic 
drugs as observed in the study by Nicholas et al.121  However, the use of 
carbamazepine and sodium valproate remained relatively stable over the study 
period, 1993-2008.121 In my study, use of carbamazepine and sodium valproate 
declined in pregnancy thus it is likely that overall changes in the general 
population use do not fully explain the changes observed in pregnancy.   
 
Discontinuation of antiepileptic drugs 
To my knowledge, this is the first study to examine discontinuation of antiepileptic 
drugs in pregnancy in the UK. Women were more likely to stop antiepileptic drugs 
when pregnant, and when analyses were stratified by indication, those prescribed 
antiepileptic drugs for bipolar disorder/depression were highly likely to stop. The 
reasons for discontinuation may include one or all of the following: 
1) Concerns over the risk of the teratogenic effects of antiepileptic drugs 
2) Their condition is mild enough to allow them to be untreated in pregnancy 
3) Their condition allows for alternative drugs to be prescribed 
Concerns for the risk of antiepileptic drugs in pregnancy 
Women should be aware of the risks that are associated with antiepileptic drugs 
in pregnancy when they are prescribed antiepileptic drugs for the first time, or 
once they reach child-bearing age.23 This is to avoid having to make changes to 
treatment in pregnancy and risking the effects of inadequate management of the 
underlying illness. However, a recent survey of women with epilepsy found many 
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are still not receiving appropriate pre-pregnancy counselling and advice on the 
use of antiepileptic drugs in pregnancy.118 Furthermore, a wider understanding of 
the risk of prescribed medications in pregnancy has been shown to be lower in 
certain sociodemographic groups.9;10;132;133 This lack of communication and 
knowledge may lead to poorly informed decisions to discontinuation of treatment 
in pregnancy. 
 
Less severe conditions allow discontinuation 
Disease severity is not measured directly in THIN. However, its potential for 
unmeasured confounding should not be ignored. Women with different levels of 
severity may be more or less likely to stop medication in pregnancy. One could 
argue that those with a more severe form of e.g. epilepsy, may be more likely 
continue antiepileptic drug treatment because they were highly likely to have a 
relapse if untreated. Despite this, some women may still choose to stop because 
of the worries about the teratogenic effects of the drugs themselves.  
 
Although one cannot directly ascertain severity from THIN, other variables can 
be proxies for disease severity. When the factors affecting the likelihood of 
discontinuation were examined, it was found that women on fewer co-
medications and who were prescribed fewer times in the period prior to 
pregnancy were more likely to discontinue. Both of these factors may be proxies 
for disease severity – women on fewer medications and prescribed less often 
may have a less severe form of the underlying illness which may allow them to 
stop treatment in pregnancy.  
 
Alternative drugs are prescribed 
There are no alternatives for treating epilepsy except for non-pharmacological 
interventions such as surgery and a specialised (ketogenic) diet. For bipolar 
disorder and depression, some antipsychotics and antidepressants that have a 
better safety profile can be prescribed in pregnancy – this study showed just over 
50% of those who stopped antiepileptic drugs continued on alternative 
treatments.  
 
These are all possible explanations, and the data used in this study can support 
these reasons for some women – e.g. that some women stop because they can 
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carry on with other medicines, but the data are otherwise limited in providing a 
reason for antiepileptic drug cessation in pregnancy.  
 
Strengths and weaknesses 
This study has utilised routinely collected health care data from a large population 
representative sample in the UK. In THIN data, we see that:  
- antiepileptic drug prescribing in pregnancy is well captured and 
comparable to one other study which estimated 1 in 250 women used 
antiepileptic drugs in pregnancy; 4 
- the commonly prescribed antiepileptic drugs in pregnancy are sodium 
valproate, carbamazepine and lamotrigine, which is consistent with reports 
from other UK studies;5;17 
- there is a large proportion of women stopping antiepileptic drugs in 
pregnancy implying a need for more information on the risks and benefits 
of antiepileptic drug use in pregnancy thereby reducing the number of 
women who need to make changes to treatment in pregnancy.  
The main limitation of THIN data in examining prescribing patterns has been 
mentioned in previous chapters – that is that drug adherence cannot be 
established from the data, only the act of prescribing the drug. However, the study 
of UK dispensing data showed that 98% of antiepileptic drugs prescribed are 
dispensed, which is step closer to being a proxy for adherence.134 
 
Summary 
Primary care data captures a large number of pregnant women prescribed 
antiepileptic drugs in pregnancy. The strengths listed above suggest it is a 
valuable data source for examining drug exposures in pregnancy, especially 
because prescribing in the UK is largely conducted through primary care. The 
commonly prescribed antiepileptic drugs are sodium valproate, carbamazepine 
and lamotrigine. Their use in pregnancy has changed over time, and newer 
antiepileptic drugs (lamotrigine and levetiracetam) are increasingly being 
prescribed despite there being fewer studies on their safety in pregnancy 
compared with some of the older antiepileptic drugs. Given also that pregnant 
women have been observed in this study to be likely to stop antiepileptic drugs in 
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pregnancy, this supports the need for more information to be sought on how 
antiepileptic drugs adversely affect the foetus in pregnancy in order to prevent 
unnecessary changes to treatment in pregnancy, which in itself can harm the 
foetus. 
 
5.6. How this informs the next chapter  
In this chapter, the exposure of interest – antiepileptic drug use in pregnancy - 
was examined in primary care data to establish the data’s adequacy for 
conducting the main analysis. Next, I look at whether or not primary care data 
suitably records the outcomes of interest in the main research question – major 
congenital malformations and perinatal death.  
  
109 
 
Chapter 6 
Birth prevalence of major congenital malformations and 
perinatal death in the general population in primary care 
 
6.1. Aims and objectives of chapter 
The main study in this thesis investigates the relationship between foetal 
antiepileptic drug exposure and the risk of major congenital malformations. In 
Chapter 5, antiepileptic drug exposure in pregnancy was examined in primary 
care data, and in this chapter, I examine the outcome of interest major congenital 
malformations, looking at the birth prevalence, secular changes and associated 
demographic factors. In the discussion section to this chapter, these estimates 
are compared against national estimates from external sources in order to judge 
whether or not primary care data is suitable for investigating teratogenicity.  
 
6.2. Background 
Primary care data such as that from The Health Improvement Network (THIN) 
should hold information on diagnoses of major congenital malformations since 
these are events of major importance to the GP. Major congenital malformations 
can have an impact on the life of a child whether it is surgical, physical or 
functional. However, the diagnosis is initially made in hospital at birth and its 
appearance in primary care data is dependent on the receipt of the hospital 
discharge letter and accurate entry of the details from the letter into the GP 
system. The diagnosis may be in either the mother or the child’s records since it 
is pertinent to the care of both. Clearly, this is only recorded on a child’s medical 
record if the baby was born alive. From a methodological perspective, it is 
important to gather as much information on pregnancy outcomes as possible – a 
restriction to only live born babies may introduce a bias to results and has the 
potential to underestimate teratogenic risks (if present) by excluding non-live 
births especially as some major congenital malformations may lead to the death 
or termination of the foetus. Therefore, both mother and child records need to be 
interrogated in the main study, the outcome will be a composite of major 
congenital malformations and perinatal death. Although perinatal death is a 
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possible teratogenic consequence, when such an event occurs, the recording of 
perinatal death may to take precedence over a diagnosis of a major congenital 
malformation. By capturing both events, this may reduce any selection bias 
induced by only including live births.  
 
There is little research on the validation of major congenital malformations and 
perinatal death in primary care data. Sokal et al recently analysed the validity of 
major congenital malformations recording in THIN in children born between 1990 
and 2009 by comparing prevalence rates with EUROCAT* figures for overall and 
system-specific major congenital malformations.135 They found 193 per 10,000 
births in THIN were diagnosed with a major congenital malformation in the first 
year which was slightly higher than EUROCAT estimate of 167 per 10,000. 
Nevertheless, THIN was regarded as a valuable resource for studying major 
congenital malformation by the authors. An internal validation of major congenital 
malformations has also been performed by Charlton et al who used paper records 
and free text data to verify diagnoses of major congenital malformations made 
using Read codes in the primary care database, the General Practice Research 
Database (GPRD, now Clinical Practice Research Datalink).136 This study 
covered the time period 1990 to 2006. They found that the majority of Read code 
diagnoses of major congenital malformations could be confirmed – 85% were 
supported by paper records or free text. In another study by the same authors, 
estimates of major congenital malformations in children born to women with 
epilepsy were calculated using GPRD primary care data and compared with 
estimates from the UK Epilepsy and Pregnancy Register. They found similar point 
estimates for the overall risk of major congenital malformations associated with 
antiepileptic drug monotherapy but, unlike the UK Epilepsy and Pregnancy 
Register study, did not find statistically significant differences when compared to 
unexposed groups.137 
 
In contrast, there are no studies to my knowledge which have validated non-live 
birth recording in UK primary care data. In 2012, Ban et al analysed non-live births 
in THIN data in their study of pregnancies amongst women with depression and 
anxiety, generating point estimates for perinatal death, miscarriages and 
terminations, however no validations were performed.138 
111 
 
There are some studies which indicate that major congenital malformations are 
well recorded in primary care. However, methods used to obtain major congenital 
malformation diagnoses can be varied and decisions on which congenital 
malformations are classed as major can be subjective. Thus a validation of 
methods used to determine major congenital malformations is justified if the 
methods will consequently be used in further studies. Given that little is known on 
how well perinatal death is recorded in primary care, an analysis of the 
prevalence will shed light on its representativeness of the general population and, 
furthermore, if it is sufficient to use primary care data in the main study.  
 
6.3. Methods 
6.3.1 Study design 
A retrospective cohort study of pregnant women was conducted to estimate the 
birth prevalence of major congenital malformations and perinatal death in THIN.  
 
6.3.2 Definitions 
Birth prevalence 
The birth prevalence is measured as the number of cases with the outcome 
amongst the birth population.  
 
Major congenital malformations  
Congenital malformations are recorded in primary care data as Read code 
diagnoses which may be contained in either the child’s medical records or the 
mother’s. In the child’s records, a diagnosis was searched for up to one year after 
birth. In the mother’s records, an in utero diagnosis was searched for during the 
mother’s pregnancy.  
 
The Read code system does not distinguish major and minor congenital 
malformations. Thus, congenital malformation records identified from the mother 
or child’s medical records were first excluded if they were a minor malformation 
as classified using the EUROCAT list of minor anomalies (see Appendix 3). A 
specific exclusion was diagnoses of patent ductus arteriosus (PDA) recorded 
before 37 weeks gestation. (This is a defect of the valve connecting the 
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pulmonary artery and the aorta whereby the closure of the valve has failed and 
requires pharmacological/surgical intervention to correct. It is more likely to close 
without intervention in preterm babies, therefore these are not considered major 
malformations.) The remaining malformations records were individually reviewed 
by a GP to determine whether or not the congenital malformation was major. 
Associated free text was used to glean further information and if it remained 
unclear, the malformation was categorised as minor.  
 
Perinatal death 
This is defined as the death of the foetus in utero from 20 weeks gestation, 
stillbirth and early neonatal death in the first seven days of life. A Read code list 
based on a list of key words and synonyms of perinatal death was defined and 
used to identify events recorded in the medical records of pregnant women 
between 20 weeks gestation and one week after delivery (see Appendix 3). 
Pregnancies ending in stillbirth were also found in the Additional Health Data 
records under “Birth details”. In addition, the free text entries for pregnancies 
without a link to a child in THIN were interrogated for key words which identified 
records containing synonyms of perinatal death Table 8. Each case identified in 
the free text search was reviewed to confirm a diagnosis of perinatal death. 
 
Table 8 Key words used in search of free text entries in medical records of pregnant women 
Key words for perinatal death 
 stillbirth 
 still birth 
 still born 
 stillborn 
 fetal death 
 intrauterine death 
 iud 
 neonatal death 
 foetal death 
 death of foetus 
 death of fetus 
 perinatal death 
 infant death 
 newborn death 
 
Demographic factors 
Maternal age  
Age was calculated at the time of delivery and stratified into five-year age bands 
(<20, 20-24, 25-29, 30-34… ≥50 years). Where univariable analyses showed 
similar risks between adjacent age bands, these age bands were grouped for 
multivariable analyses.  
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Sex of baby 
This was only known for pregnancies linked to a child in THIN. A separate 
“Unknown” category was indicated where there was no linked child. 
 
Social deprivation 
A score of social deprivation is measured in quintiles by the Townsend score. A 
missing category was created for those where there is no measure of social 
deprivation.  
 
Calendar year 
This is the year of the delivery and is defined from 1994-2012.  
 
6.3.3 Data analysis 
Major congenital malformations 
The overall birth prevalence of major congenital malformations in the pregnancy 
cohort was calculated. Annual birth prevalence rates were calculated for each 
year between 1994 and 2012. Univariable analyses were conducted using 
Poisson regression to obtain risk ratios and 95% confidence intervals for 
differences in the risk of major congenital malformations across each of the 
demographic variables set out above. For year of delivery and age band, the 
group with the greatest denominator (i.e. number of pregnancies) was the 
reference group. For Townsend score, those with the lowest level of social 
deprivation (i.e. Townsend score = 1) were the reference group, and for sex of 
baby, males were the reference group.  Adjusted risk ratios were calculated in 
multivariable analyses using log-likelihood ratio tests to determine the inclusion 
of each variable into an adjusted model. Clustering of pregnancies with the 
individual patient level was examined as a random effect.  
 
The number of days from the start of pregnancy to the first record of a major 
congenital malformation was calculated for all pregnancies where a major 
congenital malformation was diagnosed. Using survival analysis techniques, the 
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timing of diagnosis entry into the primary care records is illustrated on a Kaplan-
Meier graph.  
 
Perinatal death 
Similar to the analysis of major congenital malformations, overall prevalence was 
calculated and differences by socio-demographic factors examined using 
Poisson regression. Annual rates were calculated between 1994 and 2012 to 
examine time trends.  
 
6.4. Results 
6.4.1 Major congenital malformations 
Of 353,171 pregnancies captured over the study period, 6,720 (1.9%) 
pregnancies were identified with a clinical record for a major congenital 
malformation recorded in either the mother’s or the child’s data. Figure 8 
describes how 20,848 pregnancies with any malformation recorded were reduced 
to only those 6,720 with a major malformation using the methods described 
earlier (section 6.3.2).   
 
Figure 8 Identification of major congenital malformations 
 
Birth prevalence rates over time 
The overall birth prevalence of major congenital malformations was 1.9% (95% 
CI 1.9-2.0%). Figure 9 shows the prevalence rate per year for 1994-2012. A 
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general increase can be seen between 1996 and 2001 from 1.2% (95% CI 0.9-
1.5%) to 2.1% (95% CI 1.9-2.3%) respectively. Since 2001, prevalence has 
remained relatively stable between 1.7% and 2.1%.  
 
Figure 9 Birth prevalence of major congenital malformations between 1994 and 2012 
 
 
Demographic characteristics 
Table 9 shows the prevalence rate across year bands, maternal age, and level of 
social deprivation and sex of the baby.  
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Table 9 Prevalence of major congenital malformations (MCMs) in 353,171 pregnancies by demographic factors 
 Total  
pregnancies  
 (N = 353,171) 
Pregnancies with 
MCMs, n (%) 
 
Unadjusted IRR 
(95% CI) 
p-value Adjusted IRR  
(95% CI) 
p-value 
Year of delivery 
1994-1999 
2000-2004 
2005-2009 
2010-2012 
 
46,032 
92,958 
140,835 
73,346 
 
661 (1.44) 
1,836 (1.98) 
2,816 (2.00) 
1,407 (1.92) 
 
0.72 (0.66-0.78) 
0.99 (0.93-1.05) 
1 
0.96 (0.90-1.02) 
 
<0.001 
 
0.87 (0.80-0.94) 
0.99 (0.94-1.05) 
1 
0.95 (0.89-1.01) 
 
0.006 
Age band (years) 
<20 
20-24 
25-29 
30-34 
35-39 
40-44 
45+ 
 
24,363 
58,016 
98,639 
108,699 
54,101 
8,982 
371 
 
488 (2.00) 
1,106 (1.91) 
1,807 (1.83) 
2,020 (1.86) 
1,088 (2.01) 
200 (2.23) 
11 (2.96) 
 
1.08 (0.98-1.19) 
1.03 (0.95-1.10) 
0.99 (0.93-1.05) 
1 
1.08 (1.01-1.16) 
1.20 (1.04-1.39) 
1.60 (0.88-2.89) 
 
0.017 
 
1.08 (0.97-1.19) 
1.01 (0.94-1.09) 
0.98 (0.92-1.05) 
1 
1.09 (1.01-1.17) 
1.21 (1.05-1.40) 
1.92 (1.06-3.48) 
 
0.004 
Townsend score 
1 
2 
3 
4 
5 
Missing 
 
81,256 
66,691 
69,195 
64,902 
48,620 
22,507 
 
1,475 (1.82) 
1,226 (1.84) 
1,364 (1.97) 
1,327 (2.04) 
933 (1.92) 
395 (1.76) 
 
1 
1.01 (0.94-1.09) 
1.09 (1.01-1.17) 
1.13 (1.05-1.21) 
1.06 (0.97-1.15) 
0.97 (0.87-1.08) 
 
0.007 
 
1 
1.02 (0.94-1.10) 
1.09 (1.02-1.18) 
1.14 (1.05-1.23) 
1.08 (0.99-1.18) 
1.00 (0.89-1.12) 
 
0.007 
Sex of baby 
Male  
Female 
 
147,766 
140,515 
 
4086 (2.77) 
2473 (1.76) 
 
1 
0.64 (0.61-0.67) 
 
<0.001 
 
1 
0.64 (0.61-0.67) 
 
<0.001 
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Maternal age 
In univariable analyses, the incidence of major congenital malformations was 
significantly different across age bands.  Women in the higher age bands – 35-
39 and 40-44 years – had a moderately increased risk of major congenital 
malformations (35-39: IRR 1.08 95% CI 1.01-1.16; 40-44: IRR 1.20 95% CI 1.04-
1.39). Women in younger age bands were not dissimilar to the baseline group. 
Adjusting for year of delivery, Townsend score of deprivation and the sex of the 
baby did not alter the risk ratios markedly, except for in the oldest group of 
women. The adjusted model found these women aged 45 and over were nearly 
twice as likely to have a baby with a major congenital malformation than women 
aged 30-34 years (adjusted IRR 1.92 95% CI 1.06-3.48).  
 
Social deprivation 
The risk of having a baby with a major congenital malformation differed 
significantly across levels of social deprivation however the risk ratios remained 
close to one in both univariable and multivariable analyses. Women in the least 
deprived group formed the baseline category and women with Townsend scores 
of 3 or 4 were at a slightly higher risk of major congenital malformations 
(Townsend = 3; adjusted IRR 1.09 95% CI 1.02-1.18; Townsend = 4: adjusted 
IRR 1.14 95% CI 1.05-1.23).  
 
Year of delivery 
The year of delivery was grouped into bands and rates compared to pregnancies 
delivered between 2005 and 2009. In year bands 2000-2004 and 2010-2012, 
confidence intervals crossed one in both univariable and multivariable analyses 
suggesting no difference in prevalence of major congenital malformations. 
However, prevalence was lower in earlier years between 1994 and 1999 
(adjusted IRR 0.87; 95% CI 0.80-0.94).  
 
Sex of baby 
Compared to males, female babies were 36% less likely to have a record of major 
congenital malformation (unadjusted and adjusted IRR 0.64; 95% CI 0.61-0.67).  
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Time of recording of major congenital malformations  
Figure 10 describes the proportion of the 6,720 pregnancies with a major 
congenital malformation which remained undiagnosed/unrecorded according to 
time since the start of pregnancy. The earliest a major congenital malformation 
can be diagnosed is at the 20 week anomaly scan, which is reflected in this graph. 
There were 205 diagnoses recorded prior to 20 weeks gestation - 6,515 (96.9%) 
major congenital malformations remained undiagnosed/unrecorded at this point. 
At the expected delivery date, two-thirds (n = 4,476) were still undiagnosed. By 
three months after delivery, 75% of the major congenital malformations captured 
in the first year were diagnosed/recorded.  
 
Figure 10 Pregnancies with a major congenital malformation diagnosis recorded up to one year after 
birth according to time of first diagnosis (MCM = major congenital malformation; EDD = expected 
delivery date) 
 
 
6.4.2 Perinatal death 
Case identification 
Perinatal death was defined as death in utero after 20 weeks gestation, stillbirth 
and early neonatal death of the newborn within seven days of life. Amongst 
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353,171 pregnancies recorded between 1994 and 2012, a total of 1,523 (0.4%) 
pregnancies ended in perinatal death. Of these, 1,401 were identified through a 
Read code search of the mother’s medical records, whilst the remaining 122 were 
identified through mother’s free text.  
 
Prevalence rates over time 
Annual rates of recording perinatal deaths in THIN have fluctuated over the study 
period (Figure 11). Prior to 2000, the prevalence of perinatal deaths was below 
0.5%. Between 2000 and 2004, the prevalence fluctuated between 0.5% and 
0.7% before falling back down to below 0.5%.  
 
Figure 11 Prevalence of perinatal death between 1994 and 2012 
 
 
Demographic characteristics 
Table 10 describes the prevalence of perinatal deaths by the year of delivery, age 
band and level of social deprivation.   
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Table 10 Prevalence of perinatal death in 353,171 pregnancies by demographic factors 
 Total 
pregnancies 
(N=353,171) 
Perinatal deaths 
n (%) 
Unadjusted IRR 
(95% CI) 
p-value Adjusted IRR 
 (95% CI) 
p-value 
Year of delivery 
1994-1999 
2000-2004 
2005-2009 
2010-2012 
 
46,032 
92,958 
140,835 
73,346 
 
179 (0.39) 
530 (0.57) 
561 (0.40) 
253 (0.34) 
 
0.98 (0.83-1.16) 
1.43 (1.27-1.61) 
1 
0.87 (0.75-1.00) 
 
<0.001 
 
1.01 (0.86-1.20) 
1.46 (1.30-1.65) 
1 
0.86 (0.74-1.00) 
 
<0.001 
Age band (years) 
<20 
20-24 
25-29 
30-34 
35-39 
40-44 
45+ 
 
24,363 
58,016 
98,639 
108,699 
54,101 
8,982 
371 
 
139 (0.04) 
237 (0.07) 
374 (0.11) 
428 (0.12) 
285 (0.08) 
56 (0.02) 
4 (0.00) 
 
1.45 (1.20-1.75) 
1.04 (0.89-1.22) 
0.96 (0.84-1.11) 
1 
1.34 (1.15-1.55) 
1.58 (1.20-2.09) 
2.74 (1.02-7.33) 
 
<0.001 
 
1.28 (1.05-1.56) 
0.96 (0.82-1.13) 
0.94 (0.82-1.08) 
1 
1.35 (1.17-1.57) 
1.63 (1.23-2.15) 
2.88 (1.07-7.70) 
 
<0.001 
Townsend score 
1 
2 
3 
4 
5 
Missing 
 
81,256 
66,691 
69,195 
64,902 
48,620 
22,507 
 
295 (0.08) 
289 (0.08) 
272 (0.08) 
301 (0.09) 
270 (0.08) 
96 (0.03) 
 
1 
1.19 (1.01-1.40) 
1.08 (0.92-1.28) 
1.28 (1.09-1.50) 
1.53 (1.30-1.80) 
1.17 (0.93-1.48) 
 
<0.001 
 
1 
1.22 (1.04-1.43) 
1.13 (0.95-1.33) 
1.34 (1.14-1.58) 
1.61 (1.35-1.91) 
1.26 (1.00-1.59) 
 
<0.001 
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Year of delivery 
Between 1994 and 2012, the prevalence of perinatal death varied slightly from 
its lowest in 2011 (0.3%) to its highest in 2001 (0.6%) (Figure 11). Analysis of 
calendar year in bands found that prevalence was slightly higher between 
2000 and 2004 (0.6%) compared to that between 2005 and 2009 (0.4%), even 
after adjusting for age and level of social deprivation (adjusted IRR 1.46; 95% 
CI 1.30-1.65).  
 
Maternal age 
In univariate analyses, women aged under 20 years were more likely to suffer 
perinatal death compared to those aged between 30 and 34 years (IRR 1.45, 
95% CI 1.20-1.75). Women in the three age bands older than 34 years were 
increasingly likely to suffer perinatal death – 34% more likely in those aged 35-
39 years, 58% more likely in those 40-44 years and nearly three times as likely 
in those over 45 years though numbers were very small in this group. Although 
accounting for differences over time did not alter the rates dramatically, a 
likelihood ratio test deemed the combined model more informative. 
 
Townsend score 
There was a significant difference across the quintiles with increasingly higher 
likelihood of perinatal death with increasing deprivation.  
 
A full model was tested including calendar year in bands, maternal age and 
Townsend score and the results of the adjusted IRRs are presented in Table 
10. The most dramatic change in estimates was that for the women aged 
younger than 20 years compared to 30-34 years – this estimate moved 
towards the null and after adjusting was 1.28 (95% CI 1.05-1.56). 
 
6.5. Discussion 
 
Of 353,171 pregnancies recorded in THIN between 1994 and 2012, nearly 2% 
were found to have a diagnosis of major congenital malformations and just 
under half a percent (0.4%) of pregnancies ended in perinatal death. Older 
age and greater level of social deprivation were associated with an increase 
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in risk for both major congenital malformations and perinatal death. Younger 
women (< 20 years old) were also at increased risks of perinatal death. 
Additionally, major congenital malformations were less common in female 
babies than males. More than 75% of diagnoses of major congenital 
malformations diagnosed either in utero or within a year after birth were 
recorded by three months after delivery. 
 
The prevalence rate of major congenital malformations identified in primary 
care is comparable with that estimated by other data sources. Figures for the 
UK from the European surveillance group, EUROCAT, showed annual rates 
varying between 123 per 10,000 in 1994 to 223 per 10,000 in 2006 – 
equivalent to 1.23% and 2.23% - and in 2012 the rate was 175 per 10,000, 
equivalent to 1.75% (http://www.eurocat-
network.eu/accessprevalencedata/prevalencetables).  
 
Further UK estimates of the prevalence of major congenital malformations 
have, in the past, been reported by the Office for National Statistics (ONS). 
However, this ended in 2008 due to poor case ascertainment which is evident 
from their rates estimated as low as 62 per 10,000 in 2008. A more reliable 
estimate of major congenital malformations prevalence in the UK is provided 
by BINOCAR (British Isles Network of Congenital Anomaly Registers). 
BINOCAR collate data from six regional registers covering approximately 36% 
of the births in England and Wales. Their latest estimates based on data 
collected in 2011 was 179 per 10,000 births (equivalent to 1.79%).139 
BINOCAR also records the timing of a diagnosis of major congenital 
malformations and, in 2011, 68% were diagnosed at birth and the remainder 
within a month after birth.139 This is faster than recording in primary care, and 
may reflect greater efficiency in notification of major congenital malformations 
to congenital anomaly registers compared to primary care.  
 
The prevalence of perinatal deaths estimated in THIN (0.4%) was slightly 
lower than national figures reported by the ONS. In 2012, 4.9 per 10,000 
equivalent to 0.49% pregnancies ended in perinatal death; in previous years 
back to 1992, the rate was just above 5 per 10,000 
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(http://www.ons.gov.uk/ons/publications/re-reference-
tables.html?edition=tcm%3A77-320855).  
 
Both maternal age and social deprivation were associated with the likelihood 
of a major congenital malformation or perinatal death. Older maternal age has 
long been associated with higher risks in pregnancy, particularly with 
chromosomal defects such as Down’s syndrome.140;141 However, the 
association with structural malformations such as those captured in this study, 
has been debated. Despite positive associations in several studies between 
older age and a specific malformation, cleft lip, some reviews have concluded 
that the overall risk of malformations is not substantially greater than in women 
of younger age. 142-145 My study found a higher risk of perinatal death was also 
increased in women younger than 20 years old. Adolescents are more likely 
to suffer certain complications such as anaemia and preterm birth,146-148 which 
may be contribute to the increased proportion of perinatal deaths observed in 
this age group. Other studies have conflicted, but the one of the largest studies 
conducted on data from the Center for Disease Control and Prevention's 
Linked Birth-Infant Death and Fetal Death database supported my finding 
when they compared women <15 years old to those ≥ 15 years and identified 
a higher prevalence of stillbirths in the younger population.149 Similar findings 
have been apparent amongst women of older maternal age – a greater 
likelihood of pregnancy complications and higher rates of foetal death in older 
women.150;151 The link between greater deprivation and poor pregnancy 
outcomes has also been observed in other studies.142;152;153 Women living in 
areas of higher deprivation are more likely to be smokers and consume alcohol 
in excess – behaviours which can affect the foetus if continued in 
pregnancy.154-156 A recent study recently found a disparity in the use of 
preconceptional folic acid between women from different levels of social 
deprivation.157 This may indicate a lower level of education on health in 
pregnancy in women from poorer areas.   
 
The results of this study have both research and clinical implications. Clinically, 
these results once again highlight certain groups which have a higher risk of 
serious adverse outcomes in pregnancy – older women and those in areas of 
greater deprivation – further reinforcing the need to continue efforts in 
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identifying and managing women who may need more support ante- and 
postnatally. In terms of research, this study shows that UK primary care data 
from THIN adequately captures cases of major congenital malformations and 
would therefore be ideal for research into drug teratogenicity, however 
perinatal deaths are slightly underestimated.  
 
The main strength of this study is that a large number of pregnancies in UK 
primary care were included, nearly 80% of which could be linked to a child. 
Thus the prevalence rate is likely to be representative of the UK population – 
this is evident from the comparison with EUROCAT and BINOCAR. However, 
there is a limited data on the outcome of pregnancies which could not be linked 
to a child. Despite a search of free text information for these pregnancies, there 
are still unknown outcomes which may have not been recorded in primary care 
such as terminations due to in utero diagnosis of a major congenital 
malformation. In this study, I used Read code diagnoses to identify which 
malformations were major, not minor. Given the complexity of diagnosing 
major congenital malformations, an ideal approach would be to gather 
information at the point of diagnosis with an examination of the 
foetus/newborn. This would reduce the likelihood of misclassification bias that 
may be prevalent without the option of examining each foetus/newborn. 
 
6.6. The next chapter 
Major congenital malformations and perinatal death are well recorded in 
primary care. The study confirms that THIN is a valid data source for 
examining major congenital malformations, and informs how THIN data can 
be used in the main study which is presented in the next chapter. 
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Chapter 7 
Antiepileptic drugs in pregnancy and the risk of major 
congenital malformations or perinatal death 
 
7.1. Aims and objectives of the chapter 
The aim of this chapter is to examine the drug specific associations between 
antiepileptic drug use in pregnancy and the risk of major congenital 
malformations and perinatal death. 
 
The objectives are as follows: 
1) In women who were prescribed antiepileptic drugs before pregnancy, 
determine the absolute risk of major congenital malformations or 
perinatal death for: 
a. each group of pregnancies prescribed individual antiepileptic 
drug monotherapy in the first trimester of pregnancy. 
b. pregnancies prescribed sodium valproate polytherapy in the first 
trimester of pregnancy. 
c. pregnancies where no antiepileptic drug therapy was prescribed 
in the first trimester of pregnancy. 
 
2) In women who were prescribed antiepileptic drugs before pregnancy, 
conduct head to head pairwise comparisons of the risk of the major 
congenital malformations or perinatal death between each of the 
following first trimester regimens, adjusting for differences in 
demographic and clinical characteristics: 
a. Lamotrigine monotherapy 
b. Carbamazepine monotherapy 
c. Sodium valproate monotherapy 
d. Sodium valproate polytherapy 
e. No therapy 
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7.2. Background 
Antiepileptic drugs are used by approximately two-thirds of people with 
epilepsy, and in recent years, are increasingly prescribed for mental health 
conditions, particularly bipolar disorder.30;34 
 
There are a wide variety of antiepileptic drugs available and drug regimens are 
tailored to individual needs and lifestyle preferences with respect to symptom 
control and side effects. For women, additional considerations are made 
because some antiepileptic drugs may be teratogenic – thus treatment choices 
should address how women wish to proceed with treatment in pregnancy.  
 
This can be a difficult decision because, as the literature review in Chapter 1 
revealed, there is lack of consistent findings from good quality research on 
some commonly used antiepileptic drugs in pregnancy and whether or not 
there are differential risks for the foetus between these drugs.  
 
In the UK, primary care is the first point of contact for over three-quarters of 
women when they become pregnant.109 It is also the main source of 
prescribing once a treatment regimen is established. Prescribing by general 
practitioner continues if a woman becomes pregnant, and thus primary care 
data provides crucial information on the type and timing of use of antiepileptic 
drugs in pregnancy.  This information is crucial in attributing major congenital 
malformations to drug exposures.  
 
In Chapter 5, I showed that 1 in 200 pregnant women in the UK were 
prescribed antiepileptic drugs during pregnancy, and furthermore that they 
were most commonly prescribed lamotrigine, carbamazepine and sodium 
valproate. Chapter 6 showed that, in UK primary care data, the prevalence of 
major congenital malformations and perinatal death were well captured in the 
patient records.  
 
This study therefore uses UK primary care data from The Health Improvement 
Network to examine whether there are specific associations between 
antiepileptic drug used in the first trimester and major congenital 
malformations and perinatal death. Furthermore, to compare risk estimates 
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amongst commonly used antiepileptic drugs in pregnancy and no therapy in 
pregnancy.  
 
7.3. Methods 
 
7.3.1. Study design 
This was a retrospective cohort study using primary care data from The Health 
Improvement Network. 
 
7.3.2. Definitions 
Study population 
The pregnancy cohort described in Chapter 3 was used. To recap, this 
included women if they met the following criteria: 
 Pregnant in the study period from 1994 to 2012, with the delivery date 
ending in the study period; 
 Aged 13-55 years at the time of delivery; 
 At least nine months of data prior to pregnancy start date; 
 At least six months of data after the delivery date; 
From this cohort, women were required to have at least two prescriptions of 
any antiepileptic drug within a three month period, of which at least one 
prescription was prior to pregnancy (six months to one month before 
pregnancy) in order to be included in the study population. This inclusion 
criterion was used to identify those women who were regularly receiving 
antiepileptic drugs rather than those who may be one-off users.  Figure 12 
below illustrates this criterion. Where a woman had more than one pregnancy, 
one pregnancy was selected at random. 
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Figure 12 Women were required to have two prescriptions within 3 months, and at least one 
prescription inside the inclusion period 
 
 
Exposure 
Exposure was defined as having received a prescription of an antiepileptic 
drug in the first trimester.  
 
Monotherapy exposure was defined as having received a prescription of only 
one type of antiepileptic drug. 
 
Polytherapy exposure was defined as having received prescriptions for more 
than one type of antiepileptic drug. 
 
First trimester was the period from one month before pregnancy to 105 days 
after the start of pregnancy (date of last menstrual period). The month before 
pregnancy has been included in the definition to capture accidental foetal 
exposure to antiepileptic drugs in the early weeks of pregnancy, before the 
pregnancy is known.  
 
Outcome 
The outcome was a composite of major congenital malformations and 
perinatal death i.e. babies with either a major congenital malformation or 
pregnancies ending in perinatal death being the outcome of interest. They 
were defined using the same methods as in Chapter 6. Perinatal death was 
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included to increase the sensitivity of the measure capturing those major 
congenital malformations which resulted in foetal death. 
 
Demographic and clinical characteristics 
To describe the characteristics of the women in each group, several 
demographic and clinical variables were extracted. Any differences in 
characteristics were then accounted for in the analysis.  
 
Year of delivery 
This was categorised as 1994-2000, 2001-2004, 2005-2009, 2009-2012 
based on the year in which the pregnancy ended.  
 
Maternal age 
This was the age of the mother at the time of delivery, stratified into five year 
age bands (<20, 20-24, 25- 29, 30-34, 35-39, 40-44, 45+). 
 
Social deprivation 
Social deprivation was measured by the quintiles of Townsend score, as has 
been used in the previous studies. 
 
Indication for antiepileptic drugs 
This was categorised into epilepsy, bipolar disorder/depression and other. 
Read code lists created for the prescribing patterns study in Chapter 5 were 
used to identify clinical records of epilepsy and bipolar disorder/depression 
made prior to the start of pregnancy. If a woman had more than one condition 
which could be treated with antiepileptic drugs, the hierarchy epilepsy > bipolar 
disorder/depression > other was used to categorise indication. 
 
Previous history of very heavy drinking 
Women who were heavy drinkers were identified through: 
- Alcohol consumption of greater than 35 units  a week recorded in 
additional health data made either in pregnancy or in the preceding 
three years;  
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- A Read code diagnosis for a very heavy drinker recorded either in 
pregnancy or in the preceding three years; 
- A prescription for alcohol cessation drugs received either in pregnancy 
or in the year before. 
 
Smoking status 
Women who were last recorded as a current smoker in the period from three 
years before pregnancy to delivery date were identified in three ways: 
- One or more cigarettes smoked per week recorded in additional health 
data;  
- Read codes indicating current smoker; 
- A prescription for smoking cessation drugs. 
 
Previous history of substance misuse 
Women who had a record of substance misuse in the three years before 
pregnancy or during pregnancy were identified through: 
- A Read code diagnosis indicating substance misuse; 
- A prescription for drugs to treat opioid dependence. 
Obesity 
Woman who were obese any time before pregnancy, excluding periods of 
previous pregnancies, were identified through 
- A recorded or calculated BMI ≥ 30 in additional health data before 
the start of pregnancy;   
- A Read code diagnosis of obesity before the start of pregnancy.  
 
Diabetes (uncontrolled glucose levels in pregnancy) 
Women with gestational diabetes, newly diagnosed diabetes in pregnancy or 
those with poorly controlled glucose levels in pregnancy. These were identified 
in three ways: 
- A Read code diagnosis for gestational or incident diabetes in 
pregnancy.  
- Abnormal (high, or greater than 6mmol/L)  results from fasting 
glucose tests and glucose tolerance tests in additional health data; 
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- A Read code for abnormal glucose tolerance tests in pregnancy.  
 
Co-medications 
Other drugs taken in pregnancy have been associated with an increased 
malformation risk. A binary variable was created indicating two or more 
prescriptions of each of the following drugs in the first trimester of pregnancy: 
- Antidepressants; 
- Antipsychotics; 
- Hypnotics and anxiolytics; 
- Non-steroidal anti-inflammatory drugs. 
 
7.3.3. Data analysis 
Absolute risks 
The absolute risk (AR) of major congenital malformations or perinatal death 
was calculated, with 95% confidence intervals (CIs), for each antiepileptic drug 
prescribed as monotherapy, for polytherapy regimens including sodium 
valproate and amongst pregnancies where no antiepileptic drugs were 
prescribed in the first trimester.  
 
Baseline characteristics 
Baseline demographic and clinical characteristics of women included in the 
study and in each of the sub groups of interest (lamotrigine monotherapy, 
carbamazepine monotherapy, sodium valproate monotherapy, sodium 
valproate polytherapy and no therapy) were described.  
 
Pairwise comparisons 
Unadjusted and adjusted analyses were conducted using Poisson regression 
to estimate incidence risk ratios (IRRs) and associated 95% CIs. A manual 
stepwise procedure to selecting pairwise comparisons was taken to reduce 
the likelihood of finding a falsely significant association due to multiple 
comparisons. This is described in Figure 13. Significant associations were 
determined at the 5% level.  
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Figure 13 Stepwise process for selecting pairwise comparisons 
 
CBZ = carbamazepine; LTG = lamotrigine; VPA = sodium valproate; MT = monotherapy; PT = 
polytherapy; AR = absolute risk 
 
Confounders 
All variables listed above were considered for inclusion in multivariable 
analyses of each pairwise comparison. Inclusion in the model was based 
examining the distribution of each variable amongst the exposure groups and 
clinical input.  
 
Sensitivity analysis 
Extending the first trimester period for pregnancies receiving no therapy 
The first trimester is the crucial period of foetal development during which 
major congenital malformations are likely to occur. In this study, the definition 
of first trimester has included the month before pregnancy – this is to capture 
foetal exposure to antiepileptic drugs from prescriptions made before 
conception and this is represented in Figure 14 as “Prescribing period 1”. 
Women with no antiepileptic drug prescriptions in prescribing period 1 are 
classed as the “no therapy” group in the analysis.  
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Given it is possible for prescriptions to be issued by a general practitioner for 
periods as long as three months, there may be some women in this group who 
have exposed their baby to antiepileptic drugs in utero if the prescription was 
made any time after two months before the start of pregnancy.  
 
A sensitivity analysis was conducted extending the prescribing period to three 
months before the start of pregnancy to the end of the first trimester, as per 
“Prescribing period 2” in Figure 14. This absolute risk was recalculated in this 
newly defined “no therapy” group and if different to the absolute risk obtained 
in the previous definition, pairwise comparisons were reanalysed using the 
new “no therapy” group.  
 
Figure 14 Sensitivity analysis - changing the length of the prescribing period 
 
 
7.4. Results 
Of 353,171 pregnancies, 1,933 had received more than one prescription of an 
antiepileptic drug in three months, with at least one prescription in the six 
months before pregnancy, and these were thus eligible for inclusion in the 
study. Selection of one pregnancy per woman reduced this to 1,633 
pregnancies. 
 
Table 11 sets out the different therapeutic regimens prescribed in the first 
trimester of the 1,633 pregnancies, including those not prescribed as a 
separate group. 
 
Most women in the study were prescribed carbamazepine monotherapy 
(22.1%; n = 361) followed by lamotrigine monotherapy (20.5%; n = 334) and 
sodium valproate monotherapy (13.9%; n = 227) in the first trimester. Other 
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monotherapy regimens were prescribed in 14.6% (n = 240) of pregnancies. 
Polytherapy including sodium valproate was prescribed in 5.1% of 
pregnancies (n = 83). Other polytherapy regimens were prescribed in 9.4% (n 
= 154) of pregnancies. No therapy was given in 14.3% (n = 234) pregnancies.  
 
Absolute risks 
Table 11 further describes the number of pregnancies with a major congenital 
malformation, or that ended in perinatal death by the different antiepileptic drug 
regimens. Overall, there were 54 cases of major congenital malformations or 
pregnancies ending in perinatal death, thus the overall absolute risk was 3.3% 
(95% CI 2.5-4.3%). Amongst the different regimens, the absolute risk of the 
composite outcome was highest in the sodium valproate polytherapy group 
where 10 out of the 83 pregnancies were cases (AR 12.0%; 95% CI 5.9-
21.0%). Among those prescribed monotherapy regimens, the absolute risk of 
major congenital malformations or perinatal death was highest in the 
carbamazepine group (AR 4.4%; 95% CI 2.6-7.1%), followed by sodium 
valproate (AR 3.5%; 95% CI 1.5-6.8%) and lamotrigine (AR 2.4%; 95% CI 1.0-
4.7%). Of those women who were prescribed antiepileptic drugs before, but 
not in the first trimester of pregnancy, the absolute risk was 3.0% (95% CI 1.2-
6.1%). There were 3 cases amongst 154 pregnancies prescribed polytherapy 
without sodium valproate, 1 case in the gabapentin monotherapy group and 
another case in the phenytoin monotherapy group. Figure 15 illustrates the 
absolute risks graphically. 
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Table 11 Absolute risks of major congenital malformations or perinatal death by drug regimen 
 
Number of 
pregnancies, 
 n (%) 
Number of 
cases, 
 n (%) 
 
 
AR (95% CI) 
All pregnancies  1633 (100.0) 54 (100.0) 3.3 (2.5-4.3) 
Monotherapy regimens    
carbamazepine 361 (22.1) 16 (29.6) 4.4 (2.6-7.1) 
lamotrigine 334 (20.5) 8 (14.8) 2.4 (1.0-4.7) 
sodium valproate 227 (13.9) 8 (14.8) 3.5 (1.5-6.8) 
gabapentin 70 (4.3) 1 (1.9) 1.4 (0.0-7.7) 
pregabalin 51 (3.1) 0 (0.0) - 
phenytoin 28 (1.7) 1 (1.9) 3.6 (0.1-18.3) 
topiramate 28 (1.7) 0 (0.0) - 
levetiracetam 25 (1.5) 0 (0.0) - 
clonazepam 15 (0.9) 0 (0.0) - 
acetazolamide 12 (0.7) 0 (0.0) - 
phenobarbital 4 (0.2) 0 (0.0) - 
ethosuximide 2 (0.1) 0 (0.0) - 
oxcarbazepine 2 (0.1) 0 (0.0) - 
zonisamide 2 (0.1) 0 (0.0) - 
primidone 1 (0.1) 0 (0.0) - 
Sodium valproate polytherapy 83 (5.1) 10 (18.5) 12.0 (5.9-21.0) 
No therapy in pregnancy 234 (14.3) 7 (13.0) 3.0 (1.2-6.1)  
 
Figure 15 Absolute risks of major congenital malformations or perinatal death by drug regimen 
 
CBZ = carbamazepine; LTG = lamotrigine; VPA = sodium valproate; GBP = gabapentin; PHT 
= phenytoin; MT = monotherapy; PT = polytherapy 
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Baseline characteristics 
 
Table 12 describes the characteristics of all 1,633 pregnancies included in the 
study and in the sub groups which were analysed in pairwise comparisons – 
(i.e. no therapy, carbamazepine monotherapy, lamotrigine monotherapy, 
sodium valproate monotherapy and sodium valproate polytherapy). 
 
Overall, the median age of the cohort was 30 years old [IQR 26-34]. Within 
each group, the median age did not differ from the overall median. The level 
of social deprivation varied slightly between groups. Amongst those prescribed 
no therapy in pregnancy, sodium valproate monotherapy and sodium 
valproate polytherapy in the first trimester, there were a higher proportion of 
women living in more deprived areas.  
 
The indication for antiepileptic drug prescribing was mainly epilepsy for each 
of the sub groups, with the exception of the no therapy group. Here, 50% of 
women were prescribed antiepileptic drugs for reasons other than epilepsy 
and bipolar disorder, approximately 30% for epilepsy, and around 20% for 
bipolar disorder. In each of the other groups, epilepsy was the indication for 
over 80% of women. However, in women prescribed lamotrigine monotherapy 
and women prescribed sodium valproate polytherapy, the proportion was 
closer to 95%. There were only 8 women (2%) and just 1 woman (1%) with 
bipolar disorder, and 7 women (2%) and 2 women with other reasons for 
antiepileptic drugs in the lamotrigine monotherapy group and sodium valproate 
polytherapy group respectively.  
 
Only 1% (n=16) of all women in the study population were found to have a 
record indicating they had been a very heavy drinker i.e. consuming more than 
35 units a week. There were less than 5 women in each subgroup. Similarly, 
few women were found to have incident or gestational diabetes in pregnancy 
affecting less than 2% of the study population.  
 
Around a quarter of women were most recently current smokers at the time of 
pregnancy – this was closer to 30% amongst women in those who received 
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no therapy in the first trimester and 20% in the carbamazepine monotherapy 
and sodium valproate polytherapy prescribed groups. A history of obesity was 
found in 20% of all pregnancies, as well as within each sub group - the 
exception was the carbamazepine monotherapy group where approximately 
15% of women had history of obesity. A history of substance misuse was low, 
around 2-3% in each group. 
 
Co-medication use varied across the subgroups - notably few women in the 
sodium valproate polytherapy group received other co-medications, possibly 
explained by the lower number with indications other than epilepsy. 
Antidepressant use was common in the first trimester, prescribed to 16% (n = 
266) overall, but only 6% (n = 5) in the sodium valproate polytherapy group. 
Overall antipsychotics use in the first trimester was low, approximately 4%. 
Very few were prescribed these in the lamotrigine monotherapy group and 
sodium valproate polytherapy group (n = 8 and 3, respectively). The use of 
hypnotics or anxiolytics was greater in those who received no therapy in the 
first trimester and in the sodium valproate group (~10%) compared to the 
carbamazepine and lamotrigine prescribed women (~5%).The use of NSAIDs 
was low (<5%) across all groups.  
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Table 12 Baseline characteristics of women in the study population 
  
 
All 
N = 1633 
n (%) 
First trimester antiepileptic drug treatment 
 
No therapy 
N = 234 
n (%) 
Carbamazepine 
monotherapy 
N = 361 
n (%) 
Sodium valproate 
monotherapy 
N = 227 
n (%) 
Lamotrigine 
monotherapy 
N = 334 
n (%) 
Sodium valproate 
polytherapy 
N = 83 
n (%) 
Maternal age (years) median [IQR] 30 [26-34] 30 [26-34] 27 [31-34] 30 [25-33] 29 [26-32.25] 30 [27-33] 
Maternal age (5 year age band)       
13-19 62 (3.8) 11 (4.7) 12 (3.3) 11 (4.8) 14 (4.2) 2 (2.4) 
20-24 230 (14.1) 31 (13.2) 41 (11.4) 37 (16.3) 51(15.3) 14 (16.9) 
25-29 451 (27.6) 66 (28.2) 97 (26.9) 59 (26.0) 104 (31.1) 20 (24.1) 
30-34 534 (32.7) 74 (31.6) 122 (33.8) 79 (34.8) 113 (33.8) 31 (37.3) 
35-39 286 (17.5) 43 (18.4) 74 (20.5) 36 (15.9) 44 (13.2) 11 (13.3) 
40-44 67 (4.1) 9 (3.8) 15 (4.2) 4 (1.8) 7 (2.1) 5 (6.0) 
44-55 3 (0.2) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 0 (0.0) 
Social deprivation Townsend score       
1 288 (17.6) 41 (17.5) 77 (21.3) 34 (15.0) 60 (18.0) 13 (15.7) 
2 251 (15.4) 35 (15.0) 58 (16.1) 32 (14.1) 53 (15.9) 8 (9.6) 
3 300 (18.4) 36 (15.4) 76 (21.1) 34 (15.0) 77 (23.1) 7 (8.4) 
4 367 (22.5) 56 (23.9) 58 (16.1) 75 (33.0) 61 (18.3) 24 (28.9) 
5 317 (19.4) 49 (20.9) 70 (19.4) 37 (16.3) 54 (16.2) 22 (26.5) 
Missing 110 (6.7) 17 (7.3) 22 (6.1) 15 (6.6) 29 (8.7) 9 (10.8) 
Year of delivery       
1994-1999 191 (11.7) 15 (6.4) 76 (21.1) 45 (19.8) 5 (1.5) 22 (26.5) 
2000-2004 361 (22.1) 46 (19.7) 115 (31.9) 71 (31.3) 47 (14.1) 21 (25.3) 
2005-2009 611 (37.4) 84 (35.9) 115 (31.9) 69 (30.4) 164 (49.1) 29 (34.9) 
2010-2012 470 (28.8) 89 (38.0) 55 (15.2) 42 (18.5) 118 (35.3) 11 (13.3) 
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All 
N = 1633 
n (%) 
First trimester antiepileptic drug treatment 
 
No therapy 
N = 234 
n (%) 
Carbamazepine 
monotherapy 
N = 361 
n (%) 
Sodium valproate 
monotherapy 
N = 227 
n (%) 
Lamotrigine 
monotherapy 
N = 334 
n (%) 
Sodium valproate 
polytherapy 
N = 83 
n (%) 
Indication for AEDs       
Epilepsy 1177 (72.1) 69 (29.5) 295 (81.7) 185 (81.5) 319 (95.5) 80 (96.4) 
Bipolar disorder/depression 137 (8.4) 46 (19.7) 26 (7.2) 23 (10.1) 8 (2.4) 1 (1.2) 
None/other 319(19.5) 119 (50.9) 40 (11.1) 19 (8.4) 7 (2.1) 2 (2.4) 
History of very heavy drinking** 16 (1.0) 2 (0.9) 3 (0.8) 1 (0.4) 4 (1.2) 0 (0.0) 
Smoker†† 400 (24.5) 66 (28.2) 79 (21.9) 59 (26.0) 79 (23.7) 18 (21.7) 
Diabetes in pregnancy 24 (1.5) 4 (1.7) 6 (1.7) 6 (2.6) 3 (0.9) 0 (0.0) 
History of obesity‡‡ 334 (20.5) 49 (20.9) 53 (14.7) 41 (18.1) 66 (19.8) 17 (20.5) 
Substance misuse§§ 47 (2.9) 9 (3.8) 7 (1.9) 9 (4.0) 6 (1.8) 1 (1.2) 
Antidepressants*** 266 (16.3) 32 (13.7) 59 (16.3) 27 (11.9) 31 (9.3) 5 (6.0) 
Antipsychotics*** 60 (3.7) 10 (4.3) 17 (4.7) 11 (4.8) 8 (2.4) 3 (3.6) 
Hypnotics/Anxiolytics*** 110 (6.7) 22 (9.4) 16 (4.4) 15 (6.6) 16 (4.8) 8 (9.6) 
NSAIDs*** 92 (5.6) 6 (2.6) 15 (4.2) 7 (3.1) 11 (3.3) 2 (2.4) 
                                            
 
 
** > 35 units alcohol per week recorded in the period from three years prior to pregnancy to delivery date 
†† Last recorded as a current smoker in the period from three years prior to pregnancy to delivery date 
‡‡ Record of obesity or body mass index > 30 recorded ever before pregnancy (excluding periods of previous pregnancies) 
§§ Recorded in the period from three years prior to pregnancy to delivery date 
*** Two or more prescriptions in the first trimester 
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Pairwise comparisons 
Carbamazepine and lamotrigine monotherapy prescribed groups 
In Chapter 6, I described that 1.9% (95% CI 1.9-2.0%) of pregnancies in the 
general population were diagnosed with a major congenital malformation. The 
absolute risk for major congenital malformations or perinatal death in 
carbamazepine and lamotrigine monotherapy prescribed pregnancies was 
greater than this (AR 4.4%; 95% CI 2.6-7.1% and AR 2.4%; 95% CI 1.0-4.7% 
respectively), therefore for the purposes of pairwise comparisons, these two 
groups were not combined.  
 
Unadjusted analyses 
Table 13 shows the unadjusted incident rate ratio (IRR) and associated 95% CIs 
of each pairwise comparison. The risk of major congenital malformations or 
perinatal death was significantly higher in sodium valproate polytherapy 
prescribed pregnancies compared to no therapy in pregnancy (IRR 4.03; 95% CI 
1.53-10.58), carbamazepine monotherapy (IRR 2.72; 95% CI 1.23-5.99), 
lamotrigine monotherapy (IRR 5.03; 95% CI 1.99-12.74) and sodium valproate 
monotherapy (IRR 3.42; 95% CI 1.35-8.66) in the first trimester. For each of the 
other comparisons, there was no evidence of a difference in risk.  
 
Adjusted analyses 
History of very heavy drinking, diabetes in pregnancy and history of substance 
misuse were excluded from every model due to low numbers. Further exclusions 
were made in the below pairwise comparisons where frequencies were below 5. 
These are also set out in Table 13. 
 First trimester antipsychotic and NSAIDs use between sodium valproate 
polytherapy and carbamazepine monotherapy and also between sodium 
valproate polytherapy and monotherapy 
 First trimester NSAIDs use between sodium valproate polytherapy and 
lamotrigine monotherapy 
 First trimester use of antidepressants, antipsychotics and NSAIDs 
between sodium valproate polytherapy and no therapy 
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Adjusted results are shown in Table 13. The impact was minimal on the 
previously significant findings from unadjusted comparisons between sodium 
valproate polytherapy and each of the other drugs – effect estimates changed 
slightly. However, the adjusted model comparing the risk in the lamotrigine 
monotherapy group with the no therapy groups finds a lower likelihood in the 
lamotrigine prescribed group, (adjusted IRR 0.27; 95% CI 0.08-0.82 and 
unadjusted IRR 0.80; 95% CI 0.29- 2.21). 
 
I conducted a further adjusted analysis on each of the four comparisons with 
sodium valproate polytherapy, restricting to only women with epilepsy. This is 
because there were few women given sodium valproate polytherapy for other 
indications - one woman had bipolar disorder and two had other indications 
Table 12). After restricting the analysis to women with epilepsy, and adjusting for 
other variables, the association between sodium valproate polytherapy and those 
who received no therapy was no longer significant (adjusted IRR 1.67; 95% CI 
0.63-4.45). There was little change in the IRRs for the other comparisons with 
sodium valproate polytherapy (Table 13).  
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Table 13 Drug specific pairwise comparisons of incidence of major congenital malformations or perinatal death 
Drug 1 
Drug 2  
(Reference group) 
Unadjusted IRR 
(95% CI) 
Adjusted IRR* 
(95% CI) 
Adjusted IRR* 
(95% CI)  
(WWE only) 
Variable 
exclusions 
Sodium valproate 
polytherapy (PT) 
No therapy  4.03 (1.53-10.58) 4.07 (1.77-9.38) 1.67 (0.63-4.45) 
Antidepressants; 
antipsychotics; 
NSAIDs 
Sodium valproate PT Carbamazepine 
monotherapy (MT) 
2.72 (1.23-5.99) 2.45 (1.19-5.04) 2.24 (1.07- 4.67) Antipsychotics; 
NSAIDs 
Sodium valproate PT Lamotrigine MT 5.03 (1.99-12.74) 4.46 (1.62-12.27) 4.53 (1.61-12.69) NSAIDs 
Sodium valproate PT  Sodium valproate MT 3.42 (1.35- 8.66) 3.40 (1.38-8.34) 3.51 (1.37-8.99) Antipsychotics; 
NSAIDs 
Sodium valproate MT No therapy  1.18 (0.43-3.24) 0.89 (0.27-2.98)   
Sodium valproate MT Carbamazepine MT 0.80 (0.34-1.86) 0.82 (0.32-2.10)   
Sodium valproate MT Lamotrigine MT 1.47 (0.55-3.92) 1.77 (0.57-5.48)   
Lamotrigine MT Carbamazepine MT 0.54 (0.23-1.26) 0.49 (0.20-1.23)   
Lamotrigine MT No therapy  0.80 (0.29-2.21) 0.27 (0.08-0.82)   
Carbamazepine MT No therapy  1.48 (0.61-3.60) 0.92 (0.32-2.67)   
*Full model comprised maternal age band, Townsend, year of delivery, indication for AEDs, smoker, history of obesity, antidepressants, antipsychotics, 
hypnotics/anxiolytics, NSAIDs use in the first trimester. Some of these variables were excluded, as stated in the table, due to few numbers (less than 5 events). WWE 
= women with epilepsy 
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Sensitivity analyses 
Extension of prescribing period 
To recap, the definition of the first trimester was altered for identifying women 
who received no therapy in the first trimester as follows: 
- Previous definition: women who were not prescribed antiepileptic drugs 
from one month before pregnancy to the end of the first trimester 
- New definition: women who were not prescribed antiepileptic drugs 
from three months before pregnancy to the end of the first trimester  
Using the new definition, the number of women receiving no therapy in the first 
trimester was reduced from 234 to 120 pregnancies. Of these, four cases of major 
congenital malformations or perinatal death were identified resulting in an 
absolute risk of 3.3% (95% CI 0.9-8.3%). This was similar to the risk obtained 
using the previous definition (AR 3.0%; 95% CI 1.2 -6.1%).  
 
Additional analysis of polytherapy regimens 
Table 14 below provides a breakdown of the antiepileptic drugs which were 
prescribed with sodium valproate, and the number of cases found according to 
each regimen. Nearly a third were prescribed lamotrigine, and nearly 20% 
prescribed carbamazepine with sodium valproate. The 10 cases were spread out 
amongst different treatment regimens showing no clear pattern due to the small 
numbers found in each regimen.  
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Table 14 Polytherapy regimens in women prescribed sodium valproate in the first trimester of 
pregnancy 
Polytherapy regimen with sodium 
valproate 
(N = 83) 
 
n (%) 
Number of 
cases 
(N = 10)  
lamotrigine 27 (32.5) 2 
carbamazepine 16 (19.3) 2 
phenytoin 8 (9.6) 2 
levetiracetam 5 (6.0) 1 
clonazepam 5 (6.0) 0 
topiramate 5 (6.0) 1 
lamotrigine, carbamazepine 4 (4.8) 0 
ethosuximide 2 (2.4) 0 
lamotrigine, levetiracetam 2 (2.4) 0 
vigabatrin 1 (1.2) 0 
clobazam 1 (1.2) 0 
carbamazepine, acetazolamide 1 (1.2) 0 
carbamazepine, ethosuximide 1 (1.2) 0 
carbamazepine, clonazepam 1 (1.2) 1 
carbamazepine, phenytoin 1 (1.2) 0 
lamotrigine, clobazam 1 (1.2) 0 
lamotrigine, topiramate 1 (1.2) 1 
lamotrigine, carbamazepine, 
topiramate 
1 (1.2) 0 
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7.5. Summary 
This was a retrospective cohort study of women who were prescribed antiepileptic 
drugs, examining their pregnancies between 1994 and 2012 for first trimester use 
of antiepileptic drugs and the associated drug specific risks of major congenital 
malformations or perinatal death using UK primary care data. 
 
Approximately 3% (AR 3.3%; 95% CI 2.5-4.3%) of pregnancies in primary care 
between 1994 and 2012 resulted in a major congenital malformation or ended in 
perinatal death. Of pregnancies where carbamazepine monotherapy was 
prescribed in the first trimester, 4% (AR 4.4%; 95% CI 2.6-7.1%) had a major 
congenital malformation or ended with perinatal death. A similar risk was 
observed for first trimester sodium valproate monotherapy prescribed 
pregnancies (AR 3.5%; 95% CI 1.5-6.8%). Around 2% (AR 2.4%; 95% CI 1.0-
4.7%) of first trimester lamotrigine monotherapy prescribed pregnancies were 
affected. The highest risk was found amongst women prescribed sodium 
valproate as polytherapy in the first trimester where 12% (AR 12.0%; 95% CI 5.9-
21.0%) of pregnancies led to major congenital malformations or ended in 
perinatal death. Women who were prescribed antiepileptic drugs before 
pregnancy but not during the first trimester, had a similar risk to the overall study 
population (AR 3.0%; 95% CI 1.2-6.1%) 
 
There is a significantly greater risk of the major congenital malformations or 
perinatal death associated with sodium valproate polytherapy compared to other 
antiepileptic drug monotherapy regimens. Specifically, a three-fold greater risk 
compared to women taking first trimester carbamazepine monotherapy (IRR 
2.72; 95% CI 1.23-5.99), three-fold compared to women taking first trimester 
sodium valproate monotherapy (IRR 3.42; 95% CI 1.35-8.66) and five-fold 
compared to women taking lamotrigine monotherapy (IRR 5.03; 95% CI 1.99-
12.74). The risk of major congenital malformations or perinatal death was 
comparable between pregnancies prescribed first trimester lamotrigine 
monotherapy, carbamazepine monotherapy, sodium valproate monotherapy and 
no therapy.  
 
In this study there was a risk of 3.0% (95% CI 1.2-6.1%) among those who were 
receiving antiepileptic drugs prior to pregnancy but were not prescribed 
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antiepileptic drugs in the first trimester. This was similar to the Australian Register 
of Antiepileptic Drugs in Pregnancy (3.3%),158 the UK Epilepsy and Pregnancy 
Register17 (3.5%) and in Finland (2.8%)11 but higher than the North American 
AED Pregnancy Registry (1.1%).129   
 
Many studies have found a low risk of major congenital malformations amongst 
lamotrigine exposed pregnancies, which is consistent with the findings in this 
study where 2.4% (95% CI 1.0-4.7%) of pregnancies were affected. The UK, 
North America, and several international collaborative studies including the 
International Lamotrigine Pregnancy Registry,15;81;129;159;159-161 have found 
estimates of risk to be between 1 and 3%. 
 
However, estimates of risk in carbamazepine monotherapy pregnancies vary - in 
this study, the risk was 4.4% (95% CI 2.6-7.1%) whereas other studies produced 
a wide range of estimates from the 2.6% (95% CI 1.9-3.5%) in the UK Epilepsy 
and Pregnancy Register to 8.2% (95% CI 3.8-15.0%) in the US/UK 
Neurodevelopmental Effects of Antiepileptic Drugs study.15;81;131;160  
 
Similarly, estimates of risk in sodium valproate monotherapy exposed 
pregnancies has been varied in previous research from 6.3% to 20.3%.15;81;131;158 
The absolute risk amongst sodium valproate monotherapy users was lower in this 
study (3.5%; 95% CI 1.5-6.8%) compared to previous findings.  
 
Few studies have examined the risk of foetal outcomes associated with 
polytherapy regimens. In Norway, Veiby et al studied foetal growth restriction and 
major congenital malformations in antiepileptic drug prescribed pregnancies.131 
There were 77 pregnancies with exposure to sodium valproate polytherapy, of 
which only four children had a major congenital malformation (5.2%). A larger 
study in the UK by Morrow et al used data from the UK Epilepsy and Pregnancy 
Register which included 304 pregnancies with sodium valproate polytherapy 
exposure, of which 9% had a major congenital malformation.17 In the Australian 
Pregnancy Registry, Vadja et al identified a risk of 10.2% in sodium valproate 
polytherapy exposed pregnancies.158 
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Due to the few studies which have examined women on sodium valproate 
polytherapy, there is little research to corroborate the associations found between 
sodium valproate polytherapy prescribed pregnancies and the other 
monotherapy regimens in this study. The Australian Pregnancy Registry found a 
higher rate of malformation in the sodium valproate polytherapy group compared 
to lamotrigine monotherapy, carbamazepine monotherapy and no therapy 
(10.2% vs. 4.6%, 5.5% and 3.3% respectively), however it was lower than that in 
women who took sodium valproate monotherapy (13.8%).158 Similarly, Veiby et 
al found rates in sodium valproate polytherapy exposed pregnancies higher than 
that in lamotrigine monotherapy, carbamazepine monotherapy but not compared 
to sodium valproate monotherapy (5.2% vs. 3.4%, 2.9% and 6.3% 
respectively).131  
 
There was evidence from the UK Epilepsy and Pregnancy Register that there is 
a greater risk amongst women who take sodium valproate polytherapy compared 
to lamotrigine monotherapy, carbamazepine monotherapy and sodium valproate 
monotherapy (9.0% vs. 3.2%, 2.2%, 6.2% respectively).17 Another study from the 
North American AED Pregnancy Registry in 2011 also identified a negative effect 
of sodium valproate in polytherapy.161  They examined specific polytherapy 
regimens involving only two drugs, one drug being sodium valproate, and 
compared the rate of malformations with pregnancies exposed to the other drug 
in monotherapy. The difference was stark – carbamazepine monotherapy had a 
risk of 2.9% whilst carbamazepine plus sodium valproate carried a risk of 15.4% 
(OR 6.2; 95% CI 2.0-16.5). For lamotrigine monotherapy, the risk was 1.9%; 
lamotrigine plus sodium valproate 9.1% (OR 5.0; 95% CI 1.5-14.0).  
 
The significantly higher risk pregnancies with sodium valproate polytherapy could 
be due to the teratogenic properties of sodium valproate, however, there is a 
differential in risk between sodium valproate polytherapy and sodium valproate 
monotherapy regimens indicating that there is an alternative, or additional, 
reason. Polytherapy itself may play a role - this is an understudied area due to 
the low numbers that are generally observed to be prescribed polytherapy in 
pregnancy, which is a further compounded when studying specific regimens. This 
study did not investigate all polytherapy regimens, and Table 14 shows that there 
were too few women in specific polytherapy regimen groups to study separately. 
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Another explanation is that women who are prescribed polytherapy in pregnancy 
have a greater disease severity than those who were prescribed monotherapy 
regimens. If the severity of an underlying condition for which antiepileptic drugs 
are prescribed is associated with a higher risk of malformations independent of 
the specific drug treatment then this may explain the findings. Unfortunately, 
disease severity is one measure that cannot be directly measured in THIN data.  
 
In contrast to other studies, the risk amongst sodium valproate monotherapy 
exposed pregnancies, in this study, was not significantly higher than in the other 
regimens. In Chapter 1, the literature search found consistent evidence of 
elevated teratogenic risks in sodium valproate exposed pregnancies which has 
been key in changing practice guidelines for women with epilepsy.31;63 Therefore 
one questions whether or not the observed relatively low risk of 3.5% is 
representative. A possible explanation is the under recording of termination data. 
Sodium valproate is associated, specifically, with spina bifida – a malformation 
which can be detected in the 20 week anomaly scan conducted on all 
pregnancies.14;81;162 According to EUROCAT, approximately 75% of prenatally 
diagnosed cases of spina bifida are terminated (Figure 16). Without knowledge 
of terminations, prenatal diagnoses may be missed and therefore risks 
underestimated.  
 
Figure 16 Proportion of cases of spina bifida terminated following prenatal diagnosis 
(http://www.eurocat-network.eu/accessprevalencedata/prevalencetables) 
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A second explanation for the observed lower risk in women prescribed sodium 
valproate monotherapy may be due to misclassification. Women may be 
prescribed the treatment, but do not take the drugs in the first trimester thus 
incorrectly defined as exposed leading to a dilution of the true effect in this group.  
 
This study used real-world data to explore the comparative teratogenicity of 
antiepileptic drugs. In the UK, the use of real-world data for this study has several 
advantages: 
- A medical history including diagnoses, medications prescribed, and 
test data is collected for the purposes of patient management, 
therefore UK primary care data should be accurate and complete; 
- Prospective collection of data reduces bias in the recalling of risk 
factors; 
- The UK operates a “gatekeeper” health care system whereby the 
general practitioner must be the first point of contact for onward referral 
to specialist care; 
- Unlike pregnancy registry studies, selection bias is minimised since 
over 95% of pregnant women consult their GP in pregnancy in the 
UK;109  
- Medical record based information on prescriptions provides a more 
reliable method for ascertainment of the timing an type of exposure 
than a retrospective interview; 
- An internal comparison group who had previously been prescribed 
antiepileptic drugs but were not given further antiepileptic drug 
treatment in their first trimester was available. 
However, there are limitations which must be borne in mind: 
- The use of prescriptions to examine teratogenicity assume that the 
woman has consumed the drugs as prescribed;  
- The pregnancy cohort was large, however when examining specific 
drugs, the sample size was reduced and may not have been adequate 
to detect moderate differences in risk; 
- Despite a reasonable estimate of birth prevalence of major congenital 
malformations in the general population, there may be cases of non-
live birth not captured, particularly from terminations;  
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- As described earlier, a measure of disease severity is difficult to find in 
the given data, which may be an issue if it is associated with the 
outcome. 
 
7.6. How this informs the next chapter 
The results of this study help to inform women and health care professionals on 
their choice of antiepileptic drug treatment in pregnancy, and furthermore, it 
provides direction for future research in this area. The next chapter summarises 
the three studies covered in this thesis and returns to the literature bringing 
together the findings from this PhD with the current understanding of the 
teratogenic effects of antiepileptic drugs. This overview informs overall 
recommendations for clinical practice and how research should be conducted in 
this area in the future.  
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Chapter 8 
Thesis discussion 
 
8.1. Summary of key points in the thesis 
The broad aim of this PhD was to develop an understanding of the 
pharmacoepidemiology behind antiepileptic drugs in pregnancy. This is 
demonstrated by this thesis. The main research contained in this thesis aimed to 
provide quantitative estimates of comparative risks of major congenital 
malformations and perinatal death between common antiepileptic drugs 
regimens, thus increasing the information available to treating physicians and 
women taking antiepileptic drugs. 
 
At the beginning of the thesis, I provided a broad background to assist the reader 
in understanding the content of the thesis, along with a current review of the 
literature around the comparative risk of major congenital malformations between 
common antiepileptic drugs taken in the first trimester of pregnancy. Here, I 
highlighted that although research into these adverse effects has been conducted 
for decades, the overall understanding of the effects of individual drug regimens, 
and the effect relative to other regimens, is unclear. Studies find conflicting 
evidence of a difference in risk when comparing carbamazepine, lamotrigine and 
no therapy. However, the exception to this was the one drug, sodium valproate 
which according to national guidelines one needs to avoid in pregnancy, if 
possible. Research consistently found an increased risk of major congenital 
malformations amongst women who took sodium valproate in pregnancy – risk 
increases as high as fivefold.17;18;20 With respect to study design, the literature 
review also highlighted a series of biases in previous studies including selection, 
information and recall bias.  
 
For the three studies in this thesis, I have used data from The Health 
Improvement Network (THIN). This holds routinely collected data from UK 
primary care GP consultations for over 11 million patients since 1994. The main 
advantage of using such data was that it would provide a large sample size 
without selection bias which accompanies the use of pregnancy registries for 
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these types of studies. Furthermore, it holds prospectively collected data based 
on information which, by nature, should be accurate as the primary purpose of 
the database is for patient care and management.  
 
Between 1994 and 2012, a cohort of over 350,000 pregnancies was identified in 
THIN, of which 80% of the mother’s medical records could be matched to a set 
of child’s records. This cohort of pregnancies formed the basis of each study in 
this thesis. Specifically, these three studies were: 
 
1. Antiepileptic drug prescribing in pregnancy in primary care 
2. Prevalence of major congenital malformations and perinatal death in 
primary care 
3. Antiepileptic drugs in pregnancy and the risk of major congenital 
malformations or perinatal death 
 
The first study revealed around 1 in 200 pregnant women in UK primary care 
were prescribed antiepileptic drugs during their pregnancy. Amongst these 
women, the most commonly used drugs were carbamazepine, sodium valproate 
and lamotrigine. However, the order of preference over these three drugs varied 
over the study period 1994-2012 with carbamazepine and sodium valproate 
declining in use whilst lamotrigine became increasingly prescribed. Many women 
with epilepsy, approximately 60%, prescribed antiepileptic drugs before 
pregnancy, continued to do so throughout pregnancy however there was a 
different picture for the smaller group of women prescribed antiepileptic drugs for 
mental health conditions. Here, the discontinuation rate was steep at the 
beginning of pregnancy with only 25% continuing therapy past the first six weeks 
of pregnancy.  
 
In the second study, the focus was on the outcome of interest for the main study 
– major congenital malformations and perinatal death. It was necessary to 
examine overall recording of these outcomes in the data since these are usually 
diagnosed in hospital – thus, the reliance is on effective communication of such 
diagnoses from hospital to primary care. Of the 350,000 pregnancies in the 
cohort, nearly 2% were identified to have a diagnosis of a major congenital 
malformation. Compared to a number of external sources, this was a reasonable 
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estimate and this suggested that these data were well recorded.  The recording 
of perinatal death was 0.4%, slightly lower than figures from the Office for 
National Statistics (0.49%). 
 
The third and final study was the main feature of this thesis. The aim was to be 
able to provide quantified differences in risk between antiepileptic drug regimens 
in order that women and health care professionals can balance their individual 
risks and benefits of continued drug therapy in pregnancy. Of women who were 
taking antiepileptic drugs prior to pregnancy, the overall risk of major congenital 
malformations or perinatal death was higher than that estimated in the general 
population – 3.3% (95% CI 2.5-4.3%) vs. 1.9% (95% CI 1.9-2.0%). When dividing 
this cohort into sub groups according to their treatment in the first trimester, risks 
varied between common monotherapies – carbamazepine (AR 4.4%; 95% CI 
2.6-7.1%), lamotrigine (AR 2.4%; 95% CI 1.0-4.7%) and sodium valproate (AR 
3.5%; 95% CI 1.5-6.8%)  Women who were not prescribed antiepileptic drug 
treatments in the first trimester, had a risk similar to the overall cohort, around 3% 
(95% CI 1.2-6.1%). The greatest concern is for women taking sodium valproate 
polytherapy. Of those prescribed this in their first trimester, there was an absolute 
risk of 12% (95% CI 5.9-21.0%) and a threefold increase in risk compared to 
carbamazepine monotherapy, and sodium valproate monotherapy and fivefold 
compared to lamotrigine monotherapy.  
 
8.2. Discussion of findings  
8.2.1. Background 
It is important to recall the fundamental reasons for studying adverse effects of 
drugs in pregnancy. It is known that a foetus undergoes significant development 
in the first trimester of pregnancy. It is known that some drugs ingested by the 
mother can cross the placental barrier. It is known that some drugs that cross this 
barrier have the potential to interfere with foetal development causing structural 
deformities. Yet, what is not known is the extent to which certain drugs have these 
effects prior to new drugs being marketed for general use. Therefore the only way 
of assessing adverse effects of drugs in pregnancy is to study this in post 
marketing observational studies.  
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Major congenital malformations can occur in any pregnancy – the risk being 
between 1 and 3%.3 Major malformations are distinguished from minor ones by 
the extent of the malformation and the need for intervention such as surgery or 
long term care, as well the associated risk of death as a result. The historic 
scandal of thalidomide and its devastating malformations of the foetus marked 
the initiation of a wave of regulation, monitoring and research. Since then 
research into drug safety in pregnancy has developed in all forms from 
observational cohort studies to the establishment of pregnancy registries.  
 
Research on antiepileptic drugs has spanned decades – one of the earliest by 
Spediel and Meadow in 1972 found pregnant women with epilepsy were twice as 
likely to result in a congenital abnormality or foetal death.163 There have since 
been a large number of studies into these older antiepileptic drugs. However, 
research on many of these older drugs is no longer necessary, with the exception 
of sodium valproate and carbamazepine which are still commonly used in the 
general population as well as in pregnancy.121;164;165  This past research is likely 
to have led to the generally used statistic that, on average, antiepileptic drugs 
increase the risk of major congenital malformations by two to three times. 
However, many studies used women in the general population as a comparator 
and were possibly subject to confounding by indication should the disease 
indication be a risk factor itself. Despite this and other limitations to the studies 
on these older drugs, the common finding was that sodium valproate bore a high 
risk of teratogenic effects.17;18;20;73;166;167 As for the newer antiepileptic drugs 
which have been increasingly used in the general population,121;164;165 examining 
the effect of the drug in pregnancy has been limited since it requires observation 
of a large numbers. Previous studies have mostly been based on small sample 
sizes because research was carried out in years soon after the drug was 
marketed. More recent studies have been larger in size (these are discussed in 
a later section), reflecting the increased use of lamotrigine in pregnancy, however 
at the time of the starting this PhD, little could be inferred from the limited 
evidence available on lamotrigine. Of studies that had been reviewed in Chapter 
1, all but one found no evidence of a difference in risk of major congenital 
malformations for lamotrigine. 
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8.2.2. Discussion of results in relation to current literature 
8.2.2.1. Key points of the thesis 
The primary question of this thesis was, what are the risks of major congenital 
malformations associated with first trimester antiepileptic drug use? Further, it 
was to examine how the risks were relative to other regimens. Using UK primary 
care electronic health records from THIN to study this research question, the first 
two studies were conducted to gain an understanding of THIN data so as to allow 
the exploration of antiepileptic drugs and the recording of adverse foetal 
outcomes which are not generally diagnosed in the primary care setting.  
 
The drug utilisation study described in Chapter 5 confirmed well-recorded data 
on antiepileptic drug prescribing. The findings were similar to several other 
studies, specifically, the most commonly used drugs in pregnancy and the secular 
trends in prescribing. As expected, sodium valproate, carbamazepine and 
lamotrigine were preferred treatments in pregnancy. Over time, an increasing 
number of pregnant women were prescribed lamotrigine, and fewer getting 
sodium valproate and carbamazepine, the two older drugs associated with 
negative foetal effects in previous studies. This study also examined whether or 
not pregnancy was a determinant for discontinuation. There has to my 
knowledge, been little research on this despite the need to be aware of the risks 
of abrupt discontinuation of medication in pregnancy. There was a disparity in 
discontinuation rates between pregnant and non-pregnant women.  Pregnant 
women were more likely to discontinue treatment and this differed depending on 
whether the woman had epilepsy or bipolar disorder. Women with bipolar disorder 
were highly likely to cease medication in the first trimester. Bipolar disorder is a 
severe mental illness with characteristic illness peaks and troughs and hence, 
must be managed to prevent mood relapses. Of the small number of women 
treated for bipolar disorder, only half continued on alternative antidepressant or 
antipsychotic drugs.  An interesting finding that emerged from this work is that 
discontinuation amongst women with epilepsy was more likely to occur in women 
prescribed sodium valproate rather than carbamazepine and lamotrigine.  This 
indicates that there is an awareness of the greater negative effects of the use of 
sodium valproate in pregnancy.  
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Having examined the recording of antiepileptic drug prescribing in pregnancy, the 
next step was to validate the outcomes of interest in the main study. Although, 
antiepileptic drug prescribing occurs predominantly in primary care, major 
congenital malformations and perinatal death are generally diagnosed elsewhere 
and communicated back to the general practitioner after the event. Thus the 
purpose of the second study (Chapter 6), was to estimate the incidence in the 
general population in THIN and assess whether this compared favourably with 
other external sources. The incidence of major congenital malformations was 
estimated to be 1.9%, which was within the background risk of 1-3%. Comparison 
with external sources such as EUROCAT (an international congenital 
malformation registry) and BINOCAR (a UK congenital malformation registry) 
suggested that this compared favourably with their figures suggesting that most 
major congenital malformations were captured in THIN. The estimate of incidence 
of perinatal death was very slightly lower when compared to ONS figures – 0.4% 
compared to 0.5%.  
 
These two studies supported the decision to use data from THIN for the main 
study looking into the relative risks of major congenital malformations or perinatal 
death associated with first trimester antiepileptic drug use. In unadjusted 
comparisons between the three most commonly prescribed monotherapy 
regimens (lamotrigine, carbamazepine, sodium valproate), I found the risks of 
major congenital malformations or perinatal death were similar (lamotrigine 
monotherapy vs. carbamazepine monotherapy, IRR 0.54, 95% CI 0.23-1.26; 
sodium valproate monotherapy vs.  carbamazepine monotherapy, IRR 0.80, 95% 
CI 0.34- 1.86; sodium valproate monotherapy vs. lamotrigine monotherapy, IRR 
1.47, 95% CI 0.55-3.92). Furthermore, there was no evidence of a difference in 
each of these groups compared to the risk amongst women who were not treated 
in the first trimester. The major concern drawn from this study was the risk 
associated with sodium valproate polytherapy – an absolute risk of 12%, 
increases the risk fivefold compared to lamotrigine monotherapy (IRR 5.03; 95% 
CI 1.99-12.74), threefold compared to sodium valproate monotherapy (IRR 3.42; 
95% CI 1.35-8.66), threefold compared to carbamazepine monotherapy (IRR 
2.72; 95% CI 1.23-5.99) and fourfold in comparison with women who were 
untreated in the first trimester (IRR 4.03; 95% CI 1.53-10.58). 
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8.2.2.2. Updated literature review 
These findings need to be considered in light of current research conducted after 
I had started working on these data. In Chapter 1, it was clear that there was a 
high level of heterogeneity between research studies which had investigated the 
teratogenicity of antiepileptics. I described relevant studies detail rather than 
combined into a meta-analysis. Since this review was conducted in 2010, there 
have been several key papers published in this area thus in order to discuss my 
results relative to current understanding, I have conducted a second review 
identifying relevant literature available since 2010.  
 
I used the same search strategy as used in the original review (Appendix 1), 
covering a new time period from 1 October 2010 to 31 June 2015. The studies 
are, once again, described rather than meta-analysed. Most studies provided 
only absolute risk estimates. I used these figures, I to calculate odds ratios in 
order to provide a crude estimate of the relative risk. 
 
Selection of articles for review  
A total of 1187 articles were identified, of which 54 were selected for a review of 
their abstracts based on the titles. Full text reviews were then performed on 40 
studies. Several articles were excluded:  
 One duplicate study 
 Eight were comments on a study 
 Two reviews 
 Nine had no estimates of risk for any of the interest groups  
 Six no comparison group of interest 
 Two did not examine major congenital malformations as an outcome 
 Two were unavailable 
Of the remaining 10 papers, in view of duplicate publications, there were seven 
studies included in the review. 
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Description of selected articles 
Three studies were published from Australian Pregnancy Register158;168;169 
between 2010 and 2015, each an update on the last. Therefore, only the latest 
study published in 2014 was included in the review. With data up to November 
2013, this study examined 1,725 pregnancies where antiepileptic drugs were 
taken at some stage in pregnancy. It was not limited to women with epilepsy, and 
contained some pregnancies with no first trimester use of antiepileptic drugs 
(these women had to have been exposed later in pregnancy in order to be 
included in the register). Information was ascertained through interviews 
antenatally and postnatally and through liaison with the woman’s medical 
practitioners.  Derived unadjusted odds ratio and associated 95% confidence 
intervals are below (Table 15).  
 
Table 15 The teratogenicity of the newer antiepileptic drugs - an update; Vadja (2014) 
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Untreated 5/153 
(3.3) 
3.35 
(1.21-9.25) 
4.75 
(1.82-12.41) 
1.41 
(0.50-4.00) 
1.72 
(0.63-4.69) 
Lamotrigine 
monotherapy 
14/307 
(4.6) 
2.37 
(1.15-4.89) 
3.36 
(1.76-6.40) 
- 1.22 
(0.60-2.47) 
Carbamazepine 
monotherapy 
19/346 
(5.5) 
1.95 
(1.00-3.82) 
2.76 
(1.54-4.96) 
- - 
Sodium 
valproate 
monotherapy 
35/253 
(13.8) 
0.71 
(0.39-1.29) 
- - - 
Sodium 
valproate 
polytherapy 
18/177 
(10.2) 
- - - - 
 
                                            
 
 
††† Derived unadjusted odds ratio and 95% confidence intervals 
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The significant findings were a threefold increase in risk in women exposed to 
sodium valproate polytherapy compared to women untreated in the first trimester, 
(unadjusted OR 3.35; 95% CI 1.21-9.25), a twofold increase compared to 
lamotrigine monotherapy (unadjusted OR 2.37; 95% CI 1.15-4.89) and similarly 
compared to carbamazepine monotherapy (unadjusted OR 1.95; 95% CI 1.00-
3.82) (Table 15). Women treated with sodium valproate monotherapy were nearly 
five times more likely to have a major congenital malformation compared to 
untreated women (unadjusted OR 4.75; 95% CI 1.82-12.41), three times as likely 
as women treated with lamotrigine monotherapy (unadjusted OR 3.36; 95% CI 
1.76-6.40) and carbamazepine monotherapy (unadjusted OR 2.76; 95% CI 1.54-
4.96). Risks were comparable between carbamazepine monotherapy, 
lamotrigine monotherapy and women untreated in the first trimester. 
Furthermore, they found no evidence of a difference in risk between sodium 
valproate users on monotherapy and polytherapy. No adjustment for confounding 
was performed. 
 
Two studies from the North American Antiepileptic Drug Pregnancy Registry have 
been published since 2010, and therefore the latest was included.129;161 
Pregnancies enrolled in the registry up to 2011 were examined for first trimester 
antiepileptic drug exposure which was ascertained through interviews and 
medical records. The authors compared the risk of major congenital 
malformations between different exposure groups, adjusting for confounding 
factors, and found no difference in risk between carbamazepine and lamotrigine, 
but a five times greater risk in sodium valproate monotherapy compared to 
lamotrigine monotherapy (adjusted RR 5.1; 95% CI 3.0-8.5) and a threefold 
increase compared to carbamazepine (unadjusted OR 3.3; 95% CI 2.0-5.6) 
(Table 16).  
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Table 16 Comparative safety of antiepileptic drugs during pregnancy, Hernandez-Diaz (2012) 
Reference 
group 
Malformations 
n/N (%) 
Comparator group 
RR (95% CI) 
Carbamazepine 
monotherapy 
Sodium 
valproate 
monotherapy 
Lamotrigine 
monotherapy 
31/1862 (2.0) 1.5 (0.9-2.5) 5.1 (3.0-8.5) 
Carbamazepine 
monotherapy 
31/1033 (3.0) - 3.3 (2.0-5.6)††† 
Sodium 
valproate 
monotherapy 
30/323 (9.3) - - 
 
An update from the UK and Ireland Epilepsy and Pregnancy Registers was 
recently published with pregnancies enrolled up to 2012.81 Similar to the 
Australian Pregnancy Register and the North American AED and Pregnancy 
Registry, no evidence of a difference was found between lamotrigine and 
carbamazepine monotherapy groups. However, sodium valproate monotherapy, 
once again, was associated with a three times greater likelihood of major 
congenital malformations compared to both carbamazepine monotherapy and 
lamotrigine monotherapy (Table 17). 
 
Table 17 Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results 
from the UK and Ireland Epilepsy and Pregnancy Registers, Campbell (2014) 
Reference group 
Malformations 
n/N (%) 
Comparator group 
OR (95% CI) 
Carbamazepine 
monotherapy 
Sodium 
valproate 
monotherapy 
Lamotrigine 
monotherapy 
49/2198 (2.3) 1.1 (0.7-1.7) 3.0 (2.1-4.3) 
Carbamazepine 
monotherapy 
43/1718 (2.6) - 2.7 (1.9-3.9) 
Sodium valproate 
monotherapy 
82/1290 (6.7) - - 
 
The International Registry of Antiepileptic Drugs and Pregnancy (EURAP), which 
collects data from 42 countries, examined dose dependent risks of major 
congenital malformations across different first trimester regimens.170 EURAP 
collects data prospectively from participating physicians on pregnancies prior to 
foetal outcome being known. Exposure to antiepileptic drugs was examined in 
161 
 
the first trimester and major congenital malformations were identified within 12 
months of birth.  
 
Table 18 Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from 
the EURAP epilepsy and pregnancy registry, Tomson (2011) 
Reference group 
Malformations 
n/N (%) 
Comparator group 
OR (95% CI)††† 
Carbamazepine 
monotherapy 
Sodium 
valproate 
monotherapy 
Lamotrigine 
monotherapy 
37/1280 (2.9) 2.0 (1.4-3.0) 3.6 (2.5-5.3) 
Carbamazepine 
monotherapy 
79/1402 (5.6) - 1.8 (1.3-2.5) 
Sodium 
valproate 
monotherapy 
98/1010 (9.7) - - 
 
Contrary to the previously mentioned studies, there was evidence of a difference 
in risk between lamotrigine and carbamazepine (unadjusted OR 2.0 95% CI 1.4-
3.0). Furthermore, a fourfold increase in risk between sodium valproate and 
lamotrigine monotherapy (unadjusted OR 3.6 95% CI 2.5-5.3) and nearly twofold 
increase in sodium valproate exposed pregnancies compared to carbamazepine 
exposed pregnancies (unadjusted OR 1.8 95% CI 1.3-2.5) (Table 18). However, 
these are not adjusted results and, importantly, do not account for cross country 
differences.  
 
Using EUROCAT data, Jentink et al studied specific malformations associated 
with first trimester carbamazepine monotherapy use in pregnancy.127 In adjusted 
analyses, compared to untreated women, the risk of spina bifida was twice as 
likely (OR 2.6 95% CI 1.2-5.3) but was lower compared to women exposed to 
sodium valproate (OR 0.2 95% CI 0.1-0.6). However, there was no evidence of 
an association between carbamazepine and other malformations compared to 
untreated women.  
 
The Medical Birth Registry of Norway was used by Veiby et al to study foetal 
outcomes of antiepileptic drug use in pregnancy.131 The registry is a population 
wide database of all deliveries from 12 weeks gestation containing information 
pertinent to maternal health, pregnancy and perinatal outcomes. Data is supplied 
to the registry through the attending physicians and midwife at delivery. The study 
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also included linked data from the Register of Pregnancy Terminations on 
induced abortions. Use of antiepileptic drugs in pregnancy (not limited to the first 
trimester) was stratified according to selected regimens. Women with epilepsy 
untreated in pregnancy formed an internal comparison group. 
 
Table 19 Fetal growth restriction and birth defects with newer and older antiepileptic drugs 
during pregnancy, Veiby (2014) 
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Untreated 106/3773 
(2.8) 
1.9 
(0.7-5.3) 
2.3 
(1.4-3.8) 
1.2 
(0.8-1.8) 
1.0 
(0.6-1.7) 
Lamotrigine 
monotherapy 
28/833 
(3.4) 
1.6 
(0.5-4.6) 
1.9 
(1.1-3.5) 
- 0.9 
(0.5-1.6) 
Carbamazepine 
monotherapy 
20/685 
(2.9) 
1.8 
(0.6-5.5) 
2.2 
(1.2-4.2) 
-  
Sodium valproate 
monotherapy 
21/333 
(6.3) 
0.8 
(0.3-2.4) 
- - - 
Sodium valproate 
polytherapy 
4/77 (5.2) - - - - 
 
Unadjusted odds ratios show evidence of a difference in risk between sodium 
valproate monotherapy and the women with untreated epilepsy (OR 2.3; 95% CI 
1.4-3.8), lamotrigine monotherapy (OR 1.9; 95% CI 1.1-3.5) and carbamazepine 
monotherapy (OR 2.2; 95% CI 1.2-4.2). There was no evidence to suggest 
sodium valproate polytherapy was higher risk than the other regimens of interest, 
or between carbamazepine and lamotrigine monotherapy exposed pregnancies 
(Table 19). 
 
Kulaga et al studied data from the Quebec Pregnancy Registry.171 This registry 
combines data from three administrative databases – the Régie de l’Assurance 
Maladie du Québec (a database of medical services used by all residents of 
Quebec, and prescription fills for Quebec residents under the Quebec Public 
Prescription Drug Insurance Plan), Med-Echo (acute hospitalisations for all 
residents including planned and spontaneous abortions and deliveries), and the 
Institut de la Statistique du Québec (database on all births and deaths in Quebec). 
Data was collected routinely and prospectively. Women with a diagnosis of 
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epilepsy and having had received antiepileptic drugs prior to pregnancy were 
identified and stratified into three groups based on treatment in pregnancy – no 
treatment, monotherapy or polytherapy – however, this was also not restricted to 
the first trimester but the whole of pregnancy.  
 
Table 20 Antiepileptic drug use during pregnancy: perinatal outcomes, Kulaga (2011) 
Reference 
group 
Malformations 
n/N (%) 
Comparator group 
OR (95% CI)†††  
Any 
monotherapy 
Any 
polytherapy 
Untreated 4/20 (20.0) 0.4 (0.1-1.6) 0.9 (0.3-3.6) 
Any 
monotherapy 
11/111 (9.9) - 2.1 (0.8-5.8) 
Any 
polytherapy 
8/42 (19.0) - - 
 
This study found each of the groups were comparable in their risk of major 
congenital malformations, however, this is likely to be affected by the small 
sample sizes observed.  
Summary of findings from original and updated reviews and the main study 
1. Carbamazepine monotherapy vs. untreated 
Carbamazepine monotherapy and women untreated with antiepileptic drugs in 
pregnancy were compared in three studies in the original literature review from 
Chapter 1. Two studies were from the same cohort, the Australian Pregnancy 
Register. Using only the latest set of results from this cohort and the third study 
which was a hospitals based study in Boston, the studies concluded that there 
was no evidence of a difference in the teratogenic risk between women given 
carbamazepine monotherapy and women given no antiepileptic drugs in the first 
trimester.4;18 In updating the literature review, two more studies were identified. 
One was a further update on the Australian Pregnancy Registry. Here, Vadja et 
al continued to find similar estimates of risk to their previous study in women 
untreated and women with carbamazepine monotherapy use in pregnancy (3.3% 
and 5.5% respectively; Table 15).158 A crude estimate of the odds ratio could be 
calculated, which indicated no evidence of difference in risk of malformations 
(unadjusted OR 1.72 95% CI 0.63-4.69). Veiby et al came to a similar conclusion 
in their study in the Norwegian Birth Registry.131 They found 2.8% and 2.9% of 
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pregnancies resulting in major congenital malformations in women untreated and 
women given carbamazepine monotherapy in pregnancy (though not limited to 
the first trimester) (unadjusted OR 1.0 95% CI 0.6-1.7; Table 19). These studies 
provide support to my findings, which also did not find evidence of a difference in 
teratogenic risk between carbamazepine exposed and untreated pregnancies.  
 
2. Sodium valproate monotherapy vs. untreated 
The two studies in the original review found highly elevated risks of major 
congenital malformations in sodium valproate exposed pregnancies compared to 
untreated women.11;18 However, one of these, by Artama et al,  pooled minor and 
major malformations, potentially leading to overestimation of risk.11  Bearing this 
in mind, their study found 10.6% of sodium valproate exposed and 2.8% 
unexposed pregnancies were affected, which after adjusting was a fourfold 
increase in risk (OR 4.01, 95% CI 2.32-7.01)11. Vadja et al found 15.1% and 3.4% 
of sodium valproate and untreated women affected, which equated to a fivefold 
increase (OR 4.99, 1.73-14.44).18 The 2014 study from the same authors updated 
these estimates to 13.8% and 3.3% of pregnancies with sodium valproate 
monotherapy use and no therapy used, respectively, giving an unadjusted odds 
ratio of 4.75 (95% CI 1.82-12.41) (Table 15).158 Veiby et al found 6.3% of 
pregnancies with sodium valproate monotherapy exposure had a major 
congenital malformation, while this was only 2.8% in untreated women.131 This 
was a twofold increase in risk (OR 2.33, 95% CI 1.44-3.77) (Table 19). In my 
study, the absolute risk amongst women with sodium valproate monotherapy 
prescribed in the first trimester was much lower than these studies (3.5%), and 
thus pair wise comparisons with the untreated group where 3.0% of pregnancies 
were affected found no evidence of a difference in risk (adjusted OR 0.89; 95% 
CI 0.27-2.98). As discussed in Chapter 7, this suggests that there is either an 
under recording of cases particular to women who took sodium valproate 
monotherapy in pregnancy, or that there may be a misclassification of women in 
this group as exposed when possibly they did not take the prescribed drugs in 
the first trimester.  
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3. Lamotrigine monotherapy vs. untreated 
The UK and Ireland Epilepsy and Pregnancy Registers and the Australian 
Pregnancy Register were reviewed in Chapter 1 where women on lamotrigine 
monotherapy were compared with women not treated with antiepileptic drugs in 
pregnancy. Recall, that women in these studies are not necessary limited to those 
with epilepsy – in both registers, the untreated group are women who had been 
prescribed antiepileptic drugs either before or after the first trimester. Both studies 
found no evidence of a difference in risk of major congenital malformations.17;19 
Women with first trimester use of lamotrigine monotherapy experienced a risk of 
3.2% (21/647) and 4.9% (12/243) in the UK and Australia respectively.17;19 Whilst 
these risks are quite different from each other, and different from that estimated 
in my study, they were relatively similar to risks in women who were untreated 
(8/227 = 3.5% in the UK and Ireland Epilepsy and Pregnancy Register; 4/118 = 
3.4% in the Australian Registry).17;19 Vadja et al have since published more recent 
figures from the Registry which continue to find no difference in risk when 
lamotrigine monotherapy is prescribed in the first trimester (4.6% vs. 3.3%; OR 
1.41; 95% CI 0.50-4.00 (Table 15)).158 Similarly, the Norwegian study by Veiby et 
al also found no difference (3.4% vs. 2.8%; lamotrigine monotherapy vs. 
untreated respectively; OR 1.20; 95% CI 0.79-1.84).131 My study found 
lamotrigine monotherapy was associated with a risk of 2.4% while women with 
no antiepileptic drugs in the first trimester were slightly higher, 3.0%. The 
unadjusted comparison finds no evidence of a difference. 
 
4. Carbamazepine monotherapy vs. lamotrigine monotherapy 
In the original literature review, just one study compared risks between these two 
groups. This was the UK Epilepsy and Pregnancy study which found 3.2% of 
women on lamotrigine monotherapy were affected. In comparison, only 2.2% 
(20/900) of women on carbamazepine monotherapy had pregnancies with a 
major congenital malformation.17 With the rapid rise in the use of lamotrigine in 
pregnancy, I found a further five studies published in just the last five years which 
examined this comparison. An update on data from the UK Epilepsy and 
Pregnancy Register was published in 2014 using data up to 2012.81 Since the 
2006 study, the number of women on lamotrigine monotherapy tripled to 2,198. 
Of these, 49 (2.3%) had a major congenital malformation. There were also twice 
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as many women prescribed carbamazepine monotherapy in 2012 than in 2006. 
Of 1,718 women, 43 pregnancies were affected and after adjusting for 
confounders, there was no difference in risk between the two groups (OR 1.1; 
95% CI 0.7-1.7) (Table 17). Data from the Australian Pregnancy Registry 
identified 5.5% (19/346) and 4.6% (14/307) of pregnancies exposed to 
carbamazepine monotherapy and lamotrigine monotherapy respectively with 
major congenital malformations and no difference in risk (OR  1.22; 95% CI 0.60-
2.47 (Table 15)).158 A large study came from the North American Antiepileptic 
Drug Pregnancy Registry by Hernadez-Diaz et al.129 Of 1,862 women with 
exposure to lamotrigine monotherapy in the first trimester, 2.0% (n = 31) of babies 
had a major congenital malformation while in carbamazepine monotherapy 
exposed pregnancies, this was 3.0% (31/1033). After adjusting, there was no 
evidence that the risk differed (OR 1.5; 95% CI 0.9-2.5 (Table 16)). In Norway, 
the risks estimated by Veiby et al also suggested there was no differential 
between carbamazepine monotherapy and lamotrigine monotherapy exposed 
pregnancies (20/685 = 2.9% vs. 28/833 = 3.4% respectively; OR 0.86; 95% CI 
0.48-1.55 (Table 19)).131 In opposition to these studies, findings from the 
international collaboration, EURAP, found that women with carbamazepine 
monotherapy use were twice as likely to have a baby with a major congenital 
malformations than those who were using lamotrigine monotherapy (79/1402 = 
5.6% vs. 37/1280 = 2.9%; OR 2.0; 95% CI 1.4-3.0 (Table 18)).160 My study found 
no evidence of a difference in risk which was 4.4% in carbamazepine 
monotherapy pregnancies, 2.4% in lamotrigine monotherapy pregnancies (IRR 
0.54; 95% CI 0.23- 1.26).  
 
5. Sodium valproate monotherapy vs. carbamazepine monotherapy 
This was examined in five studies in the original review. Two from the UK Epilepsy 
and Pregnancy Register and one from each of the Australian Pregnancy Registry, 
Swedish Medical Birth Registry and the Neurodevelopmental Effects of 
Antiepileptic Drugs (NEAD) study from the UK and US. The later of the two 
studies from the UK Epilepsy and Pregnancy Registry found sodium valproate 
monotherapy to be twice as likely to lead to major congenital malformations (RR 
2.35; 95% CI 1.57-3.57).75 The Australian Pregnancy Registry also found an 
elevated risk (RR 4.34; 95% CI 1.79-10.53).18 Population based data from linked 
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national registers in Sweden was analysed by Wide et al in 2004.20 They found 
26 (9.7%) cases of major congenital malformations in 268 women who took 
sodium valproate monotherapy and 28 (4.0%) in 703 women prescribed 
carbamazepine monotherapy. This was at least a twofold increase in risk 
(adjusted OR 2.51; 95% CI 1.43-4.86). The US/UK NEAD study identified major 
congenital malformations and foetal death in a relatively small number of 
pregnancies.15 They found 5.8% (4/69) and 4.5% (5/110) pregnancies with a 
serious adverse outcome, and a relative risk of 3.83 (95% CI 1.41-10.39). Thus, 
overall from these studies, the conclusions were clear in that sodium valproate 
monotherapy was associated with a higher risk of major congenital malformations 
compared to carbamazepine monotherapy. The relative risk varied from around 
twice as likely to nearly four times. Since 2010, another six studies were 
published. Two were updates – one from the Australian Pregnancy Registry and 
another from the UK Epilepsy and Pregnancy Register, and both provided further 
data to reinforce their original findings. With more data, Vadja et al were able to 
double their denominators and refine risk estimates to 13.8% (35/253) vs. 5.5% 
(19/346) giving an unadjusted odds ratio of 2.76 (95% CI 1.54-4.96) (Table 15).158 
The UK Epilepsy and Pregnancy Register calculated an adjusted odds ratio of 
2.7 (95% CI 1.9-3.9), which was not dissimilar to their research in 2009 (Table 
17).81  Figures from the North American Antiepileptic Drug Pregnancy Registry 
supported a roughly threefold increase in risk in sodium valproate monotherapy 
pregnancies (30/323 = 9.3% vs. 31/1033 = 3.9%; unadjusted OR 3.3 (95% CI 
2.0-5.6) (Table 16).129 Comparisons in the EURAP study estimated a slightly 
lower difference in risk – women with carbamazepine monotherapy use in 
pregnancy had a major congenital malformation in 79 of 1402 pregnancies 
(5.6%), whilst in sodium valproate monotherapy 98/1010 (9.7%), equivalent to an  
unadjusted odds ratio of 1.8 (95% CI 1.3-2.5) (Table 18).160 In a case control 
study, Jentink et al used data from the malformation registry EUROCAT and 
found the risk of a specific malformation, spina bifida, was lower in 
carbamazepine monotherapy pregnancies than sodium valproate pregnancies 
(OR 0.2; 95% CI 0.1-0.6).127 Veiby et al found a twofold elevated risk of major 
congenital malformations in sodium valproate monotherapy pregnancies 
compared to those exposed to carbamazepine monotherapy (unadjusted OR 2.2; 
95% CI 1.2-4.2) (Table 19).131 In my study, the risk of major congenital 
malformations in women prescribed sodium valproate monotherapy in the first 
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trimester was lower than expected (3.5%), and lower than in women prescribed 
carbamazepine monotherapy (4.4%). The difference was not statistically 
significant (IRR 0.80; 95% CI 0.34-1.86) thus conflicting with the overwhelming 
body of research that suggests a greater detrimental effect of sodium valproate 
monotherapy.  
 
6. Sodium valproate monotherapy vs. lamotrigine monotherapy 
In their earlier study, Vadja et al only had 61 women with lamotrigine 
monotherapy use in pregnancy, of which there were no cases of major congenital 
malformations. The risk in the sodium valproate monotherapy group relative to 
lamotrigine monotherapy was calculated as 5.58 (95% CI 2.06-15.09).18 A 
similarly small study from NEAD found one case in 98 pregnancies with 
lamotrigine monotherapy exposure and a relative risk of 17.04 (95% CI 2.27-
128.05).15 The UK Epilepsy and Pregnancy Register found a relative risk of 2.4 
(9% CI 1.6-3.7) in their 2009 study.75  Apart from the UK Epilepsy and Pregnancy 
Register study where only the relative risk was reported, the size of these other 
two studies were very small compared to more recent studies. In the most recent 
study, Vadja et al were able to include 307 women with lamotrigine monotherapy 
exposure in pregnancy, finding a risk of 3.3%. The risk was threefold in women 
who were taking sodium valproate monotherapy (unadjusted OR 3.4; 95% CI 1.8-
6.4) (Table 15).158 Hernandez-Diaz et al also found a higher risk associated with 
sodium valproate monotherapy in their study of the North America Antiepileptic 
Drugs Registry (30/323 = 9.3% vs. 31/1862 = 2.0%; sodium valproate vs. 
lamotrigine monotherapy respectively; RR 5.1; 95% CI 3.0-8.5) (Table 16).129 The 
UK Epilepsy and Pregnancy Register had the largest number of women with 
lamotrigine monotherapy use in pregnancy – 49 of 2,198 (2.3%) had a major 
congenital malformation. Sodium valproate monotherapy pregnancies were three 
times more likely to have a major congenital malformation (OR 3.0; 95% CI 2.1-
4.3) (Table 17). 81 Data from EURAP further corroborated a threefold elevated 
risk – 98/1010 = 9.7% vs. 37/1280 = 2.9%; sodium valproate monotherapy vs. 
lamotrigine monotherapy respectively; OR 3.6; 95% CI 2.5-5.3) (Table 18).170 
Veiby et al examined 833 women with lamotrigine monotherapy, 28 (3.4%) of 
which had a major congenital malformation. There were 21 cases in 333 (6.3%) 
women with sodium valproate monotherapy exposure in pregnancy thus an odds 
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ratio of 1.94 (95% CI 1.08-3.46) (Table 19).131 These studies vary in size however 
they are all in agreement that the risk of major congenital malformations is higher 
in pregnancies where the mother took sodium valproate monotherapy in 
pregnancy compared to those who took lamotrigine. In my study, the risk between 
sodium valproate monotherapy and lamotrigine monotherapy prescribed 
pregnancies was no different (IRR 1.47; 95% CI 0.55-3.92).  
  
Sodium valproate polytherapy 
The most recent study from the Australian Pregnancy Registry included 177 
women on sodium valproate polytherapy in pregnancy of which 18 (10.2%) (Table 
15) resulted in a major congenital malformation.158 This was a threefold increase 
in risk compared to the untreated group (3.3%; unadjusted OR 3.35 95% CI 1.21-
9.25), a twofold increase compared to lamotrigine monotherapy (4.6%; 
unadjusted OR 2.37 95% CI 1.15-4.89) and to carbamazepine monotherapy 
(5.5%; unadjusted OR 1.95 95% CI 1.00-3.82), whilst no difference was found 
compared to sodium valproate monotherapy (13.8%) (Table 15). 
 
The study by Veiby et al from the Norwegian Birth Registry found a much lower 
rate – four in 77 (Table 19) women with sodium valproate polytherapy exposure 
in pregnancy had a major congenital malformation giving and absolute risk of 
5.2%.131 When compared to the untreated group, and each of the three 
monotherapy groups, there was no evidence of a difference in risk in this study. 
 
The 2006 study from the UK Epilepsy and Pregnancy Register included 304 
women with sodium valproate polytherapy exposure and found 9.0% (6.3% to 
12.8%) were affected.17 There was evidence of a higher risk in pregnancies with 
sodium valproate polytherapy use compared to lamotrigine monotherapy 
(unadjusted OR 2.9; 95% CI 1.6-5.2) and carbamazepine monotherapy 
(unadjusted OR 4.3; 95% CI 2.4-7.8), but not compared to sodium valproate 
monotherapy (unadjusted OR 1.5; 95% CI 0.9-2.4) (Table 21). 
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Table 21 Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the 
UK Epilepsy and Pregnancy Register, Morrow (2006) 
Reference group Malformations 
n/N (%) 
OR (95% CI)†††  
Lamotrigine 
monotherapy 
21/647 (3.2) 2.9 (1.6-5.2) 
Carbamazepine 
monotherapy 
20/900 (2.2) 4.3 (2.4-7.8) 
Sodium valproate 
monotherapy 
44/715 (6.2) 1.5 (0.9-2.4) 
Sodium valproate 
polytherapy 
27/304 (9.0) - 
 
Two studies agree that there is an increased risk associated with sodium 
valproate polytherapy compared to carbamazepine and lamotrigine 
monotherapy, thus supporting my findings (vs. carbamazepine monotherapy IRR 
2.72; 95% CI 1.23- 5.99; vs. lamotrigine monotherapy IRR 5.03 95% CI 1.99- 
12.74). However, the effect sizes vary between all three studies, and one study 
conflicted these studies by finding no difference between sodium valproate 
polytherapy, lamotrigine monotherapy and carbamazepine monotherapy. Each 
of the three studies also found that the risk of malformations in sodium valproate 
polytherapy and monotherapy did not differ. This is in contrast to my study where 
women with sodium valproate prescribed in pregnancy were three times more 
likely to have a  baby with major congenital malformations than those prescribed 
this drug as monotherapy (IRR 3.42 95% CI 1.35- 8.66). 
 
Summary of current literature 
Bringing together the research published elsewhere with those observed in my 
study, one can summarise the current understanding of the relative risks of major 
congenital malformations between specific antiepileptic drug regimens. 
 
 Carbamazepine monotherapy and women with no antiepileptic drugs 
use in pregnancy exhibit similar risks of major congenital 
malformations in pregnancy. 
 
 Sodium valproate monotherapy is associated with a higher risk of major 
congenital malformations compared to no antiepileptic drug use in the 
first trimester of pregnancy. The effect size is around fivefold, however 
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some studies found a slightly lower effect. My study did not support 
these findings.  
 
 Lamotrigine monotherapy bears no differential risk of major congenital 
malformations compared to no antiepileptic drug use in pregnancy. 
 
 Most studies, including my study, find no difference in risk between 
carbamazepine monotherapy and lamotrigine monotherapy. One 
study, which involved a large sample size, found higher rates in women 
who took carbamazepine monotherapy in pregnancy compared to 
those who took lamotrigine monotherapy. However, cross country 
differences may have confounded these estimates since the data 
examined was from an international malformation registry.  
 
 Sodium valproate monotherapy increases the risk of major congenital 
malformations compared to carbamazepine monotherapy by around 
two to four times. Despite consistent evidence from several research 
studies, this was not observed in my study. 
 
 Sodium valproate monotherapy increases risk to around threefold of 
that in lamotrigine monotherapy, however an association was not found 
in my study.  
 
 There are few studies which examine sodium valproate polytherapy in 
comparison with monotherapy regimens. Bar one study, there is some 
evidence, including that from the main study of this thesis, that sodium 
valproate polytherapy use in pregnancy has a detrimental effect over 
other monotherapy regimens, however the studies are few and 
importantly lack adjustment for confounding factors.  
 
The studies identified in the updated literature review built upon conclusions 
drawn from the original review by providing larger sample sizes particularly with 
respect to lamotrigine monotherapy. However, there are some key limitations to 
this combined review which have to be considered alongside the above summary. 
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Confounders  
Most studies provided observations of risk in populations exposed to specific 
regimens in pregnancy. However, very few conducted a comparison to estimate 
the relative risk. In these cases, I calculated a crude odds ratio, however this 
would not account for baseline differences in the compared groups which may 
confound the observed effect. 
 
Timing of exposure 
It was not always clear whether or not women were exposed specifically in the 
first trimester. Two studies stated that their exposure definition spanned the 
length of pregnancy – these studies included for a different reason however it is 
important to restrict analyses to women who have used antiepileptic drugs in the 
first trimester since this is the period in which malformations occur. Including 
women who used antiepileptic drugs in later stages of pregnancy, but not in first 
trimester as “exposed” may dilute any true teratogenic effect of the drugs in 
question. 
 
Non-live births 
Some studies are able to provide data on foetal deaths and terminations (these 
were the two studies mentioned above which included women exposed to drugs 
at any point in pregnancy). Other studies, particularly the registries, provide some 
data on non-live births but are unable to capture all data due to loss to follow-up. 
Some studies actively exclude terminations and deaths with the reasoning that 
the cause is not certainly due to a malformation. There are two problems with not 
including non-live births. Firstly, this reduces the denominator and thus it may 
underrepresent the study population of pregnant women. Secondly, if there is a 
higher likelihood of death in pregnancies which have developed a malformation, 
then the risk estimated from a live birth population will not reflect this, but will 
underestimate the true effect.  
 
Sample size 
This was mainly an issue with regards to sodium valproate polytherapy. 
Polytherapy regimens are prescribed to fewer people, and are mainly to be 
prescribed for epilepsy, rarely for other indications (Table 12). Thus, the number 
of pregnant women taking such regimens is very low in comparison to 
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monotherapy regimens. Consequently, when estimating risks and comparing 
polytherapy to other regimens, studies may be underpowered to detect a 
difference if there is one. The studies in this review, and my study, have found 
evidence of a difference but a greater sample size is needed to improve the 
precision of the estimates.  
 
It must be borne in mind that these comparisons are largely unadjusted for 
confounding factors. However, studies are substantially larger in numbers – from 
the Australian Pregnancy Registry alone, there were three times more 
pregnancies with lamotrigine use in 2013 than there were in 2006. Results from 
recent larger studies therefore provide a good base from which conclusions may 
be drawn. It is hoped that future studies will continue to accumulate larger 
samples of antiepileptic drug exposure in women in pregnancy, and adjusted 
analyses of teratogenic risk may be more prevalent. 
 
8.3. Strengths and weaknesses  
The main study in this PhD was a population representative study of pregnant 
women in the UK which used real time clinical data to examine the teratogenic 
effects of first trimester antiepileptic drug use. There were several strengths to 
this study which addressed some of the common weaknesses found in previous 
studies reviewed in Chapter 1.  
 
Primary care in the UK is accessed freely, and for many women it is the first point 
of contact with a health care professional in pregnancy. The selection bias that 
can affect pregnancy registries is likely to be much lower in data which is collected 
out of routine visits, such as THIN, forming one of the major strengths of this 
study.  
 
A second strength in this study is the accuracy of information on the use of 
antiepileptic drugs. Most GPs in the UK only use the computerised system for 
prescribing so the data captures nearly all prescriptions issued with details on the 
type of drug prescribed, and when it was prescribed. In a study of teratogenicity, 
the timing of exposure to drugs in utero is crucial to attribute the drug to a 
malformation, thus data with accurate information will reduce misclassification 
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bias. In addition to this, the use of prescription data extracted from medical 
records counteracts the problem of recall bias – where women may incorrectly 
recall details of antiepileptic drug exposure depending on whether or not their 
child was affected.  
 
The benefits of THIN data to study the maternal population is overwhelmingly 
strong. The pregnancy cohort used in this study contained over 350,000 
pregnancies. These numbers provide the potential to study rare exposures, such 
as specific drug regimens, and rare outcomes, such as major congenital 
malformations. Moreover, this study was able follow-up on child health outcomes, 
including major congenital malformations, in linked mother-child records for over 
80% of pregnancies. There was also a substantial benefit of having a 
comprehensive medical history of the mother before and during pregnancy. One 
of the most difficult problems in studying teratogenicity is capturing information 
on potential confounding factors. Using THIN data, maternal history of behaviours 
such as smoking, alcohol dependency and substance misuse, alongside other 
possible contributing factors such as co-medications could be observed. 
 
This study is not without its limitations. As discussed in Chapter 7, THIN data 
does not directly capture information on disease severity. If this is a factor which 
is independently associated with the type of drug prescribed and the risk of major 
congenital malformations, then the effects observed in my study may not be 
solely due to the drug. Despite the large amount of information on maternal 
demographic and clinical characteristics that is possible to determine from THIN 
data, information on disease severity is lacking. Unfortunately, there is no ideal 
solution to this problem. In real world practice, women with a worse form of e.g. 
epilepsy may have to be given multiple drugs to treat the condition – thus the 
likelihood of capturing a comparative sample of women with the same disease 
severity on a monotherapy, is low. However, a very large study population 
potentially from international collaborations or whole population birth registers 
could assess the effect of disease severity. 
 
In my study, exposure in the first trimester included prescriptions made in the 
month before pregnancy. Drugs consumed prior to conception cannot have a 
teratogenic effect, however the inclusion of women prescribed in this period was 
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aimed at capturing women whose prescriptions continued into the early weeks of 
pregnancy prior to pregnancy being known. Despite this sensitive approach, 
there may have been women who were prescribed but did not take the drugs in 
the first trimester, perhaps if they were planning their pregnancy and chose to 
cease therapy. However, I have showed that the absolute risk estimates in my 
study were similar to several other studies for carbamazepine monotherapy, 
lamotrigine monotherapy and untreated pregnancies therefore suggesting 
misclassification may be only be minimal if at all. 
 
A limitation which has become apparent is the lack of data on terminations, in 
particular those which were terminated following a pre-natal diagnosis of a 
malformation. In my study, I found it unusual to see a low prevalence of major 
congenital malformations in sodium valproate monotherapy exposed 
pregnancies, as I have discussed earlier in this chapter and in Chapter 7. A 
possible explanation is that terminations are not well recorded in THIN since it is 
a procedure conducted outside of primary care. Given the association between 
sodium valproate exposure and spina bifida, and the high rate of termination of 
babies with spina bifida, it could be that this study has underestimated the true 
effect of sodium valproate. Terminations were initially considered for this study, 
however it was found that there were numerous inconsistencies in identifying true 
terminations and relevant dates resulted in the decision not to identify this 
outcome. Primary care data alone is insufficient for this purpose – an additional 
data source is necessary.   
 
Of the non-live births which were included in my analysis and counted as perinatal 
deaths, some of these might not be attributed to a major congenital malformation, 
thus the overall effect may be overestimated. In my study, there were seven 
perinatal deaths out of the 1,633 pregnancies in the study population. Incorrectly 
attributing all seven of these to a major congenital malformation would affect the 
absolute risks but the small number should have only minimal impact on the 
comparisons analysis.  
 
This study has demonstrated that the effects of drugs in pregnancy can be 
examined without several biases that limit other study designs and data sources. 
It has its limitations, however, these are either problems that exist in all 
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observational studies and thus are not limited to my study, or can be addressed 
in future research with access to more data and additional linked data sources. 
 
8.4. Clinical implications 
The aim of this study was to enable women and healthcare professionals to be 
better informed with regards to antiepileptic drug treatment choices in pregnancy. 
At the time of the beginning of this PhD, the literature review in Chapter 1 
demonstrated that high quality studies were lacking despite decades of research 
on older antiepileptic drugs. Furthermore, there was a clear paucity of information 
on the effects of newer antiepileptic drugs. In clinical practice, it may have been 
difficult to convey the risks if research studies had not provided consistent results 
and recent surveys of women with epilepsy have highlighted that this gap in 
knowledge exists. It is therefore important to consider how the studies conducted 
in this PhD can impact this aim to inform clinical practice.  
 
In Chapter 5, I showed the use of lamotrigine has risen rapidly in pregnancy over 
time. Lamotrigine monotherapy should be considered for treatment for women of 
child-bearing age given its relatively low teratogenic risk but health care 
professionals must act cautiously so as not to compromise the management of 
the woman’s condition. This is especially relevant for women due to faster 
clearance of lamotrigine from the blood during pregnancy, which could lead to 
relapses of the underlying condition and compromising the mother and baby’s 
health. In these situations, lamotrigine dosage can be amended accordingly.  
 
Whilst there has been much research on the risk associated with sodium 
valproate use in pregnancy, it remains more commonly prescribed in pregnancy 
than most other antiepileptic drugs. Sodium valproate continues to be highlighted 
as the drug of highest risk, however, this study shows that it is particularly high 
risk if prescribed in polytherapy. Sodium valproate should continue to be avoided. 
Where this is not possible, women should be given the minimum effective dose 
and monotherapy should be preferred over polytherapy in order to minimise the 
teratogenic risk as much as possible.  
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Carbamazepine monotherapy should be considered as an alternative treatment 
to sodium valproate. Although my study found women on these monotherapies 
to bear similar risks of major congenital malformations, the strong evidence 
against sodium valproate in polytherapy suggests this drug should be avoided, 
and that carbamazepine may be a safer alternative treatment. 
 
Since the original literature review was performed in 2010, there has been new 
advice on clinical practice in the UK related to the pharmacological treatment of 
women with antiepileptic drugs. In 2014, an update on the clinical guidelines for 
antenatal and postnatal management of women with mental health conditions 
was released.120 This states several recommendations with regards to treatment 
with antiepileptic drugs: 
- Sodium valproate and carbamazepine should not be offered to women 
planning pregnancy, pregnant or considering breastfeeding; 
- In those already taking sodium valproate, the drug should be gradually 
stopped if planning pregnancy, or stopped if the woman is pregnant; 
- In those already taking carbamazepine and who are either pregnant or 
planning to become pregnant, discontinuing treatment should be 
discussed; 
- In women taking lamotrigine during pregnancy, lamotrigine levels 
should be checked frequently.120 
 
In January 2015, the Medical Healthcare and Products Regulatory Agency in the 
UK strengthened warnings on the use of sodium valproate in women of child-
bearing potential, advising against use if possible, publishing guides for both 
health care professionals and patients, accompanied by letters to health care 
professionals.172 My study supports the recent advice on sodium valproate, 
reinforcing the need to discuss treatment decisions as soon as the woman 
reaches child bearing age, in anticipation of becoming pregnant in the future.  
 
For all women, lifestyle and preferences change over time, so it would be sensible 
to review treatment regimens annually to revisit the woman’s preferences for 
treatment should she fall pregnant, as well as to keep abreast of newer 
antiepileptic drugs which may provide more options.  
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8.5. Further research implications 
There remain gaps in the research in the teratogenic effects of antiepileptic drugs 
in pregnancy which need to be addressed. 
 
Clearly, efforts to study the teratogenicity of each of these antiepileptic drugs 
should continue in order to: 
- Corroborate the current findings 
- Obtain risk estimates with improved precision and accuracy 
- Quantify the risk differences, if any, between lamotrigine, 
carbamazepine and sodium valproate monotherapy 
This needs to be conducted on large samples with access to information on 
maternal health, antenatal events and perinatal outcomes. Particular attention 
needs to be paid to capturing information on disease severity and prenatal 
diagnoses in terminations.  
 
Antiepileptic drug polytherapy regimens are still a poorly understood area in the 
study of teratogenicity. It has been difficult to examine due to the limited numbers 
who are prescribed such more than one antiepileptic drug in pregnancy – only 
about 20% of women treated with antiepileptic drugs for epilepsy are managed 
on a polytherapy regimen.173 In addition to this, comparative estimates may be 
unattainable for polytherapy if there are no alternative medications for a particular 
types of condition or disease severity. Given these difficulties, it would be wise to 
firstly attain precise absolute risk estimates before considering the possibility of 
risk comparisons. The most important factor here is to ascertain large numbers 
of women with polytherapy regimens in pregnancy. Data from THIN could be 
used but would benefit from accumulating more pregnancies in order to increase 
the sample of women with polytherapy exposure. Population wide registers such 
as the Swedish Medical Birth Register may also be able to provide greater 
numbers since they cover the whole population.  
 
Other than lamotrigine, newer antiepileptic drugs have not been researched to 
the same extent. Chapter 5 showed however, that newer antiepileptic drug use 
is on the rise and can rise significantly quickly (like lamotrigine) without a wide 
evidence base for their safety in pregnancy. Monitoring of the numbers of women 
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using newer antiepileptic drugs in pregnancy and planning stages of analysis 
dependent on numbers available would make the most of the available 
observational data as soon as it were possible to conduct formal pairwise 
comparisons.   
 
At present, the utilisation of electronic health records in research is undergoing 
change in that such datasets are now being linked together to create richer data 
sources. One such example is the linkage of primary care data to secondary care 
data in the UK, in the form of Hospital Episode Statistics (HES). Since women 
give birth in secondary care, there may be a number of additional variables 
captured in secondary care data which primary care either lacks or poorly 
records. For example, demographic information such as ethnicity, delivery 
information such as method of delivery and information on the baby such as 
birthweight. However, preliminary explorations of such linked data found that, 
although there may be some increase in availability of variables, HES data has 
its shortcomings – particularly in the identification of a link between mothers and 
babies. Thus, further research needs to be completed on firstly how much richer 
studies in the effects of drugs in pregnancy be made if primary and secondary 
care data are linked, and furthermore do these gains in data outweigh the 
assumptions and difficulties associated with using HES data. A complement to 
the use of primary and secondary data would be the use of GP questionnaires to 
obtain information on disease severity. This is a service offered by some 
providers which helps to capture information not held in the medical records.  
 
On a similar note, there would be gains in understanding more on non-live births, 
particularly terminations, and their prenatal scans and tests. My study was unable 
to ascertain such information, which, potentially, is key to identifying further cases 
of major congenital malformations that could have been caused by antiepileptic 
drugs. Secondary care data may hold some information, but there may be further 
data sources, particularly malformation registries such as the British Isles 
Network of Congenital Anomaly Registers (BINOCAR) which, if linked to primary 
care, could provide much greater insight in these teratogenic effects.  
 
Women with bipolar disorder warrant further investigation. This PhD was only 
able to examine a small number of women with bipolar disorder who received 
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antiepileptic drug treatment. Generally, severe mental illnesses can be treated 
with other drugs – antipsychotics, antidepressants, lithium to name a few. 
Therefore the proportion on antiepileptic drugs is potentially always small. 
However, the study in Chapter 5 highlighted marked discontinuation of treatment 
in pregnancy – a larger study is needed to verify this finding, and to identify 
causes, subsequent treatment and consequences which would inform whether 
there is a need to change clinical practice.  
 
8.6. Conclusion 
Antiepileptic drugs are a necessity to some people who suffer from long term 
conditions including epilepsy and bipolar disorder which can be otherwise 
detrimental for one’s health if it is not treated properly. Pregnant women and their 
health care professionals must seek up to date information on how best to 
manage drug therapy in pregnancy weighing up the teratogenic effects with the 
benefits of managing the underlying condition. Women should be counselled on 
this prior to becoming pregnant, and support should be provided throughout 
pregnancy to ensure women have access to advice should they become 
concerned about the effects of their treatment on the unborn child.  The 
outstanding finding from my thesis is an excessive teratogenic risk which is 
associated with a sodium valproate polytherapy regimen in pregnancy. Whilst 
there is demand for additional research studies to be performed and corroborate 
these findings using larger and richer data sets, it is advisable that women and 
health care professionals consider alternatives to polytherapy to minimise the 
teratogenic harm to the foetus.   
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Appendix 1 
 
Search strategy for identifying literature in Chapter 1 
 
Below is the strategy employed in the PubMed database. Each numbered section 
ran a different search and combinations of the sections were used to perform the 
overall search for each review. 
 
1. pregnancy[MeSH Terms]  OR children[MeSH Terms] OR foetus[MeSH 
Terms] OR in utero[MeSH Terms] 
2. phenytoin[MeSH Terms] OR phenobarbital[MeSH Terms] OR sodium 
valproate[MeSH Terms] OR carbamazepine[MeSH Terms] OR 
lamotrigine[MeSH Terms] OR topiramate[MeSH Terms] OR 
levetiracetam[MeSH Terms] OR gabapentin[MeSH Terms] OR 
vigabatrin[MeSH Terms] OR zonisamide[MeSH Terms] OR 
tiagabine[MeSH Terms] OR oxcarbazepine[MeSH Terms] OR 
antiepileptic[MeSH Terms] OR lamotrigine[Title/Abstract] OR 
gabapentin[Title/Abstract] OR topiramate[Title/Abstract] OR 
levetiracetam[Title/Abstract] OR valproate[Title/Abstract] OR 
carbamazepine[Title/Abstract] OR phenytoin[Title/Abstract] OR 
phenobarbital[Title/Abstract] OR vigabatrin[Title/Abstract] OR 
zonisamide[Title/Abstract] OR tiagabine[Title/Abstract] OR 
oxcarbazepine[Title/Abstract]) OR antiepileptic[Title/Abstract] 
3. abnormalities[MeSH Terms] OR teratogens[MeSH Terms] OR foetal 
diseases[MeSH Terms] OR infant newborn[MeSH Terms] OR 
teratogen[Title/Abstract] OR congenital defect[Title/Abstract] OR 
congenital malformation[Title/Abstract] OR congenital 
anomalies[Title/Abstract] OR birth defect[Title/Abstract] 
4. Limits: Humans, English, Publication Date from 01/01/2007 to 
01/10/2010 
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Appendix 2 
 
Drug code list of ANTIEPILEPTIC DRUGS 
Drug code Generic name 
52991979 Levetiracetam 250mg granules sachets sugar free 
54822979 Phenytoin sodium 100mg capsules 
54824979 Phenytoin sodium 50mg capsules 
54828979 Phenytoin sodium 300mg capsules 
54926979 PERAMPANEL 4mg tablets 
54927979 Perampanel 4mg tablets 
54928979 PERAMPANEL 2mg tablets 
54929979 Perampanel 2mg tablets 
55600979 Phenytoin sodium 100mg capsules 
55601979 Phenytoin sodium 50mg capsules 
55602979 Phenytoin sodium 25mg capsules 
55603979 Phenytoin sodium 300mg capsules 
57803979 Topiramate 25mg capsules 
57805979 Topiramate 25mg tablets 
58118979 PREGABALIN 20mg/1mL solution 
58119979 Pregabalin 20mg/ml oral solution sugar free 
58718979 RUFINAMIDE 40mg/mL oral susp 
58783979 LACOSAMIDE 10mg/1mL s/f liquid 
59577979 Clonazepam 500micrograms/5ml oral solution sugar free 
59819979 Clonazepam 2mg/5ml oral solution sugar free 
60175979 Levetiracetam 500mg tablets 
61056979 Lacosamide 10mg/ml oral solution sugar free 
63675979 Primidone 100mg/5ml oral suspension 
64705979 Gabapentin 400mg/5ml oral solution 
65303979 Topiramate 5mg/5ml oral solution 
65489979 Sodium valproate 600mg/5ml oral solution 
69586979 Clobazam 100mg/5ml oral suspension 
79020979 Phenobarbital 50mg/5ml oral solution 
80027979 Gabapentin 300mg/5ml oral solution 
80572979 Clobazam 4mg/5ml oral suspension 
80586979 Clobazam 20mg/5ml oral suspension 
80590979 Clobazam 2.5mg/5ml oral suspension 
80592979 Clobazam 2.5mg/5ml oral solution 
80920979 LEVETIRACTAM 100mg/mL s/f soln 
80964998 Levetiracetam 250mg tablets 
81059998 Zonisamide 50mg/5ml oral suspension 
81079998 Phenytoin 90mg/5ml oral suspension 
81083998 Clonazepam 500micrograms/5ml oral solution 
81126998 Clobazam 5mg/5ml oral solution 
81127998 Clobazam 10mg/5ml oral solution 
81134979 Acetazolamide 250mg/5ml oral solution 
81142979 Acetazolamide 175mg/5ml oral suspension 
81237998 Topiramate 50mg/5ml oral suspension 
81396998 Retigabine 50mg tablets and Retigabine 100mg tablets 
81399998 RETIGABINE 400mg tablets 
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81400998 RETIGABINE 300mg tablets 
81401998 RETIGABINE 200mg tablets 
81402998 RETIGABINE 100mg tablets 
81403998 RETIGABINE 50mg tablets 
81404998 Retigabine 400mg tablets 
81405998 Retigabine 300mg tablets 
81406998 Retigabine 200mg tablets 
81407998 Retigabine 100mg tablets 
81408998 Retigabine 50mg tablets 
81479998 CARBAMAZEPINE 400mg m/r tabs 
81480998 CARBAMAZEPINE 200mg m/r tabs 
81677998 Lamotrigine 50mg Suppository 
81770998 Topiramate 25mg/5ml oral suspension 
81830998 PRIMIDONE 50mg tablets 
81842998 Primidone 50mg tablets 
81954998 Sodium valproate 750mg modified-release granules sachets sugar free 
81955998 Sodium valproate 250mg modified-release granules sachets sugar free 
81956998 Sodium valproate 100mg modified-release granules sachets sugar free 
81957998 Sodium valproate 50mg modified-release granules sachets sugar free 
81991998 Gabapentin 250mg/5ml oral suspension 
82051998 Phenobarbital 75mg/5ml oral suspension 
82052998 Phenobarbital 75mg/5ml oral solution 
82574998 ESLICARBAZPN ACETAT 800mg tabs 
82576998 Eslicarbazepine 800mg tablets 
82713998 Clobazam 25mg/5ml oral solution 
82714998 Clobazam 25mg/5ml oral suspension 
82857998 Sodium valproate 1g modified-release granules sachets sugar free 
83073998 Phenobarbital 20mg/5ml oral solution 
83321998 Sodium valproate 200mg modified-release tablets 
83479998 SOD. VALPROATE 500mg e/c tabs 
83480998 SOD. VALPROATE 200mg e/c tabs 
83507998 LACOSAMIDE 50mg tablets 
83508998 Lacosamide 50mg tablets 
83509998 LACOSAMIDE 200mg tablets 
83510998 Lacosamide 200mg tablets 
83511998 LACOSAMIDE 150mg tablets 
83512998 Lacosamide 150mg tablets 
83513998 LACOSAMIDE 100mg tablets 
83514998 Lacosamide 100mg tablets 
83515998 LACOSAMIDE 15mg/1mL s/f liq 
83516998 Lacosamide 15mg/ml oral solution sugar free 
83518998 Lacosamide 200mg/20ml solution for infusion vials 
83704998 SOD VALPROATE 750mg m/r grans 
83705998 Sodium valproate 500mg modified-release granules sachets sugar free 
83706998 SOD VALPROATE 250mg m/r grans 
83707998 SOD VALPROATE 100mg m/r grans 
83708998 SOD VALPROATE 50mg m/r grans 
83709998 Sodium valproate with valproic acid 50mg modified release granules 
83766998 Sodium valproate oral solution 
83790998 Sodium valproate with valproic acid 1000mg modified release granules 
83791998 Sodium valproate with valproic acid 750mg modified release granules 
83792998 Sodium valproate with valproic acid 500mg modified release granules 
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83793998 Sodium valproate with valproic acid 250mg modified release granules 
83794998 Sodium valproate with valproic acid 100mg modified release granules 
84001998 Mesuximide 300mg Capsule 
84089998 Sodium valproate 1g/10ml solution for injection ampoules 
84095998 Stiripentol 500mg oral powder sachets 
84096998 Stiripentol 250mg oral powder sachets 
84097998 Stiripentol 500mg capsules 
84098998 Stiripentol 250mg capsules 
84127998 Primidone 100mg/5ml oral solution 
84233998 PREGABALIN 225mg capsules 
84234998 Pregabalin 225mg capsules 
84311998 Carbamazepine 500mg/5ml oral suspension 
84415998 RUFINAMIDE 400mg tablets 
84416998 RUFINAMIDE 200mg tablets 
84418998 Rufinamide 400mg tablets 
84419998 Rufinamide 200mg tablets 
84420998 Rufinamide 100mg tablets 
84664998 SOD VALPROTE 1g/sach m/r grans 
84665998 SOD VALPROATE 500mg m/r grans 
84666998 SODUM VALPROATE 300mg m/r caps 
84667998 SODUM VALPROATE 150mg m/r caps 
84668998 Sodium valproate 1g modified-release granules sachets sugar free 
84669998 Sodium valproate 500mg modified-release granules sachets sugar free 
84670998 Sodium valproate 300mg modified-release capsules 
84671998 Sodium valproate 150mg modified-release capsules 
84720998 Sodium valproate 300mg suppositories 
85030998 Sodium valproate 300mg/3ml solution for injection ampoules 
85180998 Primidone 50mg/5ml oral suspension 
85423998 Clobazam 2.5mg capsules 
85466998 Primidone 62.5mg/5ml oral suspension 
85486998 Acetazolamide 250mg/5ml oral suspension 
85559998 Clonazepam 250micrograms/5ml oral solution 
85954998 ETHOSUXIMIDE 250mg/5mL syrup 
85968998 LEVETIRACETAM 500mg/5mL inj 
85969998 Levetiracetam 500mg/5ml solution for infusion vials 
86019998 Lamotrigine 50mg dispersible tablets sugar free 
86109998 ETHOSUXIMIDE 250mg capsules 
86161998 Clobazam 5mg/5ml oral suspension 
86349998 Primidone 25mg/5ml oral suspension 
86362998 Gabapentin 400mg/5ml oral suspension 
86429998 Acetazolamide 125mg/5ml oral suspension 
86457998 Clobazam 10mg/5ml oral suspension 
86485998 Gabapentin 250mg/5ml oral solution 
86604998 Clonazepam 500micrograms/5ml solution sugar free 
86669998 Sultiame 50mg tablets 
86670998 Sultiame 200mg tablets 
86671998 Sultiame 50mg tablets 
86841998 ZONISAMIDE 100mg capsules 
86842998 ZONISAMIDE 50mg capsules 
86843998 ZONISAMIDE 25mg capsules 
86844998 Zonisamide 100mg capsules 
86845998 Zonisamide 50mg capsules 
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86846998 Zonisamide 25mg capsules 
87030998 Phenobarbital 50mg/5ml oral suspension 
87106998 PRIMIDONE 250mg tablets 
87193998 LEVETIRACTAM 100mg/mL s/f soln 
87194998 LEVETIRACETAM 750mg tablets 
87195998 Levetiracetam 100mg/ml oral solution sugar free 
87196998 Levetiracetam 750mg tablets 
87395998 PREGABALIN 300mg capsules 
87396998 PREGABALIN 200mg capsules 
87397998 PREGABALIN 150mg capsules 
87398998 PREGABALIN 100mg capsules 
87399998 PREGABALIN 75mg capsules 
87400998 PREGABALIN 50mg capsules 
87401998 PREGABALIN 25mg capsules 
87402998 Pregabalin 300mg capsules 
87403998 Pregabalin 200mg capsules 
87404998 Pregabalin 150mg capsules 
87405998 Pregabalin 100mg capsules 
87406998 Pregabalin 75mg capsules 
87407998 Pregabalin 50mg capsules 
87408998 Pregabalin 25mg capsules 
88177998 SOD VALPROATE 300mg m/r tabs 
88178998 SOD VALPROATE 500mg m/r tabs 
88217997 CARBAMAZEPINE 400mg m/r tabs 
88396998 Topiramate 50mg capsules 
88422998 Clonazepam 2.5mg/ml drops sugar free 
88423996 Clonazepam 2mg/5ml oral solution sugar free 
88423997 Clonazepam 500micrograms/5ml oral suspension 
88423998 Clonazepam 2.5mg/ml drops sugar free 
88868996 TOPIRAMATE 50mg beads in caps 
88868997 TOPIRAMATE 25mg beads in caps 
88868998 TOPIRAMATE 15mg beads in caps 
89008998 ACETAZOLAMIDE 250mg m/r caps 
89087979 PREGABALIN 150mg capsules 
89210996 Levetiracetam 1g tablets 
89210997 Levetiracetam 500mg tablets 
89210998 Levetiracetam 250mg tablets 
89231998 OXCARBAZEPINE 600mg tablets 
89384997 CARBAMAZEPINE 400mg m/r tabs 
89384998 CARBAMAZEPINE 200mg m/r tabs 
89408996 TIAGABINE 15mg tablets 
89408997 TIAGABINE 10mg tablets 
89408998 TIAGABINE 5mg tablets 
89409996 Tiagabine 15mg tablets 
89409997 Tiagabine 10mg tablets 
89409998 Tiagabine 5mg tablets 
89991998 Fosphenytoin 750mg/10ml solution for injection vials 
90211979 Primidone 250mg/5ml oral suspension 
90424998 GABAPENTIN 300mg cap/600mg tab 
90425998 Gabapentin 600mg tablets and Gabapentin 300mg capsules 
90426997 GABAPENTIN 800mg tablets 
90426998 GABAPENTIN 600mg tablets 
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90505998 Sodium valproate 500mg modified-release tablets 
90776998 Phenytoin sodium 300mg capsules 
90780996 Phenytoin sodium 100mg capsules 
90780997 Phenytoin sodium 50mg capsules 
90780998 Phenytoin sodium 25mg capsules 
90858998 TIAGABINE 15mg tablets 
91044996 Topiramate 25mg capsules 
91044997 Topiramate 15mg capsules 
91044998 Topiramate 25mg tablets 
91045998 TOPIRAMATE 25mg tablets 
91050996 Topiramate 200mg tablets 
91050997 Topiramate 100mg tablets 
91050998 Topiramate 50mg tablets 
91051996 TOPIRAMATE 200mg tablets 
91051997 TOPIRAMATE 100mg tablets 
91051998 TOPIRAMATE 50mg tablets 
91218998 OXCARBAZEPINE 60mg/mL s/f susp 
91465997 Lamotrigine 2mg dispersible tablets sugar free 
91465998 Lamotrigine 200mg tablets 
91596997 LAMOTRIGINE 2mg disp tablets 
91596998 LAMOTRIGINE 200mg tablets 
91625996 Oxcarbazepine 600mg tablets 
91625997 Oxcarbazepine 300mg tablets 
91625998 Oxcarbazepine 150mg tablets 
91626998 OXCARBAZEPINE 300mg tablets 
91643998 ACETAZOLAMIDE 500mg injection 
91690990 Sodium valproate 200mg gastro-resistant tablets 
91839998 Oxcarbazepine 60mg/ml oral suspension sugar free 
91881990 Levetiracetam 100mg/ml oral solution sugar free 
92064998 FOSPHENYTOIN NA 750mg/10mL inj 
92131997 Carbamazepine 400mg modified-release tablets 
92131998 CARBAMAZEPINE 200mg m/r tabs 
92345998 Sodium valproate 300mg modified-release tablets 
92375996 LEVETIRACETAM 1g tablets 
92375997 LEVETIRACETAM 500mg tablets 
92375998 LEVETIRACETAM 250mg tablets 
92463990 Gabapentin 600mg tablets 
92700996 Lamotrigine 100mg dispersible tablets sugar free 
92700997 Lamotrigine 25mg dispersible tablets sugar free 
92700998 Lamotrigine 5mg dispersible tablets sugar free 
92709996 LAMOTRIGINE 100mg disp tablets 
92709997 LAMOTRIGINE 25mg disp tablets 
92709998 LAMOTRIGINE 5mg disp tablets 
92734997 Carbamazepine 250mg suppositories 
92734998 Carbamazepine 125mg suppositories 
92735997 CARBAMAZEPINE 250mg supps 
92735998 CARBAMAZEPINE 125mg supps 
92796990 Clonazepam 500microgram tablets 
92802996 SOD. VALPROATE 200mg/5mL sfliq 
92802997 Sodium valproate 500mg gastro-resistant tablets 
92802998 SOD. VALPROATE 200mg e/c tabs 
92812998 Phenytoin 90mg/5ml oral solution sugar free 
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92837996 CARBAMAZEPINE 400mg tablets 
92837997 CARBAMAZEPINE 200mg tablets 
92837998 CARBAMAZEPINE 100mg tablets 
92917996 Sodium valproate with valproic acid 500mg modified release tablets 
92917997 Sodium valproate with valproic acid 300mg modified release tablets 
92917998 Sodium valproate with valproic acid 200mg modified release tablets 
92918996 SOD VALPROATE 500mg m/r tabs 
92918997 SOD VALPROATE 300mg m/r tabs 
92918998 SOD VALPROATE 200mg m/r tabs 
93015996 Valproic acid 500mg gastro-resistant capsules 
93015997 Valproic acid 300mg gastro-resistant capsules 
93015998 Valproic acid 150mg gastro-resistant capsules 
93016996 VALPROIC ACID 500mg e/c caps 
93016997 VALPROIC ACID 300mg e/c caps 
93016998 VALPROIC ACID 150mg e/c caps 
93037992 PHENOBARBITONE SODIUM ALCOHOL FREE 50 MG/5ML MIX 
93058996 Piracetam 333.3mg/ml oral solution sugar free 
93058997 Piracetam 1.2g tablets 
93058998 Piracetam 800mg tablets 
93059996 PIRACETAM 333.3mg/mL solution 
93059997 PIRACETAM 1.2g tablets 
93059998 PIRACETAM 800mg tablets 
93148998 Sodium valproate 400mg powder and solvent for solution for injection vials 
93404992 PHENOBARBITONE 10 MG TAB 
93443990 Sodium valproate 500mg gastro-resistant tablets 
93444990 Sodium valproate 200mg gastro-resistant tablets 
93454996 Phenobarbital 60mg/1ml solution for injection ampoules 
93454997 Phenobarbital 30mg/1ml solution for injection ampoules 
93454998 Phenobarbital 15mg/1ml solution for injection ampoules 
93460992 LAMOTRIGINE 50mg tablets 
93530997 Carbamazepine 200mg chewable tablets sugar free 
93530998 Carbamazepine 100mg chewable tablets sugar free 
93531997 CARBAMAZEPINE 200mg chew tabs 
93531998 CARBAMAZEPINE 100mg chew tabs 
93532997 CARBAMAZEPINE 400mg m/r tabs 
93532998 CARBAMAZEPINE 200mg m/r tabs 
93579997 Carbamazepine 400mg modified-release tablets 
93579998 Carbamazepine 200mg modified-release tablets 
93720992 PHENOBARBITONE SODIUM 100 MG TAB 
93768992 PHENOBARBITONE 100 MG SPA 
93769997 VIGABATRIN 500mg pdr sachets 
93769998 VIGABATRIN 500mg tablets 
93770996 Vigabatrin 125mg capsules 
93770997 Vigabatrin 500mg oral powder sachets sugar free 
93770998 Vigabatrin 500mg tablets 
93913990 Clonazepam 500micrograms/5ml solution sugar free 
94010990 Lamotrigine 200mg tablets 
94011990 Lamotrigine 100mg tablets 
94012990 Lamotrigine 50mg tablets 
94013990 Lamotrigine 25mg tablets 
94068997 VALPROIC ACID 500mg e/c tabs 
94068998 VALPROIC ACID 250mg e/c tabs 
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94118990 Lamotrigine 100mg tablets 
94120990 Lamotrigine 25mg tablets 
94256992 OSPOLOT 200 MG TAB 
94278992 PHENOBARBITONE S/R 100 MG CAP 
94279992 PHENOBARBITONE 22.5 MG TAB 
94281992 PHENOBARBITONE SODIUM 50 MG TAB 
94282992 PHENOBARBITONE 15 MG CAP 
94284992 PHENOBARBITONE 7.5 MG TAB 
94285992 PHENOBARBITONE 50 MG CAP 
94288992 PHENYTOIN 150 MG SUS 
94408996 SODIUM VALPROATE 400mg/4mL inj 
94408997 SOD. VALPROATE 200mg/5mL sfliq 
94408998 SODIUM VALPROATE 200mg/5mL syr 
94409996 SOD VALPROATE 100mg crush tabs 
94409997 SOD. VALPROATE 500mg e/c tabs 
94409998 SOD. VALPROATE 200mg e/c tabs 
94455992 EPANUTIN + PHENOBARB CAP 
94521992 PHENOBARBITONE 30 MG CAP 
94525992 PHENYTOIN 25 MG SYR 
94568996 Sodium valproate 200mg/5ml oral solution 
94568997 Sodium valproate 200mg/5ml oral solution sugar free 
94568998 Sodium valproate 100mg tablets 
94606997 Sodium valproate 500mg gastro-resistant tablets 
94606998 Sodium valproate 200mg gastro-resistant tablets 
94834996 GABAPENTIN 400mg capsules 
94834997 GABAPENTIN 300mg capsules 
94834998 GABAPENTIN 100mg capsules 
94835996 Gabapentin 400mg capsules 
94835997 Gabapentin 300mg capsules 
94835998 Gabapentin 100mg capsules 
94848979 LEVETIRACETAM 250mg tablets 
94854979 Levetiracetam 500mg tablets 
94858979 LEVETIRACETAM 500mg tablets 
94914979 TOPIRAMATE 25mg beads in caps 
94921979 TOPIRAMATE 15mg beads in caps 
95045979 Gabapentin 100mg capsules 
95112979 LAMOTRIGINE 25mg tablets 
95157990 Gabapentin 600mg tablets 
95159990 Gabapentin 300mg capsules 
95160979 SODIUM VALPROATE 200mg/5mL syr 
95161990 Gabapentin 100mg capsules 
95172979 SOD VALPROATE 500mg m/r tabs 
95177979 SOD VALPROATE 300mg m/r tabs 
95180979 Sodium valproate 300mg modified-release tablets 
95184979 SOD VALPROATE 200mg m/r tabs 
95186979 SOD VALPROATE 200mg m/r tabs 
95187990 Gabapentin 600mg tablets 
95189990 Gabapentin 300mg capsules 
95190990 Gabapentin 100mg capsules 
95216990 Sodium valproate with valproic acid 500mg modified release tablets 
95217990 Sodium valproate with valproic acid 300mg modified release tablets 
95266979 CARBAMAZEPINE 400mg m/r tabs 
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95361992 OSPOLOT 50 MG TAB 
95403997 Primidone 250mg/5ml oral suspension 
95403998 Primidone 250mg tablets 
95404996 LAMOTRIGINE 25mg tablets 
95404997 LAMOTRIGINE 100mg tablets 
95404998 LAMOTRIGINE 50mg tablets 
95409992 PHENOBARBITONE 10 MG PUL 
95411992 PHENOBARBITONE 30 MG ELI 
95415992 PHENOBARBITONE SODIUM 15 MG TAB 
95417992 PHENOBARBITONE 5 MG ELI 
95418992 PHENOBARBITONE 20 MG TAB 
95419992 PHENOBARBITONE 60 MG SPA 
95420992 PHENOBARBITONE 5 MG TAB 
95421992 PHENOBARBITONE 50 MG TAB 
95444996 Lamotrigine 25mg tablets 
95444997 Lamotrigine 100mg tablets 
95444998 Lamotrigine 50mg tablets 
95531998 Phenytoin sodium 250mg/5ml solution for injection ampoules 
95532996 Phenytoin 300mg capsule 
95532997 Phenytoin 30mg/5ml oral suspension 
95532998 Phenytoin 100mg capsule 
95533996 Phenytoin 50mg capsule 
95533997 Phenytoin 25mg capsule 
95533998 Phenytoin 50mg chewable tablets 
95553998 PHENOBARBITAL 200mg/1mL inj 
95554998 Phenobarbital 200mg/1ml solution for injection ampoules 
95750992 ZARONTIN 300 MG CAP 
95810990 Sodium valproate 200mg/5ml oral solution 
95838992 PHENYTOIN SODIUM/ PHENOBARBITONE SODIUM TAB 
95852996 Methylphenobarbital 200mg Tablet 
95852997 Methylphenobarbital 60mg Tablet 
95852998 Methylphenobarbital 30mg Tablet 
96096992 PIRACETAM 400 MG CAP 
96127990 Carbamazepine 400mg modified-release tablets 
96128990 Carbamazepine 200mg modified-release tablets 
96159990 Sodium valproate 200mg/5ml oral solution sugar free 
96160992 CLOBAZAM 5 MG TAB 
96386992 PHENOBARBITONE 60MG & PHENYTOIN 100MG MG TAB 
96446989 Carbamazepine 400mg modified-release tablets 
96446990 Carbamazepine 200mg modified-release tablets 
96463992 SOD VALPROATE C/R 200 MG TAB 
96479992 CARBAMAZEPINE 100mg/5mL sf liq 
96536989 Carbamazepine 400mg modified-release tablets 
96536990 Carbamazepine 200mg modified-release tablets 
96571990 Clonazepam 2mg/5ml oral solution sugar free 
96634996 Clonazepam 1mg/1ml solution for injection ampoules and diluent 
96634997 Clonazepam 2mg tablets 
96634998 Clonazepam 500microgram tablets 
96648997 Clobazam 10mg tablets 
96648998 Clobazam 10mg capsules 
96697988 Carbamazepine 200mg tablets 
96697989 Carbamazepine 100mg tablets 
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96767997 Ethosuximide 250mg/5ml oral solution 
96767998 Ethosuximide 250mg capsules 
96817992 METHSUXIMIDE 300 MG CAP 
96885998 Carbamazepine 100mg/5ml oral suspension sugar free 
96914998 Beclamide 500mg tablets 
96916988 Carbamazepine 400mg tablets 
96916989 Carbamazepine 200mg tablets 
96977989 Sodium valproate 200mg gastro-resistant tablets 
96977990 Sodium valproate 500mg gastro-resistant tablets 
96978990 Phenytoin sodium 100mg tablets 
96986990 Sodium valproate 200mg gastro-resistant tablets 
96986998 Acetazolamide 500mg powder for solution for injection vials 
96987997 Acetazolamide 250mg modified-release capsules 
96987998 Acetazolamide 500mg modified-release capsules 
96988996 Acetazolamide 40mg/ml oral solution 
96988997 Acetazolamide powder 
96988998 Acetazolamide 250mg tablets 
97033996 Carbamazepine 400mg tablets 
97033997 Carbamazepine 200mg tablets 
97033998 Carbamazepine 100mg tablets 
97080997 Phenobarbital sodium 60mg tablet 
97080998 Phenobarbital sodium 30mg tablet 
97086998 CARBAMAZEPINE 200mg tablets 
97128989 Carbamazepine 400mg modified-release tablets 
97128990 Carbamazepine 200mg modified-release tablets 
97140989 Phenytoin sodium 100mg tablets 
97158992 CLOBAZAM 1 MG SUS 
97159992 CLOBAZAM 2.5 MG CAP 
97160992 CLOBAZAM 7.5 MG CAP 
97161992 CLOBAZAM 5 MG CAP 
97185990 Acetazolamide 40mg/ml oral solution 
97202998 Phenobarbital 100mg tablet 
97203996 Phenobarbital 60mg tablets 
97203997 Phenobarbital 30mg tablets 
97203998 Phenobarbital 15mg tablets 
97402992 ETHOSUXIMIDE POW 
97514997 PHENYTOIN 50mg chew tabs 
97514998 PHENYTOIN SODIUM 300mg caps 
97628997 Valproic acid 500mg gastro-resistant tablets 
97628998 Valproic acid 250mg gastro-resistant tablets 
97721990 Sodium valproate 200mg gastro-resistant tablets 
97736992 METHSUXIMIDE 3000 MG CAP 
97736997 PHENYTOIN 100mg tablets 
97736998 PHENYTOIN 50mg tablets 
97779988 Carbamazepine 400mg tablets 
97779989 Carbamazepine 200mg tablets 
97779990 Carbamazepine 100mg tablets 
97782998 ACETAZOLAMIDE 250mg m/r caps 
97884992 PHENOBARBITONE & PHENYTOIN 60 MG CAP 
97896992 PHENYTOIN SODIUM/ PHENOBARBITONE CAP 
97897992 PHENYTOIN 30 MG TAB 
97910989 Sodium valproate 200mg gastro-resistant tablets 
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97910990 Sodium valproate 100mg tablets 
97911989 Sodium valproate 200mg gastro-resistant tablets 
97911990 Sodium valproate 200mg/5ml oral solution sugar free 
97949992 PRIMIDONE 200 MG TAB 
98049988 Phenobarbital 60mg tablets 
98075990 Phenytoin 90mg/5ml oral solution sugar free 
98084990 Sodium valproate 500mg gastro-resistant tablets 
98087997 Phenobarbital 50mg/5ml oral solution 
98087998 Phenobarbital 15mg/5ml elixir 
98090997 Phenytoin sodium 100mg tablets 
98090998 Phenytoin sodium 50mg tablets 
98112988 Phenobarbital 15mg tablets 
98112989 Phenobarbital 30mg tablets 
98112990 Phenobarbital 60mg tablets 
98147992 SULTHIAME 50 MG TAB 
98152992 SULTHIAME 200 MG TAB 
98200998 TIAGABINE 5mg tablets 
98315996 PHENYTOIN SODIUM 100mg caps 
98315997 PHENYTOIN SODIUM 50mg capsules 
98315998 PHENYTOIN SODIUM 25mg caps 
98328998 ACETAZOLAMIDE 250mg tabs 
98338988 Carbamazepine 400mg tablets 
98338989 Carbamazepine 200mg tablets 
98338990 Carbamazepine 100mg tablets 
98360998 CARBAMAZEPINE 100mg/5mL sf liq 
98361996 CARBAMAZEPINE 400mg tablets 
98361997 CARBAMAZEPINE 200mg tablets 
98361998 CARBAMAZEPINE 100mg tablets 
98385989 Sodium valproate 500mg gastro-resistant tablets 
98385990 Sodium valproate 200mg gastro-resistant tablets 
98430990 Phenytoin sodium 100mg tablets 
98461996 METHYLPHENOBARB 200mg tabs 
98461997 METHYLPHENOBARBITONE 60mg tab 
98461998 METHYLPHENOBARBITONE 30mg tab 
98476997 PHENOBARBITAL 60mg tablets 
98476998 PHENOBARB SODIUM 30mg tablets 
98517998 CLONAZEPAM 1mg/1mL injection 
98658998 PHENYTOIN 30mg/5mL suspension 
98730998 OXCARBAZEPINE 150mg tablets 
98739990 Phenobarbital sodium powder 
98764990 Phenobarbital sodium powder 
98928998 ACETAZOLAMIDE 250mg tabs 
98929988 Sodium valproate 200mg/5ml oral solution sugar free 
98929989 Sodium valproate 500mg gastro-resistant tablets 
98929990 Sodium valproate 200mg gastro-resistant tablets 
98949997 ETHOSUXIMIDE 250mg/5mL syrup 
98949998 ETHOSUXIMIDE 250mg capsules 
98989997 Gabapentin 800mg tablets 
98989998 Gabapentin 600mg tablets 
99121989 Phenytoin sodium 100mg tablets 
99122990 Phenytoin sodium 50mg tablets 
99176997 CLONAZEPAM 2mg tablets 
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99176998 CLONAZEPAM 500mcg tablets 
99383997 PRIMIDONE 250mg/5mL susp 
99383998 PRIMIDONE 250mg tablets 
99453990 Phenytoin sodium 100mg tablets 
99454989 Phenytoin sodium 100mg capsules 
99455989 Phenytoin sodium 100mg tablets 
99457990 Phenobarbital 15mg/5ml elixir 
99458989 Phenobarbital 30mg tablets 
99458990 Phenobarbital 15mg tablets 
99459989 Phenobarbital 30mg tablets 
99459990 Phenobarbital 60mg tablets 
99622997 CLOBAZAM 10mg tablets 
99622998 CLOBAZAM 10mg capsules 
99692998 PHENYTOIN 250mg/5mL injection 
99697997 ETHOSUXIMIDE 250mg/5mL syrup 
99697998 ETHOSUXIMIDE 250mg capsules 
99751988 Carbamazepine 400mg tablets 
99751989 Carbamazepine 200mg tablets 
99751990 Carbamazepine 100mg tablets 
99752989 Carbamazepine 200mg tablets 
99752990 Carbamazepine 100mg tablets 
99762998 Acetazolamide 500mg modified-release capsules 
99880998 TIAGABINE 10mg tablets 
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Read code list for EPILEPSY 
Read code Description 
1473.00 h/o: epilepsy 
1B1W.00 transient epileptic amnesia 
1O30.00 epilepsy confirmed 
282..13 o/e - a seizure 
2828.00 absence seizure 
6110.00 contraceptive advice for patients with epilepsy 
667..00 epilepsy monitoring 
6671.00 initial epilepsy assessment 
6672.00 follow-up epilepsy assessment 
6674.00 epilepsy associated problems 
6675.00 fit frequency 
6676.00 last fit 
6677.00 epilepsy drug side effects 
6678.00 epilepsy treatment changed 
6679.00 epilepsy treatment started 
667A.00 epilepsy treatment stopped 
667B.00 nocturnal epilepsy 
667C.00 epilepsy control good 
667D.00 epilepsy control poor 
667E.00 epilepsy care arrangement 
667F.00 seizure free >12 months 
667G.00 epilepsy restricts employment 
667H.00 epilepsy prevents employment 
667J.00 epilepsy impairs education 
667K.00 epilepsy limits activities 
667L.00 epilepsy does not limit activities 
667M.00 epilepsy management plan given 
667N.00 epilepsy severity 
667P.00 no seizures on treatment 
667Q.00 1 to 12 seizures a year 
667R.00 2 to 4 seizures a month 
667S.00 1 to 7 seizures a week 
667T.00 daily seizures 
667V.00 many seizures a day 
667W.00 emergency epilepsy treatment since last appointment 
667X.00 no epilepsy drug side effects 
667Z.00 epilepsy monitoring nos 
67AF.00 pregnancy advice for patients with epilepsy 
67IJ000 pre-conception advice for patients with epilepsy 
8BIF.00 epilepsy medication review 
8IAg.00 contraceptive advice for patients with epilepsy decli 
8IAh.00 pre-conception advice for patients with epilepsy decl 
8IAi.00 pregnancy advice for patients with epilepsy declined 
8IB2.00 contraceptiv advice for patients with epilepsy not in 
8IB3.00 pre-conception advic fr patients with epilepsy not in 
8IB4.00 pregnancy advice for patients with epilepsy not indic 
9h6..00 exception reporting: epilepsy quality indicators 
9h61.00 excepted from epilepsy quality indicators: patient un 
9h62.00 excepted from epilepsy quality indicators: informed d 
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9N0r.00 seen in epilepsy clinic 
9Of..00 epilepsy screen administration 
9Of0.00 epilepsy screen invite 1 
9Of1.00 epilepsy screen invite 2 
9Of2.00 epilepsy screen invite 3 
9Of3.00 epilepsy monitoring verbal invite 
9Of4.00 epilepsy monitoring telephone invite 
9Of5.00 epilepsy monitoring call first letter 
9Of6.00 epilepsy monitoring call second letter 
9Of7.00 epilepsy monitoring call third letter 
Eu05212 [x]schizophrenia-like psychosis in epilepsy 
Eu05y11 [x]epileptic psychosis nos 
Eu06013 [x]limbic epilepsy personality 
Eu80300 [x]acquired aphasia with epilepsy [landau - kleffner] 
F132100 progressive myoclonic epilepsy 
F132z12 myoclonic seizure 
F25..00 epilepsy 
F250.00 generalised nonconvulsive epilepsy 
F250000 petit mal (minor) epilepsy 
F250011 epileptic absences 
F250100 pykno-epilepsy 
F250200 epileptic seizures - atonic 
F250300 epileptic seizures - akinetic 
F250400 juvenile absence epilepsy 
F250500 lennox-gastaut syndrome 
F250y00 other specified generalised nonconvulsive epilepsy 
F250z00 generalised nonconvulsive epilepsy nos 
F251.00 generalised convulsive epilepsy 
F251000 grand mal (major) epilepsy 
F251011 tonic-clonic epilepsy 
F251100 neonatal myoclonic epilepsy 
F251111 otohara syndrome 
F251200 epileptic seizures - clonic 
F251300 epileptic seizures - myoclonic 
F251400 epileptic seizures - tonic 
F251500 tonic-clonic epilepsy 
F251600 grand mal seizure 
F251y00 other specified generalised convulsive epilepsy 
F251z00 generalised convulsive epilepsy nos 
F252.00 petit mal status 
F253.00 grand mal status 
F253.11 status epilepticus 
F254.00 partial epilepsy with impairment of consciousness 
F254000 temporal lobe epilepsy 
F254100 psychomotor epilepsy 
F254200 psychosensory epilepsy 
F254300 limbic system epilepsy 
F254400 epileptic automatism 
F254500 complex partial epileptic seizure 
F254z00 partial epilepsy with impairment of consciousness nos 
F255.00 partial epilepsy without impairment of consciousness 
F255000 jacksonian, focal or motor epilepsy 
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F255011 focal epilepsy 
F255012 motor epilepsy 
F255100 sensory induced epilepsy 
F255200 somatosensory epilepsy 
F255300 visceral reflex epilepsy 
F255311 partial epilepsy with autonomic symptoms 
F255400 visual reflex epilepsy 
F255500 unilateral epilepsy 
F255600 simple partial epileptic seizure 
F255y00 partial epilepsy without impairment of consciousness 
F255z00 partial epilepsy without impairment of consciousness 
F256.00 infantile spasms 
F256.11 lightning spasms 
F256.12 west syndrome 
F256000 hypsarrhythmia 
F256100 salaam attacks 
F256z00 infantile spasms nos 
F257.00 kojevnikov's epilepsy 
F258.00 post-ictal state 
F259.00 early infant epileptic encephalopathy wth suppression 
F259.11 ohtahara syndrome 
F25A.00 juvenile myoclonic epilepsy 
F25B.00 alcohol-induced epilepsy 
F25C.00 drug-induced epilepsy 
F25D.00 menstrual epilepsy 
F25E.00 stress-induced epilepsy 
F25F.00 photosensitive epilepsy 
F25G.00 severe myoclonic epilepsy in infancy 
F25G.11 dravet syndrome 
F25X.00 status epilepticus, unspecified 
F25y.00 other forms of epilepsy 
F25y000 cursive (running) epilepsy 
F25y100 gelastic epilepsy 
F25y200 locl-rlt(foc)(part)idiop epilep&epilptic syn seiz loc 
F25y300 complex partial status epilepticus 
F25y400 benign rolandic epilepsy 
F25y500 panayiotopoulos syndrome 
F25yz00 other forms of epilepsy nos 
F25z.00 epilepsy nos 
F25z.11 fit (in known epileptic) nos 
Fyu5000 [x]other generalized epilepsy and epileptic syndromes 
Fyu5100 [x]other epilepsy 
Fyu5200 [x]other status epilepticus 
Fyu5900 [x]status epilepticus, unspecified 
R003400 [d]nocturnal seizure 
R003z11 [d]seizure nos 
SC20000 traumatic epilepsy 
ZS82.00 acquired epileptic aphasia 
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Read code list for DEPRESSION 
Read code Description 
1465.00 h/o: depression 
1B17.00 depressed 
1BT..00 depressed mood 
2257.00 o/e - depressed 
62T1.00 puerperal depression 
8BK0.00 depression management programme 
8CAa.00 patient given advice about management of depression 
8HHq.00 referral for guided self-help for depression 
9H90.00 depression annual review 
9H91.00 depression medication review 
9H92.00 depression interim review 
9HA0.00 on depression register 
9HA1.00 removed from depression register 
9Ov..00 depression monitoring administration 
9Ov0.00 depression monitoring first letter 
9Ov1.00 depression monitoring second letter 
9Ov2.00 depression monitoring third letter 
9Ov3.00 depression monitoring verbal invite 
9Ov4.00 depression monitoring telephone invite 
9hC..00 exception reporting: depression quality indicators 
9hC0.00 excepted from depression quality indicators: patient 
9hC1.00 excepted from depression quality indicators: informed 
9k4..00 depression - enhanced services administration 
9k40.00 depression - enhanced service completed 
9kQ..00 on full dose long term treatment depression - enh ser 
9kQ..11 on full dose long term treatment for depression 
E112.00 single major depressive episode 
E112.11 agitated depression 
E112.12 endogenous depression first episode 
E112.13 endogenous depression first episode 
E112.14 endogenous depression 
E112000 single major depressive episode, unspecified 
E112100 single major depressive episode, mild 
E112200 single major depressive episode, moderate 
E112300 single major depressive episode, severe, without psyc 
E112500 single major depressive episode, partial or unspec re 
E112600 single major depressive episode, in full remission 
E112z00 single major depressive episode nos 
E113.00 recurrent major depressive episode 
E113.11 endogenous depression - recurrent 
E113000 recurrent major depressive episodes, unspecified 
E113100 recurrent major depressive episodes, mild 
E113200 recurrent major depressive episodes, moderate 
E113300 recurrent major depressive episodes, severe, no psych 
E113500 recurrent major depressive episodes,partial/unspec re 
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E113600 recurrent major depressive episodes, in full remissio 
E113700 recurrent depression 
E113z00 recurrent major depressive episode nos 
E11y200 atypical depressive disorder 
E11z200 masked depression 
E135.00 agitated depression 
E200300 anxiety with depression 
E204.00 neurotic depression reactive type 
E204.11 postnatal depression 
E2B..00 depressive disorder nec 
E2B0.00 postviral depression 
E2B1.00 chronic depression 
Eu32.00 [x]depressive episode 
Eu32.11 [x]single episode of depressive reaction 
Eu32.12 [x]single episode of psychogenic depression 
Eu32.13 [x]single episode of reactive depression 
Eu32000 [x]mild depressive episode 
Eu32100 [x]moderate depressive episode 
Eu32200 [x]severe depressive episode without psychotic sympto 
Eu32211 [x]single episode agitated depressn w'out psychotic s 
Eu32212 [x]single episode major depression w'out psychotic sy 
Eu32213 [x]single episode vital depression w'out psychotic sy 
Eu32400 [x]mild depression 
Eu32500 [x]major depression, mild 
Eu32600 [x]major depression, moderately severe 
Eu32700 [x]major depression, severe without psychotic symptom 
Eu32800 [x]major depression, severe with psychotic symptoms 
Eu32B00 [x]antenatal depression 
Eu32y00 [x]other depressive episodes 
Eu32y11 [x]atypical depression 
Eu32y12 [x]single episode of masked depression nos 
Eu32z00 [x]depressive episode, unspecified 
Eu32z11 [x]depression nos 
Eu32z12 [x]depressive disorder nos 
Eu32z13 [x]prolonged single episode of reactive depression 
Eu32z14 [x] reactive depression nos 
Eu33.00 [x]recurrent depressive disorder 
Eu33.11 [x]recurrent episodes of depressive reaction 
Eu33.12 [x]recurrent episodes of psychogenic depression 
Eu33.13 [x]recurrent episodes of reactive depression 
Eu33.14 [x]seasonal depressive disorder 
Eu33000 [x]recurrent depressive disorder, current episode mil 
Eu33100 [x]recurrent depressive disorder, current episode mod 
Eu33200 [x]recurr depress disorder cur epi severe without psy 
Eu33211 [x]endogenous depression without psychotic symptoms 
Eu33212 [x]major depression, recurrent without psychotic symp 
Eu33214 [x]vital depression, recurrent without psychotic symp 
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Eu33y00 [x]other recurrent depressive disorders 
Eu33z00 [x]recurrent depressive disorder, unspecified 
Eu33z11 [x]monopolar depression nos 
Eu34111 [x]depressive neurosis 
Eu34113 [x]neurotic depression 
Eu34114 [x]persistant anxiety depression 
Eu3y111 [x]recurrent brief depressive episodes 
Eu41200 [x]mixed anxiety and depressive disorder 
Eu41211 [x]mild anxiety depression 
Eu53011 [x]postnatal depression nos 
Eu53012 [x]postpartum depression nos  
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Read code list for BIPOLAR DISORDER 
 
Read code Description 
146D.00 h/o: manic depressive disorder 
212T.00 psychosis, schizophrenia + bipolar affective disord r 
212V.00 bipolar affective disorder resolved 
E11..11 bipolar psychoses 
E111.00 recurrent manic episodes 
E111000 recurrent manic episodes, unspecified 
E111100 recurrent manic episodes, mild 
E111200 recurrent manic episodes, moderate 
E111300 recurrent manic episodes, severe without mention psyc 
E111400 recurrent manic episodes, severe, with psychosis 
E111500 recurrent manic episodes, partial or unspecified remi 
E111600 recurrent manic episodes, in full remission 
E111z00 recurrent manic episode nos 
E114.00 bipolar affective disorder, currently manic 
E114.11 manic-depressive - now manic 
E114000 bipolar affective disorder, currently manic, unspecif 
E114100 bipolar affective disorder, currently manic, mild 
E114200 bipolar affective disorder, currently manic, moderate 
E114300 bipolar affect disord, currently manic, severe, no ps 
E114400 bipolar affect disord, currently manic,severe with ps 
E114500 bipolar affect disord,currently manic, part/unspec re 
E114600 bipolar affective disorder, currently manic, full rem 
E114z00 bipolar affective disorder, currently manic, nos 
E115.00 bipolar affective disorder, currently depressed 
E115.11 manic-depressive - now depressed 
E115000 bipolar affective disorder, currently depressed, unsp 
E115100 bipolar affective disorder, currently depressed, mild 
E115200 bipolar affective disorder, currently depressed, mode 
E115300 bipolar affect disord, now depressed, severe, no psyc 
E115400 bipolar affect disord, now depressed, severe with psy 
E115500 bipolar affect disord, now depressed, part/unspec rem 
E115600 bipolar affective disorder, now depressed, in full re 
E115z00 bipolar affective disorder, currently depressed, nos 
E116.00 mixed bipolar affective disorder 
E116000 mixed bipolar affective disorder, unspecified 
E116100 mixed bipolar affective disorder, mild 
E116200 mixed bipolar affective disorder, moderate 
E116300 mixed bipolar affective disorder, severe, without psy 
E116400 mixed bipolar affective disorder, severe, with psycho 
E116500 mixed bipolar affective disorder, partial/unspec remi 
E116600 mixed bipolar affective disorder, in full remission 
E116z00 mixed bipolar affective disorder, nos 
E117.00 unspecified bipolar affective disorder 
E117000 unspecified bipolar affective disorder, unspecified 
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E117100 unspecified bipolar affective disorder, mild 
E117200 unspecified bipolar affective disorder, moderate 
E117300 unspecified bipolar affective disorder, severe, no ps 
E117400 unspecified bipolar affective disorder,severe with ps 
E117500 unspecified bipolar affect disord, partial/unspec rem 
E117600 unspecified bipolar affective disorder, in full remis 
E117z00 unspecified bipolar affective disorder, nos 
E11y.00 other and unspecified manic-depressive psychoses 
E11y000 unspecified manic-depressive psychoses 
E11y100 atypical manic disorder 
E11y300 other mixed manic-depressive psychoses 
E11yz00 other and unspecified manic-depressive psychoses nos 
Eu30.11 [x]bipolar disorder, single manic episode 
Eu31.00 [x]bipolar affective disorder 
Eu31.11 [x]manic-depressive illness 
Eu31.12 [x]manic-depressive psychosis 
Eu31.13 [x]manic-depressive reaction 
Eu31000 [x]bipolar affective disorder, current episode hypoma 
Eu31100 [x]bipolar affect disorder cur epi manic wout psychot 
Eu31200 [x]bipolar affect disorder cur epi manic with psychot 
Eu31300 [x]bipolar affect disorder cur epi mild or moderate d 
Eu31400 [x]bipol aff disord, curr epis sev depress, no psycho 
Eu31500 [x]bipolar affect dis cur epi severe depres with psyc 
Eu31600 [x]bipolar affective disorder, current episode mixed 
Eu31700 [x]bipolar affective disorder, currently in remission 
Eu31800 [x]bipolar affective disorder type i 
Eu31900 [x]bipolar affective disorder type ii 
Eu31911 [x]bipolar ii disorder 
Eu31y00 [x]other bipolar affective disorders 
Eu31y11 [x]bipolar ii disorder 
Eu31y12 [x]recurrent manic episodes 
Eu31z00 [x]bipolar affective disorder, unspecified 
Eu33213 [x]manic-depress psychosis,depressd,no psychotic symp 
Eu33312 [x]manic-depress psychosis,depressed type+psychotic s 
ZRby100 profile of mood states, bipolar 
ZV11111 [v]personal history of manic-depressive psychosis 
ZV11112 [v]personal history of manic-depressive psychosis 
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Appendix 3 
 
Minor Anomalies for Exclusion (EUROCAT) 
 
For EUROCAT for use from 2005 
 
Reports of cases with the following anomalies are not to be transmitted to the 
EUROCAT Central Registry if the anomalies are isolated. It is, however, 
important to report all minor anomalies for cases with major malformations or 
syndromes. 
 
“Minor” anomalies are excluded, when isolated, because they have lesser 
medical, functional or cosmetic consequences (although they may be indicators 
of other problems) and experience shows that their definition and diagnosis and 
reporting varies considerably. At the present time, it is not useful to collect data 
at a European level on these anomalies. We also exclude anomalies which are 
not always truly congenital in origin, sometimes associated with immaturity at 
birth. In addition, we exclude poorly specified conditions and recommend that for 
any such cases more specific information be sought from medical records. 
 
Cases reported to EUROCAT should always be confirmed cases of congenital 
anomaly. Cases which had diagnosed ultrasound soft markers but who were 
found to be normal at birth or with unknown outcome should not be reported. 
 
Note that exclusions should be made locally, where all information is available. 
Many minor anomalies do not have specific ICD10‐BPA codes, but we give 
specific codes where they exist. For the codes given in the list, if any cases with 
only one or more of these codes has been inadvertently transmitted to Central 
Registry, they will be 
subsequently excluded from the central files on the basis of the code only. For 
allocation of cases to EUROCAT subgroups (see Chapter 8), only major 
malformations will be considered (codes for minor anomalies will be excluded). 
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 Specified ICD10‐
BPA –  if present 
Head  
Aberrant scalp hair patterning  
Flat occiput  
Dolichocephaly Q67.2 
Plagiocephaly – head asymmetry Q67.3 
Bony occipital spur  
Third fontanel  
Macrocephalus Q75.3 
Facial asymmetry Q67.0 
Compression facies Q67.1 
Other cong deformities of skull, face and jaw Q67.4 
  
Eyes  
Epicanthic folds  
Epicanthus inversus  
Upward slanting palpebral fissures  
Downward slanting palpebral fissures  
Short palpebral fissures  
Congenital ectropion Q10.1 
Congenital entropion Q10.2 
Other congenital malformations of eyelid Q10.3 
Dystopia canthorum  
Hypertelorism Q75.2 
Hypotelorism  
Stenosis or stricture of lacrimal duct Q10.5 
Synophrys Q18.80 
Blue sclera Q13.5 
Crocodile tears Q07.82 
  
Ears  
Primitive shape Q17.3 
Lack of helical fold Q17.3 
Asymmetric size Q17.3 
Posterior angulation Q17.3 
Microtia Q17.2 
Macrotia Q17.1 
Protuberant ears Q17.3 
Absent tragus  
Double lobule Q17.0 
Accesorry auricle, preauricular appendage, tag or lobule Q17.0 
Auricular pit  
Preauricular sinus or cyst Q18.1 
Narrow external auditory meatus  
Low set ears Q17.4 
Bat ear, prominent ear Q17.5 
Unspecified and minor malformation of ear Q17.9 
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Nose  
Small nares  
Notched alas  
  
Oral regions  
Borderline small mandible/ minor micrognathia  
Aberrant frenula  
Enamel hypoplasia  
Malformed teeth  
High arched palate Q38.50 
Tongue tie or cyst of tongue Q38.1 
Macroglossia Q38.2 
Macrostomia Q18.4 
Microstomia Q18.5 
Macrocheilia Q18.6 
Microcheilia Q18.7 
Ranula  
  
Neck  
Mild webbed neck  
Sinus, fistula or cyst of branchial cleft Q18.0 
Preauricular sinus or cyst Q18.1 
Other branchial cleft malformations Q18.2 
Congenital malformation of face and neck, unspecified Q18.9 
Torticollis Q68.0 
  
Hands  
Duplication of thumbnail  
Enlarged or hypertrophic nails Q84.5 
Single/abnormal palmar crease Q82.80 
Unusual dermatoglyphics  
Clinodactyly (5th finger)  
Short fingers (4. 5. th finger)  
Accessorry carpal bones Q74.00 
  
Feet ‐Limb  
Syndactyly (2nd‐3rd toes)  
Gap between toes (1st‐2nd)  
Short great toe  
Recessed toes (4th, 5th)  
Enlarged or hypertrophic nails Q84.5 
Prominent calcaneus  
Clicking hip, subluxation or unstable hip Q65.3‐Q65.6 
Metatarsus varus or metatarsus adductus Q66.2 
Hallux varus – other cong varus deformities of feet Q66.3 
Talipes or pes calcaneovalgus Q66.4 
Congenital pes planus Q66.5 
Metatarsus varus – other cong valgus  deformities of feet Q66.6 
Pes cavus Q66.7 
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Clubfoot of postural origin ‐ other cong deformities of feet Q66.8 
Congenital deformity of feet, unspecified Q66.9 
  
Skin  
Hemangioma (other than face or neck)  
Pigmented naevus – cong non‐neoplastic naevus Q82.5 
Neavus flammeus Q82.50 
Strawberry naevus Q82.51 
Lymphangioma  
Angioma  
Persistent lanugo  
Mongoloid spot (whites) Q82.52 
Depigmented spot  
Unusual placement of nipples  
Accessory nipples Q83.3 
Cafe‐au‐Iait spot  
  
Skeletal  
Cubitus valgus  
Prominent sternum Q67.7 
Depressed sternum Q67.6 
Sternum bifidum Q76.71 
Shieldlike chest, other cong deformities of chest Q67.8 
Congenital deformity of spine Q67.5 
Genua valgum  
Genua varum  
Genu recurvatum Q68.21 
Congenital bowing of femur Q68.3 
Congenital bowing of fibula and tibia Q68.4 
Congenital bowing of long bones of leg, unspecified Q68.5 
Spina bifida occulta Q76.0 
Sacral dimple  
Cervical rib Q76.5 
Absence of rib Q76.61 
Accessory rib Q76.62 
Congenital lordosis, postural Q76.43 
  
Brain  
Arachnoid cyst  
Choroid plexus cyst  
Anomalies of septum pellucidum  
  
Cardiovascular  
Absence or hypoplasia of umbilical artery, single umbilical 
artery 
Q27.0 
Functional or unspecified cardiac murmur  
Patent ductus arteriosus if GA < 37 weeks Q25.0 if gestational 
age <37 weeks 
Peripheral pulmonary artery stenosis  
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Patent or persistent foramen ovale Q21.11 
  
Pulmonary  
Accessory lobe of lung Q33.1 
Congenital laryngeal stridor Q31.4 
Laryngomalacia Q31.4, Q31.5 
Tracheomalacia Q32.0 
Azygos lobe of lung Q33.10 
  
Gastro‐intestinal  
Hiatus hernia Q40.1 
Pyloric stenosis Q40.0 
Diastasis recti  
Umbilical hernia  
Inguinal hernia  
Meckel’s diverticulum Q43.0 
Functional gastro‐intestinal disorders Q40.21, Q43.20, 
Q43.81, Q43.82 
Transient choledochal cyst  
Anterior anus  
  
Renal  
Vesico‐ureteral‐renal reflux Q62.7 
Hydronephrosis with a pelvis dilatation less than 10 mm  
Hyperplastic and giant kidney Q63.3 
Single renal cyst Q61.0 
  
External genitals  
Deficient or hooded foreskin  
Undescended testicle Q53 
Unspecified ectopic testis  
Retractile testis Q55.20 
Hydrocele of testis  
Phymosis  
Bifid scrotum Q55.21 
Curvature of penis lateral  
Hypoplasia of penis  
Hymen imperforatum Q52.3 
Fusion of labia Q52.5 
Prominent labia minora  
Enlarged clitoris  
Vaginal skin tag  
Cysts of vulva  
Transient ovarian cyst  
  
Other  
Congenital malformation, unspecified Q89.9 
  
Chromosomal  
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Balanced translocations or inversions in normal 
individuals 
Q95.0, Q95.1 
 
“Non‐congenital” anomalies 
 Pyloric stenosis – there is controversy about the congenital nature of the 
majority of cases. 
 Patent ductus arteriosus in babies <37 weeks. 
 Hydrocephaly where a result of preterm birth rather than congenital: all 
cases among preterm births should be thoroughly checked before 
registration. 
 
Poorly specified anomalies 
 Functional or unspecified cardiac murmur. Laryngomalacia and 
tracheomalacia. Functional gastro‐intestinal disorders. 
 Undescended testicle. Registries may choose to record this locally if they 
can follow‐up 
 all babies to ascertain whether the testis descends normally. Unspecified 
ectopic testis. 
 Vesico‐ureteral reflux. Registries should record and transmit to 
EUROCAT the underlying anomaly, if present. 
 Clicking hip. 
 Clubfoot where there is no further specification of whether malformation 
or postural origin. 
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Read code list used to identify cases of perinatal death in Chapter 6 
 
Read code Description 
633..12 stillbirth [prevention record] 
6332.00 single stillbirth 
6335.00 twins - both still born 
6339.00 triplets - 3 still born 
L264.00 intrauterine death 
L264.11 fetal death in utero 
L264000 intrauterine death unspecified 
L264100 intrauterine death - delivered 
L264200 intrauterine death with antenatal problem 
L264z00 intrauterine death nos 
Q48D.00 [x] stillbirth 
Q48D000 [x]fresh stillbirth 
Q48D100 [x]macerated stillbirth 
Q48y600 early neonatal death 
Q48y700 late neonatal death 
Q4z..11 infant death 
Q4z..12 neonatal death 
Q4z..13 newborn death 
Q4z..14 perinatal death 
Q4z..15 stillbirth nec 
ZV27.12 [v]stillbirth 
ZV27100 [v]single stillbirth 
ZV27400 [v]twins, both stillborn 
ZV27700 [v]other multiple birth, all stillborn 
ZVu2C00 [x]other multiple births, all stillborn 
L39X.00 obstetric death of unspecified cause 
Lyu7500 [x]obstetric death of unspecified cause 
Q211.00 fetal death due to labour anoxia 
Q210.00 fetal death due to prelabour anoxia 
  
 
